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Abstract 
The development and commercialisation of a new therapeutic drug is a lengthy and 
expensive process hindered with uncertainties and high attrition rates. Monoclonal 
antibodies are a major contributor to the continuous growth of the global 
biopharmaceutical industry. Chromatography remains the workhorse in antibody 
purification despite its complex process development and the high operating cost. The 
research here presents the establishment of an integrated and data-driven decision-
support framework in early-stage protein chromatography process development. The 
key focus of the research is the development of a systematic and rational methodology 
to automate and accelerate data analysis and decision-making. A novel workflow was 
developed that combined high-throughput experimentation (HTE) at micro-scale with 
design of experiments (DoE), multi-variate data analysis, multi-attribute decision-making 
and a robustness analysis technique to screen and optimise chromatography resins. 
DoE was linked with an advanced chromatogram analysis method to cope with the large 
datasets resulting from HTE by automating raw data manipulation. Additionally, the 
approach offers the ability to correlate the trade-offs between purity and yield with 
process parameters through a regression analysis. High-throughput purification data 
were further leveraged using a decision-support tool for the chromatographic purification 
train linked with a bioprocess economics spreadsheet model. The bioprocess economics 
model was also used to provide insights regarding the cost-effectiveness of pre-packed 
chromatography columns as an alternative to conventional self-packed columns for 
clinical and commercial manufacture. The implementation of the framework 
demonstrated the synergy of different decision-support tools and allowed for the rapid 
evaluation of multiple chromatographic purification trains in order to determine the most 
cost-effective resin sequence and column type considering the whole manufacturing 
process. Additionally, it is demonstrated that chromatography process development 
activities could be accelerated by defining platform purification processes and identifying 
manufacturing bottlenecks fast and with limited feedstock material.
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Research Implementation and Impact 
The overall outcome of this research is an integrated framework in chromatography 
process development linking high-throughput purification data with process economics 
and advanced decision-support tools. The research was performed in collaboration with 
the industrial sponsor, MedImmune. The Department of Biochemical Engineering at 
University College London and MedImmune have established a Centre of Excellence in 
bioprocessing with a number of researchers and industrial and academic supervisors. 
All the experimental and analytical protocols were performed according to MedImmune’s 
specifications in order to enable the direct introduction of the approach into their process 
development strategy. MedImmune has recognised the benefits of high-throughput 
experimentation in bioprocess development. This research provides a framework for the 
systematic generation, manipulation and analysis of high-throughput purification data. 
Through the implementation of a framework it was demonstrated that high-throughput 
data can be further leveraged in decision-support tools to rapidly evaluate different 
purification strategies, identify process bottlenecks and determine cost-effective 
chromatography resins across different products. 
In this research, emphasis was placed on automation and flexibility through a data-driven 
decision-making framework. The proposed framework is the consolidation of different 
tools developed throughout this research: A high-throughput process development 
workflow, a process economics model in bio-manufacturing and a decision-support tool 
for the chromatographic purification train. A key benefit of the framework is the flexibility 
that it provides on different levels. Individual components of the framework can be used 
independently without compromising the function or the structure of the rest of the 
framework. Additionally, all its major components offer to the user the ability to define 
the appropriate inputs and outputs to address a certain purification challenge. 
Outside the research scope of this thesis, the process economics model has been used 
in collaboration with other researchers at UCL. The first example of implementation was 
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performed with another UCL/MedImmune researcher to simulate the cost of bio-
manufacturing in a cash-flow model evaluating the cost of development for new biologics. 
A different example was offered by another UCL researcher that was able to modify the 
process economics spreadsheet to simulate the economics of high throughput vaccine 
manufacturing facilities. Furthermore, UCL has moved forward with the improvement of 
the process economics model and the development of a simulation engine to evaluate 
new and disruptive upstream processing technologies for the manufacture of stratified 
biologics.  
Additionally, other UCL/MedImmune researchers currently focusing of the development 
of scale-down models to mimic and predict the performance of different unit operations 
at large scale, could benefit from using the process economics model. The integration of 
process economics with scale-down models as demonstrated in this thesis could provide 
critical insights for the performance and the cost-effectiveness of a unit operation at 
commercial scales. Since the development of a working version of the bioprocess 
economics engine, new UCL researchers have been offered training on the use of the 
engine and additional training sessions would provide the necessary skills to further 
develop the engine. Through proper training, current and new researchers could benefit 
from previous work and accelerate their research through the mitigation of the model 
development effort. 
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Chapter 1. Introduction and research scope 
1.1. Introduction 
The road, from discovery to development and commercialisation of a new therapeutic 
drug, is an extremely time-consuming and expensive process, hindered by high risk 
(Mehta, 2008). There is a continuous effort to develop and establish the necessary 
methods and tools to accelerate research and development (R&D) activities, achieve an 
in-depth level of product and process understanding and provide affordable medicines. 
Monoclonal antibodies (mAbs) have a significant impact on the continuous growth of the 
biopharmaceutical industry (Aggarwal, 2014). Chromatography is still the preferred 
choice in antibody purification despite associated challenges in process development 
and manufacturing (Vunnum et al., 2009). This thesis focuses on the establishment of 
an integrated framework in early-stage protein chromatography process development 
linking high-throughput experimentation with advanced decision-making techniques. The 
overall objective was to provide a data-driven decision-support tool for the rapid 
manipulation and analysis of high-throughput purification data to evaluate different 
chromatographic purification strategies and accelerate process development activities. 
Despite the obstacles and the complexity, the biopharmaceutical sector is a significant 
and fast growing segment of the global pharmaceutical market (Walsh, 2010). Over the 
past decade, the dependence of the pharmaceutical industry on biopharmaceuticals has 
increased substantially and there is a mutually beneficial relationship between biotech 
and pharmaceutical companies, with a significant surge in the negotiating power of the 
former (Thiel 2005; Lawrence & Lahteenmaki, 2014). Global sales of biologics reached 
$289 billion in 2014 with reports projecting the sales to surpass $400 billion by 2019 
(Deloitte Touche Tohmatsu Limited, 2016). Although the total sales are increasing, year 
by year, the biotech industry suffers from low profitability. Profit is not following the same 
rising trend with total sales (Lawrence & Lahteenmaki, 2014). It is the high complexity 
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and the unique level of uncertainty, which govern the biotech industry that inhibit the 
industry from reaching its full potentials (Pisano, 2006). 
Between 2007 and 2012 the best-selling class of biologics, in the US were monoclonal 
antibodies (mAbs) (Aggrawal, 2008; Aggarwal, 2009; Aggarwal, 2010; Aggarwal, 2012; 
Aggarwal, 2014), with total US sales, in 2012, of approximately $25 billion. On a global 
scale the sales of mAbs reached $75 billion in 2013 (Ecker et al., 2015). It is the sales of 
mAbs that are mainly responsible for the continuous growth of the biopharmaceutical 
sector (Aggarwal, 2014). Table 1.1 shows the top-ten selling biologics between 2012 and 
2015. It should be noted that half of the best-selling biologics every year are mAbs with 
Humira® from AbbVie (North Chicago, Illinois) ranked number one consistently that four 
year period (Huggett, 2013; Lawrence & Lahteenmaki, 2014; Morrison & Lahteenmaki, 
2015; Morrison & Lahteenmaki, 2016). 
Table 1.1: Top-ten selling biologics for the years 2012 – 2015 (Worldwide sales in 
$billion).  
Rank 2012 2013 2014 2015 
1 Humira* (9.3) Humira* (10.7) Humira* (12.5) Humira* (13.9) 
2 Enbrel (8.0) Enbrel (8.7) Sovaldi (10.3) Harvoni (13.9) 
3 Rituxan* (7.1) Lantus (7.6) Enbrel (8.9) Enbrel (9.0) 
4 Remicade* (6.6) Rituxan* (7.5) Lantus (8.4) Rituxan* (7.4) 
5 Herceptin* (6.2) Remicade* (7.0) Rituxan* (7.5) Lantus (7.1) 
6 Avastin* (6.1) Avastin* (6.8) Remicade* (7.2) Avastin* (7.0) 
7 Neulasta (4.1) Herceptin* (6.6) Avastin* (7.0) Herceptin* (6.9) 
8 Lucentis* (4.0) Gleevec (4.7) Herceptin* (6.9) Remicade* (6.8) 
9 Avonex (2.9) Neulasta (4.4) Revlimid (5.0) Prevnar 13 (6.3) 
10 Rebif (2.4) Revlimid (4.3) Gleevec (4.8) Revlimid (5.8) 
* Monoclonal Antibodies 
Despite a slow commercial start, mAbs have managed to overcome significant 
challenges to become the most important segment of biologic drugs (Reichert et al., 
2005; Kozlowski & Swann, 2006). Until 2014, the US Food and Drug Administration 
(FDA) had approved over 40 mAbs dominating the biopharmaceutical market with 38.5% 
of the total biologics sales (Aggarwal, 2014). By 2017, the number of mAbs that had been 
approved and were in review reached 75 while 52 new mAbs were in late stage clinical 
trials with 23 and 29 for cancer and non-cancer indications, respectively (Antibody 
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Society, 2017). Although mAbs demonstrate impressive performance in the market in 
terms of sales and growth rates, there is plenty of room for more innovations and 
improvements in their development (Davidson & Farid, 2014). 
This chapter offers an overview of the development pathway for the commercialisation 
of a new therapeutic drug to present the key milestones in R&D along with associated 
costs and timelines (Section 1.2.). Furthermore, Section 1.3., describes the bio-
manufacturing process emphasising on unit operations currently employed in the 
production, harvest, clarification and purification of therapeutic antibodies. Additionally, 
Section 1.3., presents a summary of single-use technologies available in bio-
manufacturing and discusses their benefits, limitations and the major considerations 
associated with their introduction into a biologics’ facility. Subsequently, Section 1.4., 
describes different approaches used in chromatography process development and 
provides examples of implementation demonstrating some of the benefits and 
challenges associated with each method. Finally, Section 1.5., offers an overview of the 
efforts over the past two decades in the development of computer aided tools able to 
capture both process and business aspects and enhance decision-making in bio-
manufacturing. The overview in Section 1.5., starts by describing early work in 
bioprocess economics providing examples on the evaluation of single-use technologies 
in bio-manufacturing. Moreover, published work is presented focusing on different 
methods to identify and manage uncertainties on both process and business level. 
Finally, the section concludes with a summary of published work emphasising on the 
design of cost-effective purification strategies. 
1.2. New drug development pathway 
The pathway to commercialisation of new therapeutic drugs, either small molecules 
(pharmaceuticals) or large molecules (biopharmaceuticals), is extremely challenging and 
highly regulated. In the United States the government authority that regulates and 
approves therapeutic products is the Food and Drug Administration (FDA). In Europe, 
the European Medicines Agency (EMA) is responsible for regulation and approval and 
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in Japan the Pharmaceutical and Medical Devices Agency (PMDA) is the responsible 
government organisation. In 1990, the regulatory authorities of the United States, Europe 
and Japan gathered and formed the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The 
purpose of the ICH is to provide quality, safety and efficacy guidelines and harmonise 
the regulatory authorities of the US, Europe and Japan, in order to promote the discovery 
and commercialisation of new therapeutics and improve global health. 
1.2.1. From inception to pre-clinical studies 
Most commonly, the development of a new therapeutic product is driven by the necessity 
to treat a disease problem, in which either there is no treatment, or the current treatment 
is not deemed to be efficient (Mehta, 2008). The purpose of the pre-clinical studies is to 
specify the pharmacodynamic and pharmacokinetic properties of the candidate drug and 
moreover, identify toxicity levels and determine a preliminary dose (Mehta, 2008; 
Mundae & Ostro, 2010). Initially, such studies are conducted in small animals such as 
rodents and if the results are satisfactory, the studies are continued in larger animals like 
monkeys to prove safety data (Mehta, 2008; Mundae & Ostro, 2010). It is important to 
mention that all the experiments must be implemented under current good laboratory 
practices (cGLP). The guidelines provide an extensive but complex framework on how 
the studies must be planned, conducted, monitored, analysed and reported (Mehta, 
2008; Cevc, 2014). 
Subsequently, it is mandatory to submit an investigational new drug application (IND) to 
the FDA, in order to receive approval to continue the studies in humans (Mehta, 2008; 
Mundae & Ostro, 2010). The subsequent clinical trials are divided into 4 phases. The 
first three phases are conducted in order to prove safety and efficacy and acquire 
regulator’s approval to proceed in commercialisation of the therapeutic product, while the 
fourth phase is conducted after the launch of the product in the market (Mehta, 2008). 
During the clinical trials, current good clinical practices (cGCP) provide the guidelines 
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regarding the design and the execution of the studies, as well as monitoring and control 
of the studies and moreover, in regards with the analysis and report of the data (Mehta, 
2008; Cevc, 2014). 
1.2.2. From clinical trials to market approval 
Clinical trials, phase I 
In Phase I of the clinical trials, healthy subjects (20 – 200 people) between the age of 18 
and 45, receive a single dose and they are monitored very closely to identify any 
undesired reactions (Mehta, 2008; Mundae & Ostro, 2010; Cevc, 2014). The dose the 
subjects receive, is a small portion of the predetermined dose, estimated based on the 
pre-clinical results, and is increasing gradually until the limit is reached or a complication 
occurs. Therefore, Phase I is necessary to prove safety and identify a dosage therapeutic 
window, in which there is a favourable balance between the benefits of the drug and the 
risk associated with its use. It is worth mentioning that in case of anticancer therapeutics, 
usually, the studies are conducted with diseased patients unable to respond successfully 
to other treatments (Mehta, 2008).  
Clinical trials, phase II 
In Phase II, approximately 400 patients are involved in a randomised, double-blind study. 
Randomised, because there is no discrimination among the patients and thus, some of 
them are placed randomly in placebo groups and double-blind because neither the 
physician, the patients or the company, know which patient belongs in each group. The 
overall aim is to determine the optimum dose, prove safety and demonstrate preliminary 
efficacy (Mehta, 2008). 
Clinical trials, phase III 
Phase III involves a significantly larger group of patients, up to 5000 (Cevc, 2014). The 
purpose of this phase is to prove efficacy and identify undesired side-effects that were 
not detected during Phase I & II. The increased number of patients indicates that Phase 
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III intends to test enough patients in order to conduct an accurate statistical analysis of 
the results that can represent adequately the projected market share (Mehta, 2008). It is 
worth to mention that FDA normally requires Phase III to be also a randomised, double-
blind study, while with EMA this is not always the case and one such study could be 
enough to proceed in authorisation (Cevc, 2014). 
Positive and promising results from Phase III provide the green light to proceed in the 
submission of a new drug application (NDA) for small molecules, or a biologics licence 
application (BLA) for large molecules. It is highly recommended that at the end of each 
phase, a meeting between the company and the regulators should take place in order to 
evaluate the results and discuss the progression of the trials, as well as the context and 
the details that must be included in the NDA/BLA (Mehta, 2008). 
Clinical trials, phase IV 
Phase IV takes place after the therapeutic drug has launched the market and the goal is 
to ensure safety and efficacy, as the population under treatment is increasing. Moreover, 
special subpopulations can be studied to identify any malfunctions and the results must 
be analysed and reported regularly to the regulators, in order to be aware of any 
problems with the progression of the treatment (Mehta, 2008). 
New therapeutic drug development timelines 
The time that is required, from research and discovery to final market approval, of a new 
therapeutic drug, is approximately 10 – 15 years (Mehta, 2008; Mundae & Ostro, 2010; 
Cevc, 2014). Discovery and pre-clinical studies are usually extended over a 7 year 
period, while clinical trials require approximately 6 – 8 years. Additionally, the regulatory 
agencies need some time (1 – 2 years), first to evaluate the NDA/BLA application and 
then to inspect the manufacturing facilities in order to ensure that the facility and the 
process align with the guidelines and the specifications (Mehta, 2008; Cevc, 2014). In 
other words, the manufacturers must guarantee that the product meets and will continue 
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to meet the desired and predetermined quality attributes and the regulators must advise 
and inspect to make sure that the product meets the specifications. 
1.2.3 Cost of R&D and attrition rates 
Although the time required to commercialise a new therapeutic drug has remained 
unchanged over the past decade, the same cannot be claimed for the cost of R&D or the 
success rate of getting new therapeutics to market. In 2013 the public biotech industry 
had spent $28.5 billion in R&D, a 13% increase compared with 2012 while revenues 
grew by 7% in the same period (Lawrence & Lahteenmaki, 2014). Several studies have 
addressed the challenge to estimate the total cost of R&D for a new therapeutic drug 
and the transition probabilities for each stage in clinical development and market 
approval. The vast majority of these studies provide an estimate of the capitalised cost 
of R&D per successful therapeutic drug in order to capture the cost of failed drug 
candidates and the development timeframe. Although this approach offers a more 
pragmatic estimate of the total R&D cost, it is subject to the databases used and the 
assumptions made for the analysis. 
For instance, published work from different research teams reported success rates (or 
transition probabilities) from Phase I to commercialisation within a range of 21.5% to 
30.2% (DiMasi et al., 2003; Adams & Brantner, 2006; DiMasi & Grabowski, 2007; Adams 
& Brantner, 2010). Later, Paul et al. (2011) reported a much lower success rate of 11.7%.  
Deviations of this magnitude among key estimates like the attrition rates can lead to 
significant differences in the capitalised cost. Morgan et al. (2011) provided a review 
study assessing published R&D cost estimates. The authors compared the capitalised 
R&D cost from thirteen studies and identified a significant variation in the results starting 
from $160 million and reaching $1.8 billion in 2009 US dollars. Additionally, the authors 
highlighted the implications that arise from the lack of data transparency rendering it 
extremely difficult to reproduce the results and assess their accuracy and validity. It was 
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concluded that despite more than thirty years of research on the subject it is very 
challenging to identify a benchmark estimate (Morgan et al., 2011). 
More recently, new estimates for the capitalised R&D cost and the cumulative success 
rate demonstrate an even higher cost with similar attrition rates compared with previous 
studies. The latest estimate of the total post-approval capitalised R&D cost reaches $2.9 
billion (2013 US dollars) with transition probabilities of approximately 60%, 36%, 62% 
and 90% from Phase I to Phase II to Phase III, to NDA/BLA submission and finally to 
NDA/BLA approval; leading to a success rate of 11.8% (DiMasi et al., 2016). 
1.3. Biopharmaceutical manufacturing 
The production of a specific therapeutic biological drug requires a very specific cell line, 
which will provide the product with the desired conformation, at the optimum productivity 
(Birch & Racher, 2006). The intrinsic variability in bio-manufacturing is observed not only 
among different products but also between different batches of the same product 
(Steinmeyer & McCormick, 2008). Therefore, consistency of the product between 
batches must be ensured and thus, the guidelines from the regulators are extremely 
strict. Additionally, consistency may be an issue when the manufacturing capacity 
changes. As the clinical trials progress, a greater population is treated and therefore 
higher production capacity is necessary to cover the demand. Furthermore, if/when a 
therapeutic product receives the approval from the regulators to be marketed even higher 
demands might be required. Hence, efficient scale-up methods are necessary to 
demonstrate that the product has the same characteristics and the same quality from 
scale to scale (Werner, 2004). 
The long development times and the high costs force biopharmaceutical companies to 
plan and evaluate their strategy from a very early stage. Additionally, they need to 
attempt and predict the circumstances that will occur if/when a product reaches the 
market (Werner, 2004). It is extremely important to determine, from the beginning of a 
project, the criteria that will dictate if the project should be continued to the next phase 
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or to be abandoned (Mehta, 2008). Hence, a risk assessment is mandatory to evaluate 
the potential of the product to reach the market and withstand any competition, determine 
the balance between the benefits and the risks associated with the patients and estimate 
the potential market share and reimbursement (Werner, 2004). 
A very significant consideration in the biopharmaceutical industry is the accurate 
prediction of the desired manufacturing capacity. It is extremely difficult to evaluate 
accurately the market share, especially when it comes to a new type of medicine, for 
which there is no or little indication on how accepted it will become (Kamarck, 2006). An 
example is the unexpected success of the fusion protein, EnbrelTM; an anti-tumour 
necrosis factor that treats autoimmune diseases. As soon as the drug was launched on 
the market in 1998, the demands increased exponentially and within the first 6 months, 
the US sales surpassed the projected annual global sales, leading to a capacity crisis. 
To overcome the challenge, contract manufacturers were called to increase capacity and 
additionally, new facilities had to be acquired to cover demand. Nevertheless, changing 
capacities and/or expanding to new facilities, requires time and the losses from the 
potential sales can be significant (Kamarck, 2006). On the other hand, in 1992, three 
different companies (Deerfield, Bayer and Wyeth now acquired by Pfizer) were 
manufacturing the same product (Recombinant factor VIII) and they all made major 
investments to increase their capacity and meet the demands, but soon they all faced 
overcapacity problems, due to competition (Kamarck, 2006). 
Considering the above examples regarding the manufacturing capacity, it is clear that 
the risks and the uncertainties involved require methodical and precise management in 
order to gain flexibility. Bio-manufacturing is challenging and it is critical to be able to 
establish robust and flexible processes, as well as the predictive tools to make initial 
estimations regarding the facility demands for a portfolio of therapeutic drugs. 
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1.3.1. Manufacturing processes of monoclonal antibodies 
Usually, mAbs are administrated in relatively high doses and the treatment has a 
prolonged duration. Additionally, the success of mAbs, both in the clinic and the market, 
means that they are a major contributor of the continuously increasing biopharmaceutical 
market (Reichert et al., 2005; Shukla & Thommes, 2010). 
Until the early 1990s, bio-manufacturing processes varied significantly across the 
industry (Kelley et al., 2009). The main differences in early bio-manufacturing processes 
can be observed in the purification train with a diverse chromatography sequence. The 
existence of different purification strategies can be explained, partially by the antibodies’ 
nature and how it evolved from murine to humanised and fully human. Despite the high 
degree of homology among the same type of antibodies (in terms of nature), it is 
extremely difficult to establish a generic process, with a generic sequence of unit 
operations that will operate under the same conditions. Nevertheless, platform 
manufacturing processes show significant benefits in terms of process development. 
Essential efforts have been made, both from industry and academia, to develop platform 
processes and to identify operating windows, in which different types of products and 
feed-streams can potentially be operated efficiently with minimum modification and 
adjustment (Kelley et al., 2009). 
1.3.1.1. Upstream processing of mAbs 
The large-scale production of mAbs is dominated by mammalian host cell lines and they 
have been established as the standard production platform, due to their ability to perform 
post-translational modifications (human-like N-glycosylation) and produce proteins 
compatible with the human immune system (Farid, 2009; Shukla & Thommes, 2010; Ho 
et al., 2013). Full length antibodies are glycosylated proteins and although the 
glycosylated domain does not interact directly with the antigens, it promotes stability. 
Incorrect glycosylation can result in undesired immune responses (Ho et al., 2013). 
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Mammalian cell lines 
The most commonly used mammalian cell lines are: the Chinese hamster ovary (CHO), 
murine lymphoid NS0 and Sp2/0, murine hybridoma and human cell lines. Among 
different human cell lines the human embryonic retinoblast derived cell line (Per.C6) is 
considered the most promising (Ho et al., 2013). Nevertheless, CHO cell lines are the 
preferred option since they can produce mAbs with the correct conformation and post-
translational modifications and provide higher biocompatibility with the human immune 
system and, therefore, demonstrate potentially an increased safety and efficacy (Shukla 
& Thommes, 2010; Ho et al., 2013). Modifications and advances have been made also 
with mammalian cell lines, to accelerate cell line development and optimisation and 
increase productivity and yield. Titres of 3 – 5 g/L are considered now typical for mAbs 
(Farid, 2009) with reports in the order of 10g/L being reported for some cases within the 
industry (Li et al., 2010). Production capacity and titre are closely related to cost of goods 
per gram (COG/g). For instance, a 10-fold increase in titre can reduce COG/g by 
approximately 80% (Werner, 2004). Alldread et al. (2014) compiled a data table 
summarising the evolution of COG/g over the past five decades. The authors reported 
an increase in the specific cell line productivity along with an increase in the cell culture 
duration leading to a significant surge in the cell culture titres. Considering also 
improvements in downstream processing with the total process yield reaching 
approximately 70 – 80% compared to 40% reported almost 50 year ago, the COG/g have 
experienced a significant reduction from 1000s to 10s of $/g. The uncertainties and risk 
associated with alternative host cell lines in combination with the advantages and the 
improvements in mammalian cell lines, demonstrate the strong reliance of large-scale 
bio-manufacturing processes on mammalian cell lines, at least for the foreseeable future 
(Farid, 2009; Alldread et al., 2014)). 
Large scale production strategies: Fed-batch and perfusion culture 
Two mammalian cell culture manufacturing strategies dominate the large scale upstream 
processes; fed-batch and perfusion culture (Lim et al., 2006). In fed-batch mode, first the 
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culture goes through a batch phase until the carbon source becomes limited and 
subsequently fresh media is introduced periodically to supplement the required nutrients. 
The duration of the culture is approximately 2 – 3 weeks. Fed-batch is usually the 
preferred mode of operation due to its simplicity in operation and control, its robustness 
and flexibility (Lim et al., 2006). However, large bioreactors are required to meet the 
demands resulting in high capital investment and large facility footprints (Pollock et al., 
2012). 
In perfusion mode, the culture starts with a batch phase and during the exponential 
growth phase, fresh media is added continuously while culture broth containing toxins 
and inhibitors, are removed continuously. Additionally, a cell retention device is 
necessary to maintain (or recycle) the cells in the bioreactor. The duration of the cell 
culture can be prolonged for weeks or even months and the resulted productivity is 
significantly higher compared with the fed-batch mode. Furthermore, perfusion culture 
requires smaller bioreactor capacity and thus the capital investment and the size of the 
facility may be reduced compared with the fed-batch mode (Pollock et al., 2012). 
However, the operational complexity and the increased risk of equipment failure can 
discourage inexperienced manufacturers to make a change from fed-batch to perfusion 
culture (Farid, 2009). 
Lim et al. (2006) evaluated the trade-offs in productivity, cost and uncertainty between 
fed-batch and spin-filter perfusion culture. They concluded the perfusion mode of 
operation was more cost-effective, demonstrating a significant reduction in capital 
investment and higher net present value, relative to the fed-batch mode. Nevertheless, 
when the uncertainties of each mode of operation were considered, perfusion was shown 
to be incapable of meeting demand. It was also commented that a further decrease in 
equipment failure rates would be needed, to increase the reward/risk ratio, if perfusion 
is to become more attractive as an option (Lim et al., 2006). 
33 
 
Alternative tangential flow (ATF) perfusion demonstrates advantages compared with 
spin-filter perfusion in terms of equipment failure and reliability. The ATF system utilises 
an external filtration unit to remove the broth and retain the cells, which results in a 
considerable reduction in the filter fouling. Pollock et al. (2012) evaluated the feasibility 
of fed-batch, spin-filter perfusion and ATF perfusion culture strategies under uncertainty. 
They concluded that ATF perfusion was the most cost-effective option even under 
uncertainty, demonstrating approximately a 20% decrease in the COG/g, for all the 
investigated titres and across different scales of production (Pollock et al., 2012) for 
single product facilities. 
Alternative cell lines 
Significant efforts have been made to introduce microbial cell lines for the production of 
mAbs, due to their significant advantages regarding productivity, yield, cell density, as 
well as simpler culturing media requirements (Farid, 2009; Spadiut et al., 2014). 
Currently, microbial cell lines such as yeast and bacteria are utilised for the production 
of antibody fragments (Fabs), which are not glycosylated proteins and thus, do not 
require the advanced post-translational machinery of mammalian cells (Spadiut et al., 
2014). Furthermore, eukaryotic microbial cells like Pichia pastoris have been genetically 
modified in order to perform human-like N-glycosylation (Li et al., 2006). 
1.3.1.2. Downstream processing of mAbs 
Harvest and clarification technologies 
In mammalian cell culture, mAbs are extracellular products, secreted into the cell culture 
broth and the first step in the downstream process is to separate the liquid from the solid 
phase (Shukla et al., 2007). Mammalian cells are sensitive to hydrodynamic forces and 
cell breakage is a common phenomenon. It is desirable to minimise cell disruption and 
prevent the release of impurities like proteases and other host cell proteins (HCPs), 
which can potentially affect the stability of the product. Moreover, holding times play a 
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significant role in product stability and in microbial contamination of the culture media 
(Shukla & Kandula, 2009).  
In large scale production of mAbs, centrifugation is typically the preferred harvest choice. 
Initially, centrifugation was inflexible and scalability was hindered by inadequate 
predictive models that lacked the ability to mimic the shear stresses occurred during 
large scale operations (Shukla & Kandula, 2009). Moreover, it was believed that large 
scale centrifuges require a substantial capital investment and therefore, often 
microfiltration was the preferred option (Low et al., 2007). Microfiltration is an alternative 
that offers a significant advantage over centrifugation by requiring fewer additional 
filtration steps in order to achieve an acceptable clarification level at which product 
purification can proceed. However, membrane fouling is an important consideration 
especially with large culture volumes and high cell concentrations (Zhao et al.,  2000; 
Charcosset, 2006).  
Centrifugation can handle large culture volumes and high cell concentrations and the 
development of scale down models and devices helped to overcome some important 
drawbacks. Continuous disk-stack centrifuges are most commonly utilised for harvest, 
providing the advantage of low residence times. Maybury et al. (1998) developed a scale 
down set-up to evaluate the performance of centrifugation and managed to reduce the 
required separation area and the volume of the centrifuge, enabling the use of less feed 
material. The study demonstrated an experimental set-up with interlocking inserts that 
can provide adequate information in early process development and has the ability to 
reduce substantially pilot-scale studies. Additionally, in another study, Maybury et al. 
(2000) reported a bench-top method to mimic shear stresses in laboratory scale 
centrifuges and predict the performance of large scale centrifuges. Hutchinson et al. 
(2006) developed an ultra scale-down method using a rotating disc device to predict the 
performance of industrial scale centrifuges using millilitre quantities of material. More 
recently, a capillary shear devise first developed by Westoby et al. (2011) was integrated 
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in an automated high-throughput experimental method in order to mimic the shear 
stresses observed at industrial scale disk-stack centrifuges (Joseph et al., 2016). 
The use of centrifugation as the harvesting method implies the use of additional filtration 
units to remove completely cells and cell debris that would compromise the subsequent 
purification steps. Usually, dead-end depth filtration follows centrifugation to achieve the 
desired level of clarification (Shukla et al., 2007; Shukla & Kandula, 2009). Depth-filters 
have the ability to retain particles throughout the filter matrix and not only on the surface 
of the membrane, providing a larger surface area for separation. It is a common practice 
to use filter aids like diatomaceous earth, in order to reduce compressibility of the formed 
cake on the surface of the filter (Shukla et al., 2007; Shukla & Kandula, 2009). 
Furthermore, charged matrices have been evaluated as an efficient primary removal of 
HCPs during mAb purification (Yigzaw et al., 2006). Most commonly depth filters are 
single-use and thus no cleaning is required resulting in less validation requirements and 
faster turnaround times. Process development and filter capacity studies usually take 
place at constant flow requiring a substantial amount of feedstock material and time. 
Joseph et al. (2017) correlated constant flow with constant pressure operation providing 
an alternative approach in filter capacity quantification reducing time and materials 
requirements.   
Dead-end microfiltration membranes with an absolute pore size (0.2 – 1 μm) are utilised 
for final clarification and particle removal prior to chromatographic purification. It is 
possible to combine the depth filter with an absolute filter attached on the bottom. 
Strategies utilising multiple depth filters for harvest and clarification tend not to be so 
robust and cost-effective at large scale and thus not favoured (Shukla & Kandula, 2009). 
Purification technologies 
Purification and polishing steps are major contributors to the COG/g and significant 
efforts have been made to improve productivity and yield. Manil et al. (1986) investigated 
the performance in terms of yield and purity of several purification techniques for mouse 
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mAbs and they concluded that Protein A chromatography was the best performing 
option. Precipitation was one of the first techniques used to purify mAbs and there are 
studies suggesting the re-introduction of such an approach in antibody purification to 
replace traditional chromatography (Alahari, 2009; Ma et al., 2010; Oelmeier et al., 
2013). 
Capture step in the purification sequence  
Nowadays, the majority of the purification schemes employ Protein A affinity 
chromatography as the first purification step (Shukla et al., 2007). Protein A is a 
polypeptide originally found in the cell wall of Staphylococcus aureus, that has a high 
binding specificity for the fragment crystallisable (Fc) domain of antibodies (Vunnum et 
al., 2009). Due to the physicochemical stability of Protein A, the ease of process 
development and the exceptional purification factors that can be achieved, Protein A 
chromatography is considered the workhorse of antibody capture and purification 
processes (Shukla et al., 2007; Vunnum et al., 2009). The duty of Protein A 
chromatography as the capture step in the purification sequence is to remove high 
molecular weight (HMW) species and degradation products (LMW) (product-related 
impurities), HCPs, DNA, potential adventitious viruses and cell culture media 
components (process-related impurities) (Vunnum et al., 2009). Moreover, it offers 
significant reduction in the volume that has to be processed downstream by 
concentrating the product (Kelley et al., 2009; Vunnum et al., 2009). 
Protein A chromatography operates in bind-and-elute (BE) mode, meaning that the target 
mAb interacts strongly and binds to Protein A, during loading, while HCPs and other 
impurities flow through due to their weaker interactions. Initially, the column is 
equilibrated with the loading buffer to achieve the appropriate environment and promote 
product binding. Subsequently, the clarified feed is loaded into the column, typically at a 
constant flow rate. In general the loading step is considered the rate-limiting step as it is 
desired to achieve the greatest possible dynamic binding capacity, which typically varies 
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among different mAbs (Vunnum et al., 2009). Ghosh et at, (2004) demonstrated a 
loading strategy involving a high flow rate followed by a lower flow rate and they 
concluded that their strategy can offer higher throughput, compared with the typical 
single flow rate strategy, and therefore mitigate the required loading time. 
During loading of the product, nonspecific binding occurs due to electrostatic and/or 
hydrophobic interactions between impurities, ligand and product. Hence, it is favourable 
to introduce a washing step before elution in order to remove weakly bound impurities 
and provide a ‘’cleaner’’ eluate. The pH of the washing buffer has to be between the 
loading pH (neutral) and the elution pH (acidic), to promote impurities removal, while 
keeping the product bound (Vunnum et al., 2009). If a single washing step is incapable 
of reducing the concentration of impurities, then a second step is usually employed, using 
additives such as salt, detergent and/or a solvent. Subsequently, pH is reduced to an 
acceptable level to promote product elution while avoiding aggregation and precipitation 
(Vunnum et al., 2009). Different mAbs have different optimum elution pH values, usually 
between 3 and 4.5. It is critical to maintain the pH at a level sufficient to provide high 
product yield and avoid destabilisation. Additives such as NaCl, urea, ethylene glycol are 
used to minimise interactions between the product and the ligand and permit the 
operation at higher pH and thus avoid the formation of aggregates (Vunnum et al., 2009). 
Then a stripping step usually takes place at pH 2.5 – 3 to remove strongly bound product 
and impurities. Subsequently, regeneration of the column is required to prepare the 
column for further runs. More often, chaotropes like urea and guanidine hydrochloride or 
low concentrations of sodium hydroxide (NaOH) are used for column regeneration 
(Vunnum et al., 2009). Traditionally, Protein A resins are sensitive under strong alkaline 
conditions that, in general, offer better column sanitisation. However, due to the low cost 
of NaOH and its efficiency to clean and regenerate the column and prevent any microbial 
growth, efforts have been made to develop resins resistant to alkaline treatments, such 
as MabSelect SuReTM (GE Healthcare, Uppsala, Sweden). 
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Wang et al. (2013) investigated the performance of MabSelectTM (GE Healthcare, 
Uppsala, Sweden) after cleaning and regenerating the column with NaOH, sodium 
sulphate (Na2SO4) and benzyl alcohol at different concentrations. They reported an 
increase in the number of cycles from 30 to 55 using their cleaning strategy over the 
cleaning strategy proposed by the manufacturer, without compromising the performance 
of the column in terms of dynamic binding capacity (DBC), yield and Protein A leaching. 
In another study, Jiang et al. (2009) compared two Protein A resins under three different 
cleaning strategies, using NaOH and sodium chloride (NaCl) at different concentrations, 
with and without a stripping step before regeneration. They reported that 50mM NaOH 
with 0.5M NaCl, without a striping step, was the most efficient strategy for both resins 
and moreover that the addition of protective additives like sucrose, xylitol and ethylene 
glycol reduced sufficiently the decline in binding capacity and provided greater stability 
against the strong alkaline conditions. 
With increasing titres and bioreactor volumes, the number of chromatography cycles 
needed to process a batch is expected to increase significantly (Lain et al., 2009). 
Therefore, column re-use plays a significant role, especially in Protein A 
chromatography, in which the cost of the resin is substantially higher compared to other 
resins, like ion exchangers. Kelley (2007) demonstrated a two-column very large-scale 
purification process, utilising a Protein A capture step followed by an anion exchange 
chromatography (AEX) column and reported that Protein A unit operation accounts for 
half of the total downstream process cost, with the cost of the resin being the major 
contributor. 
Protein A chromatography is associated with several limitations including the cost of the 
resin, number of cycles, low throughput, Protein A leaching and aggregation and/or 
precipitation due to the low elution pH values (Vunnum et al., 2009). Therefore, 
alternative purification technologies are being developed and evaluated, in order to 
replace Protein A chromatography and mitigate the associated drawbacks. 
39 
 
Cation exchange (CEX) chromatography is a key alternative and has been applied as a 
capture step in manufacturing of Synagis® by MedImmune (Gaithersburg, Maryland) 
and Humira® by AbbVie (North Chicago, Illinois) (Chon & Zarbis-Papastroitsis, 2011). 
Miesegaes et al. (2012) investigated the performance of five different CEX resins for the 
capture chromatography step at loading capacities similar to Protein A resins (25g/L and 
40g/L). They demonstrated a significant trade-off between purity and yield leading to 
infeasible windows of operation where high yield results in low purity and vice versa. 
Moreover, they mentioned that the operating conditions must be specified for each mAb 
to obtain optimum efficiency. The authors concluded that CEX chromatography is a 
promising alternative to replace Protein A for the capture chromatography step mainly 
due to the economic benefits it offers. 
More advanced CEX resins have been developed with high DBC values up to 100g 
mAb/L of resin to cope with the increased upstream titres (Chon & Zarbis-Papastroitsis, 
2011). Lain et al., (2009) evaluated two CEX resins for the capture step and reported 
binding capacities of 75 – 100g/L. Further investigation showed high yield (>97%) and 
purity (~99%) and up to 95% removal of HCPs. Other alternatives include mixed-mode 
resins that take advantage of both electrostatic and hydrophobic interactions. Pezzini et 
al. (2011) evaluated four mixed-mode resins and concluded that all of the tested resins 
were capable of replacing Protein A capture step and provide sufficient HCP clearance.    
Polishing steps in the purification sequence  
Downstream the capture chromatography step, two polishing steps are usually employed 
to remove remaining product- and process-related impurities. It is common practice to 
utilise two tandem ion exchange (IEX) chromatography columns post Protein A 
chromatography to achieve the desired level of purity and product quality (Ghose et al., 
2009). IEX chromatography takes advantage of the electrostatic interactions between 
the product and the resin. Antibodies, as all proteins, have a net charge that enables 
them to interact with the charged groups on the IEX resin. The isoelectric point (pI) of 
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the mAb under consideration determines the mode of operation for each type of the IEX 
resin. Anion exchange (AEX) resins are positively charged and thus bind anions while 
CEX resins are negatively charged and hence bind cations (Carta & Jungbauer, 2010) 
 AEX chromatography 
Murine mAbs usually have a more acidic pI than fully human mAbs and therefore, AEX 
chromatography is operated in BE mode. However, human mAbs have higher pIs and 
thus bind very weakly on AEX resins, which promotes a flow-through (FT) mode of 
operation (Gagnon, 2012). The increasing interest in human mAbs due to the low 
likelihood of immunogenicity, has established FT as the selected mode of operation for 
AEX chromatography (Arunakumari & Wang, 2009). The major advantage of operating 
in FT mode is that the AEX resin binds impurities, which constitute the smallest fraction 
of the product stream and therefore, high load challenges can be applied, increasing 
throughput and improving processing time (Kelley et al., 2008). 
Membrane AEX chromatography has attracted much attention as an alternative to AEX 
packed bed chromatography. Although membranes have lower binding capacity, their 
operation in FT mode minimising this drawback, since only trace levels of contaminants 
have to be retained (Zhou & Tressel, 2006). Additionally, conventional packed-bed AEX 
chromatography usually operates at linear velocities of 100 – 150 cm/hr, requiring large 
column diameters to cope with pressure drop limitations of the resin (Lim et al., 2007). 
Moreover, the transport phenomena involved with porous beads are more complex 
compared with membranes, where pore diffusion is not required and thus processing 
time can be mitigated (Lim et al., 2007). Another advantage is that membrane 
chromatography uses disposable single-use membranes and thus no clean-in-place 
(CIP) step is required. This is also beneficial from a validation point of view. Membrane 
chromatography offers significantly reduced buffer consumption, while providing very 
high yields (98 – 99.9%) and acceptable levels of virus removal (Zhou & Tressel, 2005). 
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Knudsen et al. (2001) compared the Q-Sepharose® Fast Flow AEX resin (GE 
Healthcare, Uppsala, Sweden) with Q membranes (Sartorius & Pall Biopharmaceuticals) 
and demonstrated that flow rate had an insignificant effect on the shape of the DNA 
breakthrough curve, providing the advantage of high throughput. Additionally, they 
compared the Sartobind® Q15 membrane (Sartorius, Göttingen, Germany) with the Q-
Sepharose® FF, in terms of HCP clearance and virus removal and concluded that HCP 
clearance was similar while virus removal was lower for the membrane, presumably 
because of membrane fouling. 
Kelley et al. (2008b) established an alternative mode of packed-bed AEX 
chromatography, known as weak partitioning chromatography (WPC). The difference 
stems from the distribution coefficient (Kp), which is the proportion of the amount of 
product bound to the stationary phase (AEX resin) over the amount of product that flows 
through without binding. In BE mode usually Kp is higher than 100 and in FT mode Kp 
is often lower than 0.1, while in WPC the distribution coefficient is between 0.1 and 20 
and preferably between 1 and 3. By manipulating the buffer’s pH and ionic strength, the 
authors identified the optimum Kp, which promotes strong binding of the impurities, while 
providing high product yield. By increasing Kp more product is bound on the resin, 
however once equilibrium is reached, no more product is able to bind. Consequently, 
high load challenges (>250g/L) are preferred in order to minimise product losses and 
increase recovery (Kelley et al., 2008). Additionally, the authors suggest that a wash 
step, after the load phase is completed, is necessary to recover bound product and 
increase yield. WPC demonstrates efficient removal of HCPs, HMW species and leached 
Protein A, while achieving high product recovery (>95%). The major disadvantage is that 
specific tuning is required for each mAb, to identify the optimum operating conditions 
(Kelley et al., 2008). However, the increased performance of WPC makes possible the 
establishment of a two-column purification process and thus offers significant economic 
benefits (Kelley, 2007; Kelley et al., 2008). 
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 CEX chromatography 
Another polishing step, frequently used in the chromatographic purification of mAbs, is 
CEX chromatography, most commonly operated in BE mode. Binding capacity is a major 
factor in the selection of the appropriate CEX resin. CEX chromatography has the ability 
to remove HCPs, HMW species, degradation products and leached Protein A (Ghose et 
al., 2009). Staby et al. (2006) compared the DBC values of several strong and weak CEX 
resins, at the same operating conditions and reported high DBCs, up to 100g/L, for two 
Fractogel® EMD resins from Merck Millipore. In a subsequent study, the same resins 
were compared in terms of HCP clearance and it was reported that both resins were 
capable of achieving a logarithm reduction value for HCPs around 3. Moreover, the 
authors estimated the optimum pH to maximise DBC and concluded that pH 6.0 provide 
the best DBCs for both resins; 76g/L and 86g/L for the Fractogel® EMD SO3
−
  & 
Fractogel® EMD SE Hicap, respectively (Stein & Kiesewetter, 2007). 
In CEX chromatography, two operating parameters that affect significantly the binding 
capacity of the resins are pH and conductivity (Harinarayan et al., 2006; Liu et al., 2010). 
Harinarayan et al. (2006) evaluated the effect of pH and conductivity on two CEX resins 
and reported unprecedented behaviour in which DBC rose with conductivity, at all pH 
values. Initially, as conductivity and/or pH increase, DBC also increases. However, after 
a certain point any additional increase in pH or conductivity has a negative effect on 
DBC. The latter is the anticipated behaviour and the research team explained the initial 
behaviour based on the concept that by increasing pH or conductivity, protein-protein 
exclusion is mitigated and therefore binding capacity is improved. 
CEX membrane chromatography has been evaluated as an alternative column type due 
to the benefits noted earlier regarding membrane columns. Knudsen et al. (2001) 
compared packed-bed and membrane CEX chromatography in BE mode. They reported 
almost constant DBC for the membrane at increasing flow rates, in contrast with packed-
bed, where DBC decreases as flow rate increases. They concluded that the low binding 
capacity of membranes is a major disadvantage compared to packed-bed columns. 
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 Alternatives to IEX chromatography as polishing steps 
Hydrophobic interaction chromatography (HIC) and hydroxyapatite (HA) 
chromatography as well as mixed-mode chromatography have been utilised for the 
purification of mAbs (Liu et al., 2010; Gagnon, 2012). HIC depends on the hydrophobic 
interactions between regions of the antibody and the hydrophobic ligands of the resin. 
The milder conditions applied in HIC make the method more favourable than reverse 
phase chromatography where product denaturation could be an issue. Furthermore, HIC 
is preferred when HCPs and HMW species removal is the major objective. On the other 
hand, IEX chromatography has a superior ability to remove leached Protein A and DNA 
(Ghose et al., 2009). 
HA chromatography offers both positively and negatively charged binding sites and it 
has the ability to remove leached Protein A, HCPs, HMW species and DNA. Charge 
distribution and strength is affected by pH and conductivity and the isoelectric point of 
the mAb has a significant influence on the selection of the operation conditions. 
Therefore, a substantial disadvantage associated with HA chromatography is the need 
to determine the operating conditions specifically for each mAb (Ghose et al., 2009). An 
example of HIC and HA chromatography application is provided by Amgen (Thousand 
Oaks, California), which has adopted a flexible platform, involving HIC, HA and IEX 
chromatography, to process different products (Shukla et al., 2007). 
As described earlier, mixed-mode chromatography employs both electrostatic and 
hydrophobic interactions and provides great selectivity (Liu et al., 2010). Chen et al. 
(2010) compared a multi-modal, strong AEX resin with six conventional AEX resins and 
demonstrated a superior reduction of HMW species with comparable levels of HCP 
reduction. However, product recovery is significantly higher for the conventional AEX 
resins. In another study, Gao et al. (2013) evaluated the ability of the same multi-modal, 
strong AEX resin to remove aggregates, HCPs and DNA and reported that it is possible 
to use the resin as a sole polishing step after Protein A chromatography.  
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Virus inactivation/removal 
The purification sequence in the downstream process is designed to remove product- 
and process-related impurities and provide a stable and potent product that meets 
predetermined quality criteria. Although the commonly used purification sequence 
starting with Protein A chromatography and followed by CEX and AEX chromatography, 
is qualified to provide a pure product, regulators also require two distinct, orthogonal 
virus clearance/inactivation steps (ICH Q5, 1999). The acidic elution conditions in Protein 
A chromatography promotes the inactivation of enveloped viruses. However, normally a 
dedicated virus inactivation step follows Protein A chromatography and the analysis of 
the inactivation efficiency is determined for each step individually (Vunnum et al., 2009). 
Furthermore, a virus removal step is placed after the last polishing step, before final 
concentration and formulation of the product. Typically, a 20nm virus filtration step is 
preferred due to its robustness to remove most of the viral contaminants (Zhou, 2009). 
1.3.2. Disposable chromatographic purification of biopharmaceuticals 
Traditionally, manufacturing facilities for biologics operate in batch mode incorporating 
mainly reusable stainless steel equipment leading to high capital investment and facility 
footprint. Additionally, extensive requirements in terms of time and materials for cleaning 
and preparation of each unit operation along with CIP and sterilisation-in-place (SIP) 
validation are needed. Disposable, single-use technologies (SUT) present an alternative 
approach especially with improvements in cell culture titres that can exceed 5g/L (Shukla 
& Gottschalk, 2013). SUT in bio-manufacturing have been available since the 1970s, 
however they were limited to filters and liquid hold bags for the first couple of decades 
(Laukel et al., 2011; Lopes, 2015). Disposable cell culture flasks have been extensively 
used, however, they have been restricted only to inoculum expansion. The WAVE 
BioreactorTM system (GE Healthcare, Uppsala, Sweden) offered the first single-use 
platform for inoculum preparation suitable for large-scale manufacturing or as a 
replacement of the production bioreactor when cell culture volumes are low enough 
(Haldankar et al., 2006). Single-use stirred-tank bioreactors became available in 2004 
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with relatively low capacity of 250L, which a few years later improved to 2000L (Shukla 
& Gottschalk, 2013; Lopes, 2015). 
Advances in SUT in downstream processing have not fallen behind compared with 
upstream. In early 1990s the first disposable membrane chromatography column was 
introduced by Sartorius. Furthermore, filtration operations utilised disposable filters and 
membranes for many years however, the lack of single-use skids was hindering the 
manufacturers from leveraging their true benefits. Significant milestones in the area have 
been achieved with the commercialisation of disposable depth filtration, tangential flow 
filtration and chromatography skids (Laukel et al., 2011). These single-use skids utilise 
disposable parts that come in contact with buffers and product thus preventing the 
contact with fixed parts of the equipment and avoiding any cleaning activities that 
otherwise would be required (Shukla & Gottschalk, 2013). A unit operation that still poses 
a great challenge to switch to single-use is centrifugation, with only limited examples on 
the market and none of them based on disk-stack centrifuges (Shukla & Gottschalk, 
2013).    
Adopting SUT offers significant benefits: reduction in capital investment, increased 
facility flexibility, reduced turnaround times between batches and campaigns and 
mitigation of cross-contamination risk (Shukla & Gottschalk, 2013; Lopes, 2015). 
Commonly used fixed process equipment in GMP manufacturing require cleaning after 
each batch. These cleaning activities increase the manufacturing cost and require 
validation studies to prove their effectiveness. Additional utilities are necessary to 
support CIP and SIP leading to large facility footprints and high demands in terms of 
capital investment. Multi-product facilities and new-build facilities have the potential to 
benefit the most from adopting SUT. Fewer fixed process equipment would lead to less 
construction and installation work thus accelerating the timeframe for the completion of 
the facility. Moreover, with less fixed equipment in the facility it is possible to address 
capacity changes faster avoiding over- or under-production (Lopes, 2015). 
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On the other hand different challenges arise with the introduction of SUT in bio-
manufacturing. A rather obvious limitation is the manufacturing capacity of SUT with the 
largest available stirred tank bioreactor reaching 2000L (Lopes, 2015) and the biggest 
chromatography column of 60cm in diameter (Grier and Yakubu, 2016). Equipment size 
restrictions such as these could require a large number of batches for a single campaign 
and/or significant improvements in the performance of the process. For instance, 
improvements in cell line development and cell culture performance to increase the titre 
could lead to lower cell culture volumes and potentially to smaller bioreactors thus 
enabling the option of disposables. Additionally, high capacity chromatography resins 
would require smaller columns and the introduction of membrane chromatography that 
could replace the traditional packed-bed column could all make any size limitations 
obsolete. 
Another challenge the biologics manufacturers are facing is the lack of standardisation 
of disposable components rendering it difficult to inter-change parts or even connect 
equipment from different vendors. The absence of regulatory guidelines that could 
provide a level of clarity regarding the materials that could be used by suppliers of 
disposables and the level and the quality of the certification they need to provide 
enhances the complexity of the decision to introduce SUT (Shukla & Gottschalk, 2013; 
Lopes, 2015). A key concern as expressed by manufacturers is the lack of sufficient 
validation studies by the suppliers to determine the level of risk associated with 
leachables and extractables that arise with the use of plastic, disposable equipment. An 
additional consideration could include the increased dependence of manufacturers on 
suppliers not only in terms of quality assurance but also in terms of availability, 
consistency and punctuality (Ding & Martin, 2008). 
Although for the majority of the unit operations used in bio-manufacturing there is an 
SUT option available, the same cannot be claimed for ancillary process control 
instruments like sensors and monitoring devices. This issue is highlighted even more 
when a start to finish single-use process is considered where connectivity issues become 
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more apparent. Furthermore, the lack of single-use process control instruments leads to 
a decrease in automation that requires an increase in trained personnel (Lopes, 2015). 
From an environmental perspective, studies have demonstrated that single-use facilities 
offer a lower CO2 footprint compared with traditional facilities due to the reduction in heat 
consumption that comes with cleaning activities. However, the increased amount of solid 
waste that comes with disposables adds an additional consideration regarding the 
establishment of the appropriate methods and protocols for solid waste management 
(Lopes, 2015).     
As discussed earlier, manufacturing of mAbs and antibody-related products is commonly 
based on a platform process involving 2 – 3 distinct chromatography steps in the 
purification sequence (Kelley et al., 2009). Typically, reusable, self-packed 
chromatography columns are utilised and packed with the appropriate resins that can be 
operated for multiple cycles. The main drawbacks in manufacturing regarding self-
packed columns are the need for a packing/unpacking system, the materials (WFI, 
buffers etc.) and the personnel to prepare the column for operation and storage as well 
as the time requirements to perform qualification tests and documentation activities that 
are required to ensure the desired column packing quality. As mentioned earlier, 
membrane chromatography is an alternative, plug-and-play technology offering 
comparable purification performance, reduction in materials and a decrease in capital 
expenditures compared to packed-bed chromatography columns (Knudsen et al., 2001; 
Zhou & Tressel, 2005; Lim, et al., 2007; Jacquemart et al., 2016). 
Another available option is the utilisation of disposable pre-packed chromatography 
columns, which offer the advantage of eliminating the need for packing/unpacking 
activities and hence the need for a packing system. Pre-packed chromatography 
columns have been available for over a decade and were primarily used at laboratory 
scale for bioprocess development. Scharl et al. (2016) collected a large dataset over a 
period of ten years from test runs with small-scale pre-packed columns considering a 
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significant number of commercially available chromatography resins covering all steps 
in the purification sequence and their analysis concluded that pre-packed columns offer 
consistently good packing quality. 
Although pre-packed columns have been extensively used at small-scale, larger 
columns have become available only recently that could fit into pilot and commercial 
facilities. Grier and Yakubu (2016) summarised potential merits and drawbacks with pre-
packed columns in GMP and non-GMP facilities and compared their performance with 
conventional self-packed columns. Potential benefits that have not been mentioned 
earlier could include simplified technology transfer activities and column packing 
consistency across different manufacturing sites. On the other hand, potential 
disadvantages could be the lead time to obtain pre-packed columns and the loss of 
column packing know-how. Their evaluation showed minor dissimilarities in packing 
qualification between data provided by the vendors and tests runs they performed post-
shipment. Additionally, a slightly better purification performance and a lower pressure 
drop for linear velocities above 300cm/h were demonstrated for self-packed columns. 
Their evaluation concluded that these differences between pre-packed and self-packed 
columns could be attributed to differences in packing methods and materials. 
1.4. Process development approaches in chromatographic purification of 
biopharmaceuticals 
The increasing demands for mAbs, combined with intellectual property issues (expiration 
of patent(s)) and the need to be the first-in-market and acquire an advantage over other 
competitors, make it essential for process development to be rapid, efficient and off the 
critical path. Additionally, the advances in upstream processes have shifted the 
manufacturing bottleneck to downstream processes (Nfor et al., 2009). Initially, the 
traditional approach to the development of purification processes, involved the 
application of prior knowledge and the execution of an extensive number of experiments 
at bench scale. However, several restrictions such as limited or no previous knowledge, 
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the ability to screen only one set of operating conditions at a time, the relatively large 
amounts of product required and the high cost of the necessary laboratory equipment, 
prevent the in-depth evaluation of all the necessary operating parameters. As a result, 
pilot scale studies were delayed until sufficient data were gathered through clinical trials. 
A major drawback then is the incomplete determination of the design space and the 
regulatory inflexibility, coupled with the adoption of suboptimal processes (Chhatre & 
Titchener-Hooker, 2008). 
Nowadays, the regulators, through Quality by Design (QbD) and Process Analytical 
Technology (PAT) initiatives, prompt manufacturers to accommodate a more systematic 
approach in process development and optimisation in order to explore the whole design 
space, define its boundaries and determine the impact of critical process parameters 
(CPPs) on critical quality attributes (CQAs). Currently, different strategies for the 
development of purification processes are available including heuristic or knowledge-
based methods, algorithmic- and model-based methods, high-throughput experimental 
and hybrid methods combining different approaches (Nfor et al., 2008). 
1.4.1. Knowledge-based methods 
The heuristics approach is based on leveraging prior knowledge from experts on a topic 
of interest. Usually prior knowledge is captured through a set of rules-of-thumb that can 
guide process synthesis and design (Nfor et al., 2009). Wheelwright (1989) discussed 
different design methods based on heuristics from copying an already existing process 
to the development of computer-aided expert systems that rationalise that prior 
knowledge. Asenjo et al. (1989) developed a prototype expert system summarising a set 
of 65 rules-of-thumb to synthesise and select complete downstream processes in bio-
manufacturing. The authors demonstrated the efficient synthesis of primary recovery 
steps in downstream processing and highlighted the need for additional information 
regarding the physicochemical properties of the protein of interest and its impurities to 
make decisions on high resolution chromatography steps. Leser and Asenjo (1992) 
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showed that the integration to an expert system of a database with comprehensive 
information on the major mixture components identified in upstream processing offers a 
more accurate selection of purification processes. Further developments in expert 
systems introduced more accurate databases, improved tool structure and flexibility and 
mathematical correlations to model more accurately different downstream processing 
trains (Leser & Asenjo, 1994; Lienqueo et al., 1996; Leser et al., 1996; Lienqueo & 
Asenjo, 2000). 
Heuristics-based methods can be used for rapid evaluation of alternative bio-
manufacturing strategies and have been proven to provide essential insights for the 
design of a purification process when limited data on the protein of interest and its 
impurities are available. Furthermore, with such an approach complex process synthesis 
and design tasks can be organised into more manageable operations. On the other hand, 
adopting solely a heuristics approach could lead to sub-optimal manufacturing processes 
and thus further evaluation should be performed to increase the level of process 
understanding and optimise the process (Nfor et al., 2008; Nfor et al., 2009; Hanke & 
Ottens, 2014). 
1.4.2. Algorithmic- and model-based methods 
Throughout the bio-manufacturing process there is a tendency to progressively replace 
empirical correlations with mechanistic models in order to provide a higher level of 
process understanding (Hanke & Ottens, 2014). Mechanistic models are derived from 
fundamental (or first) principles (conservation of mass, heat and momentum) and thus 
have the potential to describe more accurately the phenomena occurring in any system. 
The chemical industry has a long history and sufficient databases on thermodynamic 
properties exist to support the use of mechanistic models. In contrast, the biotechnology 
industry lacks the advanced models, software tools and simulation packages to improve 
and assist in process synthesis, design and optimisation mainly due to the complex 
nature of biomolecules (Nfor et al., 2009).  
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Significant research has been done since the late 1960s in the area of mathematical 
modelling for packed-bed adsorption operations (Bellot & Condoret, 1991; Bellot & 
Condoret, 1993). A comprehensive overview has been given by Ruthven (1984) 
classifying different modelling approaches into three main categories; equilibrium, plate 
and rate models. Mathematical models based on the equilibrium theory make the 
assumption of rapid equilibrium achieved between the stationary and the mobile phase 
neglecting the effects of mass transfer resistance and axial dispersion. Models based on 
the plate theory adopt a different approach by dividing the column into a series of 
theoretical plates within which equilibrium has been achieved. The empirical nature of 
plate models cannot relate them to first principles (Gu et al., 1993). Nevertheless, their 
application has been demonstrated on the separation of multicomponent systems (Gu et 
al., 1993; Guiochon, 2002). 
Rate models are expressed mathematically through a set of differential equations that 
describe the phenomena acquiring between the stationary and mobile phase for each 
component (Gu et al., 1990). Among rate models, the general rate model is considered 
one of the most comprehensive that attempts to capture the effect of all possible 
contributions such as axial dispersion, intra-particle diffusion, external firm mass transfer 
resistance and adsorption/desorption kinetics. The complexity and non-linearity of the 
general rate model have posed great challenges in solving the system of the differential 
equations required to describe the operation and efficient algorithms are necessary to 
provide a solution (Gu et al., 1990; Gu et al., 1993; Guiochon, 2002). Gu et al. (1990) 
proposed a numerical procedure to solve the general rate model using the finite element 
and the orthogonal collocation methods. Later the authors extended their work with the 
addition of second order kinetics and size exclusion effects in their model (Gu et al., 
1993). 
Other studies have used the general rate model or a variation of it to address various 
aspects of the chromatographic performance. Degerman et al. (2006) used the general 
rate model with Langmuir isotherm kinetics and a modulator to optimise the separation 
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of an IgG from bovine serum albumin. Their model was able to simulate real gradient 
elution profiles using a constraint on the slope of the gradient embedded in their 
optimisation procedure, thus avoiding making assumptions on ideal gradients. The 
authors demonstrated their approach using six decision variables with a fixed bed-height 
and confirmed graphically the success of their optimisation method. Gerontas et al. 
(2010) integrated scale-down experimental data with general rate modelling to scale-up 
and predict the chromatographic separation at manufacturing scale. The general rate 
model with Langmuir kinetics and a mobile phase modulator was used and solved using 
the finite element method. Additionally, the authors demonstrated the use of genetic 
algorithms to calibrate model parameters and showed the validity and applicability of 
their approach using three different CEX resins. Boushaba et al. (2011) used the same 
modelling approach described by Gerontas et al. (2010) to evaluate the effect of fouling 
in the chromatographic performance. The authors demonstrated the use of windows of 
operation to visualise the trade-offs between the effort and the benefits of feed 
clarification prior to chromatography. 
A systematic approach to model chromatography operations has been developed by 
Chan et al. (2008). Their approach consists of three main parts. First a methodology was 
proposed to determine the feed concentration and identify significant components in the 
feed mixture that are required for the development of an accurate model. Then, the 
second part involves the estimation of model parameters for different rate models. The 
authors identified two models that have been studied extensively; the equilibrium-
dispersive and the general rate model and employed them to demonstrate their 
approach. The general rate model offers a more accurate description of the separation 
process however at a high computational cost. In contrast, the equilibrium-dispersive 
model makes further assumptions to simplify the general rate model thus mitigating the 
time required to solve it with potential consequences on the accuracy of the model. At 
the third and last part the authors utilised the fractionation diagram method to compare 
the accuracy of the mechanistic models they included. Three case-studies were 
53 
 
presented to illustrate the applicability and usefulness of their approach. The 
fractionation diagram method was employed due to its sensitivity to capture efficiently 
the trade-offs between purity and recovery. 
Origin of the fractionation diagram approach 
The final output of a chromatography cycle is a chromatogram, which presents how the 
concentration of the eluate changes against volume or time. However, it is difficult to 
extract straightforward relationships that can correlate performance with operating 
conditions and moreover, this task becomes more difficult when product and impurities 
concentrations are expressed in different units and when inadequate data are available 
(Ngiam et al., 2001). To address this issue, Ngiam et al. (2001) proposed a method to 
manipulate the information provided by chromatograms and construct graphical 
representations to visualise the trade-offs between purity and product recovery. 
Originally, the graphical method was developed by Richardson et al. (1990) to correlate 
product recovery and purity in protein precipitation and furthermore, to optimise the 
precipitation conditions and identify the precipitant cut points. Later a similar graphical 
method was developed to optimise high-performance tangential flow filtration operations 
(Reis & Saksena, 1997). 
Examples of implementation of the fractionation diagram approach 
The fractionation diagram approach in chromatography development was first used by 
Ngiam et al. (2001) with a hypothetical three component mixture. The authors utilised a 
mathematical model of size exclusion chromatography (SEC) to describe and simulate 
the separation of the desired component at different flow rates of the mobile phase. The 
resulting chromatograms where then translated into fractionation diagrams and 
maximum purification factor (PF) versus recovery diagrams were generated to visualise 
the effect of flow rate on the chromatographic performance. In the same study, the team 
conducted experiments with an IEX column to evaluate the removal of endotoxin and 
plasmid DNA. The fractionation approach was used to identify the collection points on 
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the chromatogram that will provide the desired level of purity and yield. In a subsequent 
study, the same approach was employed to optimise a two-column purification sequence 
(HIC followed by SEC). The authors identified the need to perform an integrated 
optimisation approach and develop the purification sequence as a whole and not as 
individual steps, which may lead to a sub-optimal result. Initially, the mobile phase flow 
rate was chosen as the investigated variable and how it affects HIC performance in terms 
of purity and yield. Subsequently, the effect of each HIC flow rate on the following SEC 
step, was evaluated in order to make decisions regarding the operating flow rate of the 
HIC step. The authors concluded that SEC is strongly affected by HIC (Ngiam et al., 
2003).  
Salisbury et al. (2006) considered the need to optimise the chromatographic purification 
sequence as a whole, utilised the fractionation diagram approach and introduced 2D 
windows of operation, capturing the trade-offs between productivity and purity. To 
generate a window of operation, initially a range of product breakthrough levels and 
operating flow rates have to be chosen based on the desired level of resolution. Then 
the time to achieve each breakthrough level was determined and the elution profiles were 
generated for each flow rate/breakthrough level combination. Subsequently, PF versus 
recovery diagrams were created for each combination of flow rate and breakthrough level 
and purity was estimated at the desired level of product recovery. Finally, productivity 
was calculated for each flow rate and breakthrough level combination. A window of 
operation for the first chromatography step was created and a feasible region within the 
window of operation was identified for the operation of the next chromatography step. 
The above studies demonstrate that the fractionation diagram approach is a powerful 
tool in purification process development and optimisation. The method offers an efficient 
solution to the issues arising from the insufficient approaches on how to extract rapidly 
useful information from a plethora of chromatograms. Moreover, it considers the 
importance of optimising each chromatography step as part of the whole purification 
sequence and not individually. Incorporation of the fractionation diagram approach with 
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other techniques has been proven to be an excellent tool in process development that 
can help make feasible decisions. 
1.4.3. High-throughput experimentation and design of experiments 
Although mechanistic models offer a high level of process understanding, there are 
challenges that arise from the selection of the appropriate modelling approach, to the 
related experimental effort to determine model parameters, to the high computational 
cost associated with some models (e.g. general rate model). Additionally, the inherent 
complexity of biopharmaceuticals and their manufacturing processes, increase the need 
for the development of novel tools and techniques to enhance the efforts towards 
accelerating bioprocess development while gaining an in-depth understanding of the 
process (Hanke & Ottens, 2014).  
High-throughput experimentation has emerged as a useful tool in purification bioprocess 
development and is characterised by miniaturisation, automation and parallelisation 
(Bhambure et al., 2011). 
 Miniaturisation due to the very small quantities of materials required to run the 
experiments, which are usually an order of magnitude lower than the requirements 
for small scale studies 
 Automation due to the ability to incorporate automated liquid-handling platforms 
 Parallelisation because a set of experimental runs can be executed simultaneously 
The major advantage with high-throughput experimentation is the ability to explore a 
large combination of operating parameters with minimal feedstock requirements. 
Additionally, pilot scale studies can be more targeted and designed to explore further 
only the conditions that appear the most promising, minimising cost and time 
requirements. Despite the significant merits of high-throughput experimentation 
techniques, there are important concerns that have to be addressed regarding the design 
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of the experiments and the organisation and manipulation of the resulting information 
(Chhatre & Titchener-Hooker, 2008; Nfor et al., 2009).  
1.4.3.1. High-throughput screening techniques in chromatography 
Currently, different high-throughput screening techniques are employed in the 
development of chromatographic purification processes. Chhatre and Titchener-Hooker 
(2008) proposed a route to chromatography process development using micro-scale 
chromatography and provided a comprehensive overview of the different formats of 
micro-scale chromatography. The authors identified three different formats most 
commonly used: 1) microliter batch incubation, 2) micropipette chromatography tips and 
3) miniature pre-packed columns. These micro-scale chromatography devices can be 
operated manually or automatically and can generate quantitative and qualitative data 
(Chhatre & Titchener-Hooker, 2008). The ability to operate these devices using a robotic 
workstation provides many advantages such as, increased productivity, consistency and 
accuracy. However, automated liquid-handling devices such as Freedom EVO® by 
Tecan require proper training and time to develop the appropriate operating protocols. 
Those protocols are especially important in platform processes where specific unit 
operations are employed and therefore the same protocol, for example for Protein A 
chromatography, can be used multiple times (Chhatre & Titchener-Hooker, 2008). Lacki 
(2012) evaluated the limitations and the advantages of the three micro-scale formats 
available and provided guidelines based on published high-throughput screening 
purification data, setting out which format is more appropriate for a given kind of 
experimental goal. 
The implementation of the first micro-scale format utilising the microliter batch incubation 
technique most commonly takes place using 96-well filter plates loaded with 
chromatography resins. Manually loaded 96-well plates have been used to identify the 
best performing chromatographic purification sequence for recombinant proteins (Rege 
et al., 2006). A plethora of different studies have been published utilising 96-well filter 
plates and automated liquid handling systems, to investigate different types of protein 
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chromatographic purification (Kramarczyk et al., 2008; Kelley et al., 2008; Kelley et al., 
2008b) and to identify the accuracy and consistency of automated liquid landing systems 
(Coffman et al., 2008). Additional studies have been conducted using 96-well filter plates 
to determine the dynamic binding capacity (Bergander et al., 2008; Carta, 2012). 
The demonstration of the second micro-scale format using pre-packed micropipette 
chromatography tips has been less extensively reported, compared to microliter batch 
incubation. Wenger et al. (2007) evaluated the purification of virus-like-particles from 
yeast lysate and developed an operating protocol using an automated robotic 
workstation. Chhatre et al. (2009) used the same micropipette chromatography tips 
format and a 2-level full factorial design of experiments to evaluate the effects of pH and 
salt concentration in the recovery and purification of polyclonal antibodies by a mixed-
mode cation exchange resin. The authors identified the challenges associated with 
scale-up of chromatography processes based on the HTE results and highlighted the 
increasing necessity for faster analytical methods to cope with the large datasets that 
result from HTE. 
The third and last micro-scale technique available incorporates miniature packed-bed 
chromatography columns with bed volumes of 100, 200 and 600μl. The miniature 
columns are a close representation of a packed-bed chromatography column, in terms 
of geometry and flow characteristics. Wierling et al. (2007) recognised the necessity for 
more rapid analytical tools and utilised these miniature columns coupled with an 
automated liquid handling system and an analytical system to evaluate the ability of four 
different chromatography resins to purify monoclonal antibodies from host cell proteins. 
In a different study, miniature chromatography columns were used to conduct 
breakthrough and elution experiments and to screen different resins and operating 
conditions. The authors concluded that there was a good agreement between micro-
scale and laboratory scale data when comparing breakthrough curves and an acceptable 
representation of purification performance. Finally, the authors highlighted the important 
role HTE has in chromatography process development and mentioned the potential 
58 
 
benefits that could be achieved by integrating HTE with model-based methods for the 
rapid evaluation of model parameters (Wiendahl et al., 2008). 
These examples all evaluate the performance of a single purification step. Treier et al. 
(2012b) demonstrated the ability to develop the whole purification sequence and 
highlighted the analytical challenges that arise from HTE. Welsh et al. (2014) 
incorporated 96-well filter plates for initial screening of binding conditions, followed by 
miniature columns to evaluate impurities removal capabilities. The authors demonstrated 
the applicability of their strategy with proof of concept examples and confirmed the HTE 
results with small-scale experiments. 
HTE offers benefits not only in terms of materials and time consumption but also in terms 
of the in-depth level of process understanding that can be achieved from very early stage 
in process development. Process limitations and manufacturing bottlenecks can be 
identified and alternatives can be rapidly evaluated with limited resources and the results 
could be used to drive and accelerate scale-up studies. The potentially vast amounts of 
data that can result from HTE require the appropriate methods and tools in order to fully 
leverage the information provided and support decision-making in bio-manufacturing. 
1.4.3.2. Design of experiments in chromatography 
Micro-scale, HTE techniques available for the chromatographic purification of 
biopharmaceuticals have increased the impetus for methodical experimental planning in 
order to maintain the number of experiments to a manageable level both in terms of 
experimental and analytical work while gaining the desired level of process 
understanding. The classical experimental approach evaluates the impact of each factor 
(or variable parameter) individually by keeping all the other independent variables 
constant. This approach is also known as one-factor-at-a-time (OFAT) and usually 
requires extensive experimentation and increased effort in data analysis and 
visualisation. The limitations of the OFAT approach become apparent even with relative 
simple systems where only a few factors have an influence. For instance, for a system 
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with four factors evaluated at four different levels each, the resulted number of 
experiments is 44=256, excluding replicates necessary to evaluate experimental errors 
and lack of fit of the proposed model. Moreover, the investigation of each factor 
independently hinders the identification of interactions among factors thus providing a 
limited level of confidence on the resulted model (Lazic, 2004). 
Design of experiments (DoE) is an alternative approach that investigates multiple factors 
simultaneously and provides empirical correlations that link factors with responses 
(Kumar et al., 2013). A comprehensive overview of the statistics involved in DoE as well 
as a review and discussion on the different designs that have been developed with 
applications in Chemical Engineering is given by Lazic (2004). Ferreira et al. (2007) 
identified chemometric tools commonly employed for the development of 
chromatographic systems. They reported that two-level full factorial, central composite, 
Box-Behnken, Doehlert and mixture design of experiments were among those more 
frequently used. Different types of experimental designs in DoE have been discussed 
also by Hibbert (2012). The author identified different designs in the DoE arsenal and 
provided a concise description summarising advantages, and limitations for each of 
them. Additionally the author offered recommendations on the procedure of reporting 
studies incorporating DoE, mentioning the inadequate description by many authors in 
their publications of the DoE methodology they followed. Furthermore, it was highlighted 
that DoE is a well-established chemometric tool with a list of different software packages 
to assist in implementation and analysis. Hence, there is no need to repeat its full history 
in every study but rather focus on the description of the details in the development of the 
DoE, the reasons behind the selection of a specific design by a researcher and the 
methodology that was followed to identify the appropriate model to describe the system.  
Following Hibbert’s (2012) paradigm, Kumar et al. (2013) used the microliter batch 
incubation technique with a 96-well filter plate loaded with a CEX resin to purify a 
therapeutic protein and they evaluated different design of experiments. The authors 
proposed a systematic approach for optimum model selection. Their approach 
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investigates different combinations of model parameters using a stepwise regression 
analysis and identifies the optimal model through a series of comparisons among key 
statistics of different models to describe a given system. Xu et al. (2012) followed the 
QbD paradigm in the development of a CEX chromatography step to separate a mAb 
from its aggregates. The authors used DoE to screen different CEX resins and develop 
a pH-conductivity hybrid elution profile. However, limited information was provided on 
the methodology that was followed to select their DoE method and model parameters 
that describe the chromatographic purification. 
1.4.4. Hybrid methods 
Another option in chromatography process development is the combination of different 
approaches that were discussed above (Nfor et al., 2008; Nfor et al., 2009; Hanke & 
Ottens, 2014). Susanto et al. (2009) integrated HTE with genetic algorithms to optimise 
chromatography operations. Their approach combined an automated liquid handling 
system with software tools to manipulate raw data and perform the experimental design 
using a genetic algorithm. The authors demonstrated their fully automated platform using 
both the microliter batch incubation and the miniature pre-packed chromatography 
columns technique.  The use of genetic algorithms in combination with HTE has also 
been discussed by Treier et al. (2012) to optimise a CEX chromatography step. The 
authors developed an automated protocol to prepare chromatography buffers based on 
conditions dictated by their platform and compared their approach with DoE and 
response surface analysis. They concluded that in case of multiple optimal solutions their 
approach to incorporate a genetic algorithm for experimental planning and analysis 
provided better correlations. However, in case of a single optimum the authors 
mentioned that it would require four times more experimental runs than using the DoE 
approach. 
An alternative methodology was presented by Osberghaus et al. (2012) linking 
mechanistic modelling with HTE. Miniature pre-packed chromatography columns were 
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operated with an automated liquid handling system and a series of experiments were 
performed to determine model parameters. The authors calibrated a lumped transport-
dispersive model to make scale-up predictions and reported an acceptable agreement 
between the predicted performance and the experimentally achieved with a laboratory 
scale chromatography column. Traylor et al. (2014) incorporated microliter batch 
incubation with 96-well filter plates operated on an automated liquid handling system with 
a multi-channel robotic arm and adjusted the pore diffusion model assuming a Langmuir 
isotherm to describe a multi-addition batch uptake. 
Another hybrid approach in chromatography process development was demonstrated by 
Nfor et al. (2011). The authors integrated HTE with model-based optimisation using a 
combination of the equilibrium-transport-dispersive and the liquid-film linear driving force 
models. HTE was implemented using the microliter batch incubation technique on an 
automated liquid handling system to acquire model parameters to describe the 
chromatographic operation. A multi-objective optimisation was performed considering 
quality and performance attributes along with process economics metrics related only to 
chromatography and Pareto frontier graphs were generated to visualise the trade-offs 
among different attributes. The authors utilised the weighted sum method to compare 
three different mixed-mode resins under their respective optimal operating conditions 
that were screened and optimised using their proposed hybrid approach for the 
purification of a particular mixture. 
The QbD paradigm in chromatography process development has also been 
demonstrated by Bhambure and Rathore (2013). The authors established a High-
Throughput Process Development (HTPD) platform combining DoE with the microliter 
batch incubation technique using prefilled 96-well filter plates. The experimental plan of 
their HTPD platform was operated manually leading to the introduction of correction 
factors to minimise experimental errors. Moreover, the authors reported a difference in 
the step recovery between their HTPD platform and laboratory-scale systems possible 
due to non-specific binding of the protein on the bottom of the filter plates, reporting the 
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high hydrophobicity of the protein as the cause of this behaviour. Overall, the study 
demonstrated the applicability and usefulness of their HTPD platform highlighting the 
enormous benefits in terms of time and feedstock material required compared with 
traditional, laboratory scale experimentation. 
More recently, Liu et al. (2017) developed a decision-support framework for the optimum 
resin selection and operation of a two-step chromatographic purification train. The 
proposed hybrid approach was developed using miniature, pre-packed chromatography 
columns on an automated liquid handling system. High-throughput purification data 
generated for each resin candidate were integrated into a multi-objective, mixed-integer 
nonlinear programming model and used Pareto frontiers to visualise the trade-offs 
between purity and yield. A key advantage of the suggested decision-support framework 
is the integration of two steps in the purification train highlighting the importance of 
considering the whole purification train when developing individual chromatographic 
operations. Although such a holistic approach offers critical insights regarding the 
interdependencies among individual chromatography steps it comes with an increased 
experimental effort when screening multiple chromatography resin sequences and 
multiple process parameters at a wide range. 
HTE has emerged as a powerful tool in chromatography process development. There is 
an increasing trend to develop hybrid approaches and incorporate HTE into platforms 
(or workflows) that combine different tools and methods forming a HTPD strategy 
(Bhambure & Rathore, 2013). Hybrid methods offer the advantage of linking different 
approaches emphasising on the merits while mitigating the limitations that each method 
offers when used individually (Hanke & Ottens, 2014). Regulatory agencies through the 
QbD initiative suggest the manufacturers to adopt a HTPD strategy in order to accelerate 
process development from a very early stage in a product’s lifecycle and achieve a high 
level of product and process understanding.  
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1.5. Process economics modelling in bio-manufacturing 
The high cost of R&D, combined with the increased necessity to provide affordable new 
biologics, is driving the biotech sector to identify solutions that can mitigate the clinical 
and commercial manufacturing cost. The design and optimisation of bio-manufacturing 
facilities for therapeutic antibodies have been evaluated in several studies. The 
Department of Biochemical Engineering at University College London has a key focus 
on the development of decision-support tools to address process (e.g. Farid et al., 2005; 
Farid et al., 2007; Simaria et al., 2012; Allmendinger et al., 2014; Yang et al., 2014) and 
business (e.g. Rajapakse et al., 2005; George & Farid, 2008) aspects in bio-
manufacturing. One key performance metric used by a plethora of studies is the cost of 
goods (COG) that provides a sum of direct (or running) and indirect (or overhead) 
manufacturing costs. 
Farid et al. (2000) developed a prototype hierarchical tool to model process and business 
aspects in bio-manufacturing. The authors provided a breakdown of COG that reflects 
the cost associated with cGMP bio-manufacturing facilities and demonstrated the 
implementation and functionality of their tool through a case study evaluating different 
stainless steel and single-use manufacturing strategies. Mustafa et al. (2004) followed 
the same modelling approach and used COG as the key metric in decision-making 
between packed-bed chromatography and expanded bed adsorption. Later Mustafa et 
al. (2006) presented a framework to address both business and process aspects related 
to retrofitting using discrete event simulations. 
The continuously increasing demands for higher annual outputs have a positive effect 
on the COG per gram of product produced (COG/g) and therefore, as the annual 
production capacity rises, COG/g reduces (Farid, 2007). At small scales the contribution 
of capital investment and labour cost in COG is typically greater compared with the cost 
of materials. However, the proportion of indirect and direct costs is reversed, as scale 
increases. Moreover, as the scale and/or the titre increase, upstream processes tend to 
provide a smaller portion of the COG compared to downstream processes (Farid, 2009). 
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It has been suggested that the proportion of upstream over downstream cost changes 
from 55/45 to 30/70, as titre increases ten-fold (Sommerfeld & Strube, 2005). The trend 
shows that downstream processes play an important role in the economic feasibility of 
the whole process and hence significant challenges have to be addressed. Innovations 
and further improvements in the existing technologies are required to minimise the cost 
of downstream processes and by extension the overall cost of manufacturing. 
Single-use technologies (SUT) are considered an alternative in order to reduce the cost 
of manufacturing. Some advantages and disadvantages associated with SUT were 
discussed earlier in Section 1.3.2. Novais et al. (2001) developed a process economics 
model to evaluate and compare conventional (fixed) and single-use bio-manufacturing 
facilities using the net present value (NPV) as the key performance metric. The authors 
estimated the capital investment for each facility following principles discussed in 
chemical engineering textbooks (Peters & Timmerhaus, 1991) by using a method initially 
proposed by Lang (1948). Their evaluation was demonstrated through a case study 
concluding that the cost of consumables increases substantially in disposable-based 
facilities while on the other hand the capital investment reduces significantly. 
Other examples on the economic evaluation of SUT have been published using 
commercially available computer aided tools. Sinclair and Monge (2002) used a 
spreadsheet-based COG model (BioPharm Services Ltd) and discrete-event modelling 
to compare the cost-effectiveness of disposable bags over stainless steel vessels 
throughout the bio-manufacturing process. The authors considered a 2000L 
manufacturing capacity and demonstrated a reduction in capital investment of 20% and 
an increase in throughput of 7% resulting in 8% drop in COG for facilities utilising 
disposable bags over stainless steel vessels. In a following study, Sinclair and Monge 
(2005) illustrated the design of a concept bio-manufacturing multi-product facility based 
on SUT.  Their concept facility was based on a 1000L bioreactor for the production of 
material for late stage clinical trials. The authors reported a 40% decrease in capital 
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investment and a 17% drop in COG for their concept facility compared with a traditional 
facility of the same capacity. 
1.5.1. Managing risk and uncertainty in bio-manufacturing    
Most of the examples discussed above regarding the economic evaluation of bio-
manufacturing facilities used a knowledge-based and deterministic approach in the 
design of the process. However, the complex nature of biomolecules and their 
manufacturing processes introduce deviations in the behaviour of a process for different 
products and even between batches of the same product. Additional uncertainties 
regarding the regulatory approval of a new product and its commercial success, all create 
a complex environment that requires the appropriate tools to identify the optimum 
manufacturing strategy and enhance decision-making. In order to attempt to address 
these challenges and consider risks associated with manufacturing and 
commercialisation of new biopharmaceuticals, Farid et al. (2005) extended a prototype 
hierarchical decision-support tool (Farid et al., 2000) and used stochastic analysis to 
evaluate different manufacturing strategies for early stage clinical manufacturing. The 
authors initially determined critical technical and market uncertainties using one-way 
sensitivity analysis and then used Monte Carlo simulations to further evaluate their 
impact on COG and project throughput. A case study was presented to demonstrate the 
application of their prototype tool comparing different manufacturing technology options 
(stainless steel, disposable and hybrid facility configuration). 
Farid et al. (2007) identified the lack of commercially available software tools in 
bioprocessing that can integrate process design calculations with logistical activities (e.g. 
resource allocation between competing tasks) and incorporate risks associated with all 
relevant activities. The authors used a task-oriented computer-aided tool combining the 
above features through a case study comparing traditional, stainless steel with 
disposable facilities in terms of COG/g and annual project throughput. A key process 
parameter that introduces a significant variability in COG and throughput is the 
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fermentation titre (Farid et al., 2007). Subsequent studies have illustrated a mixed integer 
linear programming approach to optimise medium term (1 – 3 years) planning of bio-
manufacturing facilities considering a distribution of potential titre values through Monte 
Carlo analysis (Lakhdar et al., 2006; Lakhdar & Papageorgiou, 2008). 
The integration of stochastic simulations with multivariate data analysis and visualisation 
techniques to address technology transfer challenges was presented by Stonier et al. 
(2013). Technology transfer activities related with the scale-up of manufacturing 
processes from pilot scale to late phase clinical trials and commercial facilities are typical 
based on limited information rendering very difficult to perform properly facility fit 
assessments. Stonier et al. (2013) identified though discussions with industrial experts 
in technology transfer activities significant process parameters that are most likely to 
cause process deviations at larger scale and used triangular distributions in their Monte 
Carlo analysis to evaluate their impact on key metrics (e.g. COG and product mass loss). 
Results from these stochastic simulations were leveraged using principal component 
analysis and clustering algorithms to reduce the dimensions of the process design space 
and promote visualisation. Finally, the authors demonstrated a novel visualisation 
technique using co-ordinate plots with actual process related data rather than principal 
components scores to address facility fit issues in bio-manufacturing facilities. Yang et 
al. (2014) improved upon previous work by Stonier et al. (2013) and used a data-driven, 
discrete simulation tool and a decision tree technique to leverage the large datasets from 
Monte Carlo simulations. The authors demonstrated a case-study to investigate the 
impact of process deviations on the product mass loss and provided solutions to 
debottleneck the manufacturing process based on their decision tree analysis.    
Another prototype framework was developed by Rajapakse et al. (2005) to assist in 
decision-making in portfolio management for the development of new 
biopharmaceuticals. The authors evaluated a portfolio with three different mAbs entering 
clinical trials and estimated the portfolio’s NPV through a 20-year period comparing in-
house (early and late build) with contract manufacturing. Critical technical and 
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commercial uncertainties were identified through one-way sensitivity analysis and their 
impact was further investigated using Monte Carlo simulations. A different application of 
this prototype tool in portfolio management was demonstrated by Rajapakse et al. (2006) 
to evaluate the rewards and risks related with different portfolios. The authors integrated 
the efficient frontier approach in portfolio management initially proposed by Harry 
Markowitz (1991) with Monte Carlo analysis. The authors used NPV of each portfolio as 
the metric for reward and its standard deviation as the risk metric and demonstrated the 
functionality of their approach comparing different drug portfolios for a hypothetical 
biopharmaceutical company. 
A holistic approach was presented by George and Farid (2008) to address 
simultaneously R&D portfolio management and bio-manufacturing capacity planning 
decisions. The authors developed a framework to evaluate different portfolio strategies 
by leveraging Bayesian networks and evolutionary algorithms to search efficiently a vast 
decision space and identify optimal solutions. Their approach was demonstrated with a 
case study discussing the alternative strategies a hypothetical biopharmaceutical 
company could consider when developing a portfolio under technical and commercial 
uncertainties. Two conflicting objectives were considered in the evaluation: to maximise 
the NPV and the probability of the NPV being positive. In general terms, their holistic 
approach provided insights on various aspects that need to be considered in portfolio 
management such as which drug candidates should be included in a portfolio and their 
priority in the development sequence along with scheduling of the related development 
activities and finally the decision to include (or not) third parties into the venture (e.g. 
contract research and manufacturing organisations). 
An additional study used the same framework and evaluated the impact of portfolio size 
and cash flow restrictions on the decision space. It was indicated that cash flow 
constraints could lead to a reduction in the expected rewards or the success probability 
of a strategy. Moreover, decisions regarding scheduling and third party collaborations 
are significantly influenced by the size of a portfolio (George & Farid, 2008b). 
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The majority of the studies presented so far provide a framework that considers usually 
one or two criteria in the decision-making process thus excluding potentially important 
attributes. To address this limitation Farid et al. (2005b) developed a multi-attribute 
decision-making (MADM) approach that considers qualitative and quantitative attributes 
in the evaluation of different bio-manufacturing strategies. One type of classification of 
different MADM methods is based on the dimensions in which the attributes are 
analysed. For instance, multi-dimensional methods evaluate each attribute considering 
its actual value and are typically used for initial screening of alternatives by excluding 
those that do not meet certain criteria (Farid et al., 2005). On the other hand, methods 
that involve a single dimension are more preferred when trade-offs among attributes 
require evaluation. 
Farid et al. (2005b) recognised the simplicity to formulate and utilise the simple additive 
weighting technique (also known as weighted sum method) and extended it to introduce 
uncertainty in the weight coefficient assigned to each attribute as well as the attributes. 
Hence, instead of using constant weights for the attributes in their model, the authors 
considered a distribution of values evaluated through Monte Carlo simulations. The 
proposed probabilistic additive weighting method capturing financial and operational 
attributes was demonstrated through a case study that was initially investigated by Farid 
et al. (2005) comparing stainless steel, disposable and hybrid facilities for manufacturing 
material for late phase clinical trials. The authors evaluated a range of operational to 
financial ratios and compared the aggregated scores for each ratio among the three 
different manufacturing strategies in order to provide a better understanding between 
trade-offs and their impact in decision-making. 
The simple additive weighting technique has also been used in a decision-support 
framework to evaluate strategies for achieving bio-manufacturing capacity at 
commercial-scale (George et al., 2007). A hypothetical biopharmaceutical company with 
three drugs with different development and market characteristics was used as an 
example to illustrate the implementation of the approach. Options involving third parties 
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(contract manufacturers or other partners) and/or investment in building new commercial 
facilities were considered and uncertainties associated with each option were 
determined. The authors included financial and operational attributes and evaluated 
different options based on their average aggregated score at different operational to 
financial ratios. Hence, highlighting the importance of considering multi-criteria in 
decision-making especially in the presence of conflicting attributes under uncertainty. 
A significant number of studies discussed throughout this chapter have employed Monte 
Carlo simulations in their analysis to introduce and evaluate uncertainty. Monte Carlo is 
a numerical method that attempts to describe the function of a complex system that does 
not follow a predefined pattern but rather a stochastic (Landau & Binder, 2009). Thus, 
the method has been widely accepted and used to provide solutions to very challenging 
“problems”. Nevertheless the development of the appropriate algorithm can be 
challenging; from the selection of the correct sampling method for random numbers to 
the determination of the convergence criteria (Ballio & Guadagnini, 2004; Landau & 
Binder, 2009). 
1.5.2. Design, economic evaluation and optimisation of chromatographic 
separation of biopharmaceuticals 
Significant work has been published investigating different methods in the design and 
optimisation of the chromatographic purification train. As cell culture titres increase the 
manufacturing bottleneck tends to shift from upstream to downstream processing 
(Sommerfeld & Strube, 2005). Therefore, optimal design of the purification train requires 
the consideration of multiple criteria including product quality, productivity and cost-
effectiveness along with additional restrictions associated with product, process, facility 
and business aspects. 
Process development and optimisation of chromatography unit operations require 
numerous decisions to be made: from the selection of the appropriate chromatography 
resin type, its position in the purification train, the operating conditions and the size of 
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the column(s) to scheduling of shift patterns, monitoring and control of the operation. The 
traditional approach in decision-making relied heavily on prior knowledge and experience 
of process engineers thus lacking a systematic framework to aid design and optimisation 
often leading to sub-optimal solutions. Joseph et al. (2006) developed a model-based 
framework to assist in the systematic design of the chromatographic separation of 
biopharmaceuticals. The authors evaluated different strategies comparing 
chromatography column sizes and operating conditions assessing resin degradation, 
lifetime and compression effects on productivity, COG and facility fit restrictions. An 
example case study was presented assuming a given manufacturing process to 
demonstrate their approach using windows of operation to visualise trade-offs under 
constraints among key performance metrics for the capture step in the purification train 
utilising an affinity (recombinant Protein A) resin. 
The use of mechanistic models in an integrated process synthesis and optimisation 
framework has been presented by (Nfor et al., 2013). The authors used HTE to screen 
different chromatography resins and obtain model parameters and utilised Pareto 
frontiers to visualise the trade-offs of different optimal solutions considering purity and 
purification cost as the two decision-making attributes.   
Purification sizing strategies have also been discussed by Stonier et al. (2012). A 
decision-support tool was developed to integrate process and business aspects in 
antibody manufacturing and identify the optimum sizing strategy for the purification 
sequence. All three chromatography steps were modelled in a multi-product bio-
manufacturing facility consisting of 3 x 2000L bioreactors operated in a staggered mode 
with two downstream processing (DSP) suites. The authors evaluated the effects of 
increasing cell culture titre on the chromatographic purification train and assessed the 
robustness of the process to titre fluctuations. Pareto (or efficient) frontier graphs were 
used to visualise the set of optimal solutions provided by their database-driven, discrete-
event simulation tool to visualise the trade-offs between COG and time for different 
solutions. It was demonstrated that as titre increases from 1g/L to 10g/L the COG/g of 
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the DSP reduces by approximately 50% and it was highlighted that the affinity (Protein 
A) chromatography step was the main bottleneck in DSP with high cost of consumables 
and relative low binding capacity (Stonier et al., 2012). 
Another approach has been presented considering also the effect of different impurities 
loads of the harvested feed material on the design and optimisation of the purification 
train (Simaria et al., 2012). The proposed framework was based on previous work by 
Farid et al. (2007) and linked with a meta-heuristic optimisation approach using genetic 
algorithms to identify the optimum purification train configuration. A set of heuristics 
(rules-of-thumb) were proposed after discussions with industrial experts to rationalise the 
capabilities and restrictions of different chromatography resin types. A case study 
inspired from the biopharmaceutical industry investigated a portfolio of mAbs at different 
stages in their respective lifecycle with different product and capacity specifications. The 
overall objective of the case study was to identify the optimal upstream processing (USP) 
to DSP ratio, determine the sequence of the chromatographic purification train and the 
sizing strategy for each chromatography step to minimise the COG/g for each product in 
the portfolio (Simaria et al., 2012). 
Furthermore, it was demonstrated through a case study the ability of evolutionary 
algorithms to identify global optimal solutions even when considering conflicting 
attributes. The value and benefits of evolutionary algorithms in bioprocess optimisation 
become more apparent when evaluating very large decision spaces. Allmendinger et al. 
(2013) formulated a single-objective, multi-constrained optimisation problem using 
evolutionary algorithms performing Monte Carlo trials to account for uncertainty in cell 
culture titre. Optimisation involved only the sizing strategy of the chromatographic 
purification train considering a process economics model developed by Farid et al. 
(2007). The authors demonstrated their approach with an industrially relevant case study 
for the manufacture of a mAb at commercial scale optimising bed-height, diameter, 
number of columns in parallel and number of cycles per batch for each chromatography 
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step in the purification sequence using the COG/g as the key performance metric to 
identify the optimum sizing strategy. 
A following study improved upon previous work (by Allmendinger et al., 2013) and 
developed an evolutionary multi-objective optimisation algorithm. The authors included 
chromatography resin utilisation, impurities reduction capabilities, COG/g and its 
robustness as the four objectives in their optimisation approach. Additionally, uncertainty 
was introduced in several process parameters with emphasis in the purification 
sequence and It was highlighted the importance of including uncertainty in design and 
optimisation to avoid sub-optimal manufacturing strategies. The authors demonstrated 
their approach evaluating a bio-manufacturing process for a single mAb and compared 
their results with a typical platform purification strategy from the industry and reported a 
reduction in COG/g up to 10% (Allmendinger et al., 2014). 
An alternative to evolutionary algorithms was presented by Liu et al. (2013). A mixed-
integer nonlinear programming (MINLP) approach was developed to identify the 
optimum chromatographic purification train sizing strategy with increasing cell culture 
titres. The COG/g was used as the single objective of optimisation for a 
biopharmaceutical company manufacturing a single mAb at commercial scale. Results 
from their approach suggested that for low titres, single USP and DSP trains with a single 
chromatography column for each step, offer the lowest COG/g values without any 
product loss. However, for higher titre values (>6g/L) it was presented that increased 
number of USP trains (bioreactors working in staggered mode) and parallel 
chromatography columns were necessary to avoid product loss and minimise COG/g 
(Liu et al., 2013). Subsequently, Liu et al. (2014) formulated a mixed-integer linear 
fractional programming (MILFP) model to optimise the chromatography sizing strategy 
along with the resin sequence and mitigate the computational cost of their MINLP 
approach. The authors followed an industrial relevant case study initially presented by 
Simaria et al. (2012) considering a single mAb instead of a portfolio of three products 
and discussed the advantages in computational speed of their MILFP approach. 
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Furthermore, Liu et al. (2015) improved upon previous work to consider more 
chromatography resin candidates in their optimisation approach along with continuous 
values for the bed-height of the chromatography columns in the purification train. 
1.6. Research scope and thesis layout 
The biopharmaceutical industry is a fast growing segment of the global pharmaceutical 
market and projections indicate the continuously increasing contribution of 
biopharmaceuticals in global sales. Nevertheless, the high level of uncertainty that 
governs the industry along with increased pressure from regulatory agencies and the 
necessity to commercialise affordable therapeutic drugs all create enormous challenges. 
The high R&D cost and time requirements combined with low success rates are driving 
the industry to develop cost-effective bio-manufacturing processes while demonstrating 
an in-depth level of product and process understanding.  
The continuously increasing annual product demands for mAbs combined with 
improvements in cell culture titres tend to shift the manufacturing bottleneck from 
upstream to downstream processing. Chromatography remains the workhorse in 
antibody purification despite the high cost and complex process development. The 
complexity in the development of chromatographic separation processes stems from the 
large number of factors that can potentially have a significant impact on the performance 
of the process mainly due to the complex nature of biomolecules. Additionally, process 
design and optimisation should evaluate the complete bio-manufacturing process 
considering both operational and financial criteria. The traditional approach in 
chromatography process development involves extensive experimentation at small and 
pilot scale to gain the required level of process understanding. Additionally, it relies 
heavily on prior knowledge and experience of process engineers. This approach usually 
requires substantial amount of feed material often leading to the postponement of 
process development activities until late-stage clinical trials where a lot of decisions have 
already been made regarding the manufacturing process. 
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Hence, in this thesis the research focus is the development of decision-support tools to 
assist in chromatography process development for the purification of therapeutic 
antibodies. Considering some of the drivers identified above, the overall aim of this 
research project is to establish a systematic methodology to rationalise and accelerate 
resin screening, selection and optimisation at early-stage process development. 
Additionally, emphasis is placed on evaluating the cost-effectiveness of a 
chromatographic purification train using high-throughput screening data in order to 
determine its commercial feasibility. 
Chapter 1 of the thesis discussed the development pathway of a new therapeutic drug, 
the associated R&D cost and the uncertainties related with R&D and commercialisation. 
Furthermore, key aspects in bio-manufacturing focusing on the chromatographic 
purification were presented and a series of different approaches in chromatography 
process development were discussed. Finally, alternative methodologies for the design 
and optimisation of chromatographic purification trains were identified. 
Chapter 2 outlines materials, equipment and computer software tools that were used 
throughout this research. Additionally, the experimental and data analysis methodologies 
are presented. The integration of the fractionation diagram approach with design of 
experiments is presented along with a decision-support tool to assist in chromatography 
resin comparison and selection procedure for a single chromatography step. A 
robustness analysis technique is presented to identify windows of operation considering 
multiple attributes under uncertainty. Chapter 2 continues with the description of a 
process economics model developed to capture technical and financial differences 
between self-packed and pre-packed chromatography columns. Finally, a decision-
support tool for the chromatographic purification train is presented to link high-throughput 
purification data with process economics modelling. 
Chapter 3 demonstrates the implementation of a novel High Throughput Process 
Development (HTPD) workflow integrating a scale-down chromatography 
75 
 
experimentation strategy with an advanced chromatogram evaluation method, 
multivariate data analysis and decision-making and robustness modelling techniques. 
This new approach enables efficient evaluation of vast amounts of data generated 
through high-throughput experimentation, achieves a fair comparison among different 
chromatography resins and identifies windows of operation that can meet quality and 
performance criteria under uncertainty. 
Chapter 4 presents a case study to investigate the economics of pre-packed 
chromatography columns in antibody purification as an alternative to self-packed 
columns. Single-Use technologies in antibody purification demonstrate significant 
benefits over conventional self-packed columns with the majority of the studies focusing 
on the operational and financial evaluation of membrane chromatography columns. On 
the other hand, there are limited published studies on the evaluation of pre-packed 
chromatography columns. Hence, a series of hypothetical scenarios are analysed to 
identify advantages and limitations of pre-packed columns from a process economics 
perspective at various stages in the drug development pathway. Stochastic simulations 
are performed to evaluate the uncertainty in process parameters and other model 
assumptions and identify their impact on key performance metrics. 
Chapter 5 demonstrates an integrated framework consolidating the HTPD workflow, the 
process economics model and the decision-support tool for the chromatographic 
purification train. The objective is to enable the evaluation of the performance of different 
resin candidates considering the implications on the complete manufacturing process. 
Chapter 6 is an overview of the current validation approach in bio-manufacturing 
discussing elements in Quality by Design relevant to the methodologies and the tools 
presented in the context of this research. Finally, Chapter 7 provides concluding remarks 
from the whole research, outlines the overall benefits of the proposed methods and tools, 
discusses their current limitations and offers recommendations regarding future work. 
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Chapter 2. Materials and methods 
2.1. Materials, laboratory equipment and software tools 
All chemical reagents used to prepare chromatography buffers were provided by J.T. 
Baker (Avantor Performance Materials Inc., Pennsylvania, U.S.A). All weight 
measurements were performed using a BP 3100 S balance (Sartorius, Surrey, UK) while 
pH and conductivity were measured using a PHM220 Lab pH meter and a CDM230 
conductivity meter (Radiometer Analytical, Colorado, U.S.A), respectively. Antibody 
solutions were concentrated using a tangential flow filtration system (Pall Life Science, 
Portsmouth, UK) with a 30kDa ultrafiltration membrane (Ultracel®, Merck Millipore, 
Hertfordshire, UK). High-throughput experimentation was performed using an automated 
liquid handling system, Freedom EVO® 200 (Tecan, Mannedorf, Switzerland). Small-
scale experiments were conducted using an AKTATM Avant 25 chromatography system 
(GE Healthcare Life Sciences, Uppsala, Sweden). 
Samples, throughout the experimental work, were collected in 2mL Masterblock® 96 
deep well plates (Greiner Bio-One, Stonehouse, UK) and total protein concentration was 
measured using an Xpose™ UV/VIS spectrophotometer at a wavelength of 280nm 
(Trinean, Ghent, Belgium). The Xpose™ system was operated manually analysing 16 
samples at a time. Sample composition in terms of aggregates, product and fragments 
was determined using an Acquity UPLCTM system (Waters, Milford, Massachusetts) with 
a size exclusion chromatography column (BEH200 with 200A, D=4.6mm, L=150mm and 
1.7μm bead size). The Acquity UPLCTM system can analyse eight 96-deep well plates 
without any intervention, with a sample volume of 5μL and a flowrate of 0.4mL/min. Feed 
antibody solution samples were analysed prior to the analysis of the experimentation 
samples to determine the initial composition of the mixture. 
The automated liquid handing system was programmed, operated and monitored using 
the corresponding software package (Freedom EVOware®, Tecan Group Ltd., 
Mannedorf, Switzerland). Additional software tools that were used in data handling, 
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manipulation and analysis throughout the research involve: MS Excel 2010 (Microsoft) 
including the SOLVER optimisation tool and the data analysis tool-pack add-ins along 
with @RISK 6.5 (Palisade Corporation, West Drayton, UK). The SOLVER optimisation 
tool add-in offers three optimisation engines: a Simplex LP engine for linear problems, a 
GRG Nonlinear engine for non-linear and smooth problems and an Evolutionary engine 
for non-linear and non-smooth problems. Additionally, Visual Basic for Applications 
(VBA) was used to automate and accelerate different analytical procedures. Finally, JMP 
Pro 11 (SAS Institute Inc., Marlow, UK) was used for the design and analysis of the 
experiments. 
2.2. Experimental and data analysis methodology 
2.2.1. Design of experiments 
Screening experimentation was based on definitive screening designs while for the 
optimisation purposes central composite designs were used. Central composite designs 
have been widely employed in optimisation of chromatography systems (Ferreira et al., 
2007; Hibbert, 2012; Kumar et al., 2013). On the other hand, definitive screening designs 
were introduced in 2011 (Jones & Nachtsheim, 2011) and yet have limited published 
examples in bioprocessing. Jones and Nachtsheim (2011) identified limitations of 
resolution III and IV fractional factorial designs used for early-stage screening 
experimentation and proposed a new class of screening designs known as definitive 
screening designs. 
The proposed new class of screening designs estimates main effects completely 
independent of two-factor interactions. Moreover, the evaluation of each factor at three 
levels offers the ability to estimate quadratic effects orthogonal to main effects and not 
completely confounded with second order interactions. Tai et al. (2015) implemented a 
hybrid approach combining HTE using an ambr250™ system with a 10-factor definitive 
screening design for the characterisation of fermentation processes for therapeutic 
proteins. According to Jones and Nachtsheim (2011) a definitive screening design with 
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10 factors results in 21 experimental runs. Tai et al. (2015) augmented that DoE space 
with 3 additional control runs at the centre point and reported the ability of their model to 
capture efficiently main and quadratic effects along with higher order interactions. 
The construction and the evaluation of the DoE space were performed in JMP Pro 11 
which offers a definitive screening design platform. Insights gained through screening 
experimentation were leveraged to develop the DoE space for the subsequent 
optimisation study. The resin comparison and selection methodology described in 
Section 2.2.3.3., determines the set-point of process parameters for each resin to meet 
quality and performance targets. These set-point values were used as the mid-values 
when designing the optimisation experiments. 
Having completed the experimental runs the DoE responses were estimated in MS Excel 
and imported into JMP to enable the initiation of the DoE analysis. Using the Model Fit 
platform in JMP, a stepwise regression fitting approach was followed considering all 
possible main and quadratic effects and second order interactions. The stepwise 
regression platform in JMP can be tailored to follow a similar methodology to that 
demonstrated by Kumar et al. (2013) to identify the appropriate empirical model avoiding 
under- or over-fitting issues using a series of standard statistical criteria (e.g. Akaike 
information criterion (AIC), Bayesian information criterion (BIC), R2, adjusted R2 and p-
value threshold (<0.05)). 
2.2.2. Experimental set-up 
For the estimation of the DBC10%, the flow-through volume was fractionated into fractions 
of equal volume (200μL) and collected in 96-deep well plates for further analysis to 
determine the protein concentration in each fraction. To evaluate selectivity and 
recovery, the elution pool was fractionated and each fraction (200μL) was analysed to 
determine its total protein concentration and purity. Several steps were involved in the 
experimental set-up to investigate the dynamic binding capacity as well as the capability 
for purification and recovery. 
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The process cycle started with equilibration of the chromatography resins at the 
appropriate pH and conductivity conditions. Then to evaluate the binding capacity, each 
resin was challenged at a high load mass. For the stepwise elution experiments, 
equilibration was followed by loading of the product to a specific load challenge 
expressed as a fraction of the maximum DBC10%. Product and impurities were eluted 
with increasing conductivity of the mobile phase, followed by a high pH – high 
conductivity step to clean and sanitise the chromatography resins. The same protocols 
were used for the purposes of subsequent steps in the HTPD workflow, to optimise the 
process parameters for the selected chromatography resin as well as for the model 
verification experiments at bench-scale. The only differences in the protocols were the 
volume of the fractions that was collected (300μL and 1.7mL) and the volume of the 
chromatography column (600μL and 4mL) for the optimisation and model verification 
studies at bench-scale, respectively. 
2.2.3. Data analysis methodology 
2.2.3.1. Dynamic Binding Capacity at 10% breakthrough  
The DBC10% was estimated using Eq.2.1 (Carta and Jungbauer, 2010), where V10% is the 
cumulative flow-through volume (L) at 10% breakthrough, CFeed is the protein 
concentration of the feed material (g/L) and Vcolumn is the volume of the column (L). 
DBC10% was calculated at every set of operating conditions as dictated by the DoE for 
screening and optimisation. 
DBC10%  (g L)⁄ =
V10% ∗ CFeed
Vcolumn
                                       (Eq. 2.1) 
2.2.3.2. Integration of fractionation diagram approach and design of experiments  
The execution of the experimental plan for every resin combined with the fractionation of 
the elution pool generated thousands of samples and hundreds of different 
chromatograms, posing a significant challenge in terms of sample and data analysis. To 
overcome the data analysis difficulties, the fractionation diagram approach was used to 
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rapidly analyse the resulted chromatograms (Ngiam et al., 2001 & 2003; Salisbury et at., 
2006).  
The fractionation diagram approach offers a quantitative relationship between 
purification and recovery. Any changes to the operating conditions such as pH or linear 
velocity can potentially lead to a shift to the relative position of the peaks of the product 
and its impurities in a chromatogram and hence to a different purification-recovery trade-
off. It is worth highlighting that the Y axis (Eq.2.2) in the fractionation diagram expresses 
the amount of product (MP) collected over the total amount of product eluted, while the 
X axis (Eq.2.3) displays the cumulative mass fraction of the total material (MT) eluted. In 
Eq.2.2 and Eq.2.3, “F” represents the total number of fractions, “f” is the fraction index 
(e.g. the third fraction) and “n” is the number of fractions collected in the elution pool. 
Therefore, any product loss during binding and wash steps in a typical chromatography 
cycle operating in bind-and-elute mode is ignored. Additionally, under strong binding 
conditions it is possible not to be able to recover the entire product during the elution 
step in a cycle. This issue becomes more apparent when the fractionation diagram 
method is used to screen a wide range of process parameters. 
Y =
∑ MP,f
f+n
f
∑ MP,f
F
f=1
       ∀ n ∈ ℕ, n ≤ F − 1                        (Eq. 2.2) 
 X =
∑ MT,f
f+n
f
∑ MT,f
F
f=1
       ∀ n ∈ ℕ, n ≤ F − 1                        (Eq. 2.3) 
Hence, the distance between two points on the Y axis on the fractionation diagram (Yf+n 
– Yf) in this context represents YieldElution instead of yield (Figure 2.1d). YieldElution 
changes from 0% to 100% regardless of the operating conditions thus ignoring any 
product loss. Yield can be estimated simply as the ratio of total amount of material 
collected in the elution pool over the total amount of material that was loaded onto the 
chromatography resin (Eq.2.4). To estimate yield, the total amount of material loaded is 
calculated as the product of DBC10% and the volume of the chromatography column. The 
81 
 
amount of product collected in the elution pool is estimated by multiplying the desired 
level of YieldElution with the total amount of product eluted (∑ MP,f
F
f=1 ). At a certain value 
of YieldElution there is a maximum purification factor, thus a maximum purity value (Figure 
2.1e). Purity is estimated as the product of the purification factor and the initial feed purity 
(Figure 2.1f). 
Yield (%) =
YieldElution ∗ ∑ MP,f
F
f=1
DBC10% ∗ Vcolumn
                                    (Eq. 2.4) 
 
Figure 2.1: Schematic illustration of the Fractionation Diagram methodology. a) 
Typical chromatogram of a complete chromatography cycle, b) Elution part of a 
chromatogram, c) Fractionated elution chromatogram, d) Fractionation diagram 
plotting the cumulative product fraction against the cumulative fraction of the total 
protein, e) maximum purification factor against elution yield graph, f) purity 
against elution yield graph, g) purity against yield graph, h) schematic illustration 
of the DoE – Fractionation Diagram approach integration. Steps a) through f) 
presented as described by Ngiam et al. (2001) and steps g) & h) show the extension 
to the method as proposed here to account for potential product loss and integrate 
the method with DoE 
In cases where there is no product loss (∑ MP,f
F
f=1 = MP,IN = DBC10% ∗ Vcolumn) yield 
would be equal to the YieldElution. The final step in the approach plots purity against yield 
(Figure 2.1g). Additionally, every purity-yield pair corresponds to a set of Yf+n – Yf and 
Xf+n – Xf values that define the cut-points on the respective chromatogram and thus 
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determine the volume of the elution pool that delivers that purity-yield pair. The difference 
with the method initially proposed by Ngiam et al. (2001) is that using the current 
terminology the final graph would be purity against YieldElution (Figure 2.1f) thus potentially 
overestimating the recovery capabilities of a resin at a certain set of operating conditions. 
Using the Purity versus Yield graph (Figure 2.1g) as discussed here, a series of purity-
yield pairs can be selected as dictated by the DoE space thus integrating the fractionation 
diagram approach with DoE (Figure 2.1h). Figure 2.1 shows a simplified example of the 
integration of the fractionation diagram approach with a two factor, two level DoE. The 
steps a) to f) in Figure 2.1 illustrate the fractionation diagram approach as described by 
Ngiam et al. (2001) while steps g) and h) visualise the integration of purity-yield pairs 
with DoE using the YieldElution term as an additional factor in the DoE. 
The integration of the fractionation diagram approach with DoE requires meticulous 
calculations to estimate the DoE responses (e.g. purity and yield). Considering also the 
large number of chromatograms resulted from a resin screening study the raw data 
manipulation becomes extremely challenging and prone to error. Nevertheless, the well-
defined mathematical structure of the fractionation diagram approach allows for the 
development of a tool to automate the analysis. Here, for the purpose of this research, 
the fractionation diagram approach was programmed in MS Excel. The GRG Nonlinear 
engine of SOLVER (optimisation tool add-in) was called through VBA to estimate the 
purification factors at different YieldElution values (0 – 100%). Furthermore, a procedure 
was written in VBA to automate the analysis of multiple chromatograms and for multiple 
resins.     
2.2.3.3. A decision-support tool for resin comparison and selection for a single 
chromatography step 
Statistical analysis of the DoE space for each resin candidate develops a regression 
model that describes each attribute (or DoE response) as a function of the process 
parameters (or DoE factors). Apart from screening for significant process parameters, 
the purpose of screening different chromatography resins is also to compare them and 
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identify those with the greatest performance. To standardise and automate the resin 
comparison and selection procedure a decision-support tool was developed in MS Excel 
using the SOLVER optimisation tool add-in with the evolutionary engine activated. Given 
the non-linear and non-smooth structure of the resin selection tool the only feasible 
option is the evolutionary engine. The evolutionary engine receives variable inputs and 
searches different combinations of them to achieve the objective function while satisfying 
a set of constraints. A short script was written in VBA calling SOLVER to accelerate the 
resin comparison and selection process. A generalised schematic of the structure of the 
resin selection decision-support tool is presented in Figure 2.2a. 
A record of resin candidates included in the study is created. The resin selection tool 
identifies each resin using an index (i) assigned to it in order to recognise its associated 
fixed and variable parameters. The mean value (μ) of the DoE factors investigated in the 
screening study are used as the variable inputs in the tool. Fixed inputs include the limits 
of the DoE factors and the regression coefficients of model parameters describing DoE 
responses. Additional assumptions required for the calculation of key metrics included in 
the resin selection tool are considered as fixed inputs. For instance, to calculate 
productivity it is necessary to estimate the processing time thus assuming a column bed-
height and the number of column volumes for each step in a chromatography cycle. 
Furthermore, threshold values are assigned for the decision attributes (e.g. purity and 
yield) included in the resin selection tool along with their respective weight coefficient. 
The weight coefficient of each attribute defines its relative importance among the other 
attributes and therefore, dictates its priority order in the tool. It should be noted that the 
user has the flexibility to define any metric as a decision attribute and determine its 
relative importance and its threshold value. Therefore, the resin selection tool is not 
restricted in using fixed decision attributes but provides the framework to the user to 
introduce its own metrics depending on the purification problem. 
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Figure 2.2: Schematic illustration of the decision-making components of the HTPD 
workflow. a) Structure of the resin selection tool used to screen different resin 
candidates and determine the best candidate, b) Robustness analysis 
methodology to identify a window of operation under uncertainty 
The resin selection tool operates in two steps. The first step identifies decision attributes 
(e.g. yield, purity) and their relative significance and prioritises them in descending order. 
Thus the most important attribute is evaluated first while the least significant attribute is 
considered last. The evolutionary engine in SOLVER is searching for the set-point of 
process parameters (variable inputs) to achieve the threshold value for the first decision 
attribute. Once this is achieved the search continues with the second decision attribute 
while still satisfying the previous attribute. The procedure continues for all decision 
attributes included in the analysis with the last attribute requiring the satisfaction of all 
previous attributes. This approach of satisfying criteria also known as satisficing can 
potentially exclude resin candidates that meet a significant number of criteria but 
however failed to reach an important decision criterion that was ranked high in the priority 
order. Hence, it is crucial that the appropriate weight coefficients are assigned to the 
decision attributes in order to capture specific requirements from the resin candidates 
and avoid selecting resins that meet less significant attributes. 
The evolutionary engine runs with the objective to maximise the number of decision 
attributes achieved in their respective priority order for each resin candidate while 
managing to meet the constraints. A set of constraints for each resin candidate in the 
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resin selection tool include the limits within process parameters (variable inputs) are 
allowed to vary. The lower and upper limits of variable inputs are dictated by the DoE 
and considered as fixed inputs. The role of the constraints is to ensure that variable 
inputs fall within the acceptable range and set the threshold value for each decision 
attribute. 
A number of resin candidates could potentially achieve all decision attributes due to 
either relatively low threshold values or their adequate performance. Additionally, resin 
selection would be difficult when resin candidates perform very similarly. To address 
these issues a second step in the resin selection tool is used to assign a score to each 
resin candidate that successfully meets all decision attributes. A performance score is 
estimated for each successful resin candidate using the weighted sum method 
combining all the attributes used in the first step of the tool. In Eq.2.5, wj is the weight 
coefficient of each attribute (j), “J” is the total number of attributes and Ki,j is the 
normalised value of attribute (j) for resin (i). In case an attribute needs to be maximised 
in Eq.2.5.1 the worst and best normalised values correspond to the minimum and 
maximum values of the attribute, respectively. On the other hand, in case an attribute 
needs to be minimised, worst and best refer to the maximum and minimum value, 
respectively. The term ki,j in Eq.2.5.1 represents the actual value achieved of attribute (j) 
for resin (i). Finally the sum of the weight coefficients should be equal to the unit.  
Performance Scorei = ∑ wj ∗ Ki,j
J
j=1
                                        (Eq. 2.5) 
where: 
Ki,j =
ki,j − ki,j worst
ki,j best − ki,j worst
                                             (Eq. 2.5.1) 
∑ wj
J
j=1
= 1                                                        (Eq. 2.5.2) 
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The final decision regarding the selection of the most suitable resin candidate(s) is 
performed by identifying the candidate that reached the highest number of decision 
attributes and achieved the maximum performance score, in this order. Hence, the 
comparison based on the performance score is only taking place when more than one 
resin candidates achieve the same maximum number of decision criteria. 
2.2.3.4. Window of operation and robustness analysis 
The resin selection tool suggests the most suitable resin candidate(s) and also provides 
the set-point values for the process parameters included in the regression model that 
describes the factors-response relationship. These set-point values were used as the 
centre point in the subsequent central composite designs to optimise process 
parameters and identify a window of operation. Response surface analysis of the DoE 
space as constructed by the central composite designs promoted the development of set 
of MLR equations that describe the relationship between factors and responses. The 
appropriate MLR model for each response is identified using the stepwise regression 
approach through the Model Fit platform in JMP with a minimum BIC model selection 
criterion, backward elimination and a p-value threshold of 0.05. 
To identify a window of operation that satisfies a number of quality and performance 
attributes a stochastic simulations engine was built in MS Excel (Figure 2.2b). Each 
process parameter was expressed using a triangular distribution defined by its mode, 
minimum and maximum values representing the set-point and its limits. The resulting 
probabilistic process parameters were then used to estimate each DoE response (e.g. 
purity, yield) using the MLR correlations developed through the optimisation study for the 
selected resin candidate. A series of Monte Carlo simulations were performed by varying 
the set-point and its deviation for each process parameter and deriving distributions for 
each DoE response. 
An optimisation was set up to determine the optimal set-point and range that minimised 
the objective function. This was achieved using the evolutionary engine provided by the 
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SOLVER optimisation tool add-in in MS Excel. It should be noted that although the 
smoothness of the problem allows for the use of the GRG Nonlinear engine in SOLVER, 
the evolutionary engine was much faster and easier to tune for the given optimisation 
problem. SOLVER was set to receive the set-point and its deviation for each process 
parameter (DoE factors) as decision variables. The objective function was defined as 
minimisation of the probability of process failure. In this context process failure was 
considered the probability of failing to meet the threshold value for any of the quality and 
performance attributes. For instance, assuming two attributes: purity and yield the 
probability of process failure is defined as (Ross, 2009): 
P(fail) ≡ P(A ∪ B) = P(A) + P(B) − P(A ∩ B) 
where: 
P(A) =
∑ E(A)N1
N
, P(B) =
∑ E(B)N1
N
 
E(A): the event where purity fails to meet the threshold purity value 
E(B): the event where yield fails to meet the threshold yield value 
P(A): the probability of failing to meet the threshold purity value 
P(B): the probability of failing to meet the threshold yield value 
P(A∩B): the probability of failing both purity and yield threshold values 
N: Total number of simulations (sample space) 
A potential window of operation is defined by a set-point value and an acceptable range 
for each process parameter (DoE factor) in order to minimise the probability of process 
failure. The robustness of the optimal solution as identified by SOLVER was further 
analysed by examining its associated Monte Carlo simulation dataset to determine the 
parameters with the greatest impact on each attribute and visualise its distribution using 
@RISK. 
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2.2.4. Bench-scale model verification 
To verify the predictive ability of the model, targeted experimentation within the 
suggested window of operation was performed at bench-scale using a self-packed 
chromatography column with a bed-height of 20cm and a diameter of 0.5cm. The 
sequence and configuration of the chromatography cycle was similar to that used at 
micro-scale with the only difference being the gradient elution profile. Experimentation 
related to the HTPD workflow was conducted with a stepwise gradient elution profile due 
to limitations related with the liquid handling system. On the other hand, experimentation 
at bench-scale was performed by applying a linear conductivity gradient profile so as to 
enable a more accurate determination of the conductivity range where product is 
collected in the elution pool. Experimentally achieved values (or actual values) were 
plotted against predicted values for each attribute to visualise the accuracy of the 
predictions. Additionally, statistical tests (F-test and t-test) were performed to address 
the hypothesis that actual and predicted values are all from the same distribution 
comparing the mean and standard deviation for each dataset. 
2.3. A process economics model for antibody bio-manufacturing facilities 
2.3.1. Process economics model structure 
A process economics spreadsheet model was developed in MS Excel based on previous 
work conducted at the Advanced Centre for Biochemical Engineering at University 
College London (Farid et al., 2007; Simaria et al., 2012). A schematic of the information 
flow in the process economics model is presented in Figure 2.3. 
The model receives a series of inputs form three different sources. The first source is the 
user which needs to build a scenario for evaluation by determining model parameters 
such as the annual product demand and cell culture titre. The second source is a list of 
assumptions related to the operation of different process steps and the facility. 
Additional, assumptions include process economic factors used to estimate 
manufacturing costs that are not directly captured by the model. For instance, the cost 
of equipment maintenance can be estimated based on the fixed capital investment. The 
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third and final source of inputs is a cost database with process equipment sizes and 
prices. Moreover, a list of chemical reagents and consumables (e.g. filters) is included in 
the database. The default values used in the cost database and the model assumptions 
can be found in the Appendix (Table A.1 and Table A.2). 
The user has the option to change any of the values in the list of assumptions and the 
cost database. Throughout this research a number of different assumptions were 
challenged. In order to avoid extensive user intervention into the model, VBA was used 
to automate and accelerate iterative procedures. As soon as the user has determined 
the required scenario inputs the model performs a series of mass balance and equipment 
sizing calculations across all unit operations. Individual unit operations are sized based 
on their performance and the product load that has to be processed per batch. A more 
detailed description of the model calculations is discussed in the next Section of this 
chapter (Section 2.3.2.) and process equipment sizing formulas can be found in the 
Appendix (Table A.3). 
 
Figure 2.3: Schematic of the information flow in the spreadsheet process 
economics model developed to evaluate the economics of pre-packed 
chromatography columns 
The output of the process economics model is a record containing the results regarding 
the size, the duration and the cost of each unit operation as well as a breakdown of the 
cost of goods. A level of flexibility in synthesizing the desired process sequence is offered 
focusing on the purification train. For each chromatography step (capture, intermediate 
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purification and polishing) the model offers two options: self-packed (SP) or pre-packed 
(PP) columns. 
2.3.2. Design and process economics calculations in the model 
The main objectives of the process economics model developed here is the evaluation 
of pre-packed chromatography columns as an alternative to self-packed columns and 
the integration of high-throughput purification data with process economics. Hence, a 
relative simplistic approach was followed for sizing of the unit operations in the process 
sequence. The equipment sizing calculations begin by identifying the working volume of 
the production bioreactor using the annual product demand, the cell culture titre, the total 
yield of downstream processing and the number of batches. 
The number of seed bioreactors required and their respective working volume is 
estimated based on the inoculation ratio. For the primary recovery it is assumed that a 
disc-stack centrifuge is used to harvest the cell culture broth and separate liquid from 
solid phase followed by a series of depth filters for further clarification of the supernatant. 
For the purposes of this research it is assumed that the performance of the primary 
recovery steps is satisfactory regardless of the cell culture titre and the solids load. The 
size of the centrifuge is estimated through the working volume of the bioreactor and the 
desired time window for processing that volume. The total depth filtration area is 
calculated by dividing the volume of the supernatant by the capacity of the depth filter. 
The next step in the bio-manufacturing process sequence traditionally is a 
chromatography step for which design calculations are based on the mass load the unit 
operation has to process per batch. For any given set of: number of columns in parallel, 
number of cycles per batch, bed-height and dynamic binding capacity the process 
economics model estimates the required column diameter. The available (actual) 
diameters for self-packed and pre-packed chromatography columns are stored in the 
database used in the model. Then the model identifies the actual diameter closest to the 
required diameter to process a given mass load and recalculates the number of cycles 
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to satisfy mass balance based on the actual diameter. Additionally, it might be necessary 
to tune the bed-height within an acceptable range to correct for the new number of cycles 
and diameter. The algorithm that was used to size chromatography columns, either self-
packed or pre-packed, can be visualised in Figure A.1, of the Appendix. 
Inactivation of potential enveloped viruses takes place at low pH in a stirred tank that 
receives the total eluate volume from the first chromatography step. It is common 
practice in the mAb purification field to have the low pH virus inactivation step after the 
capture chromatography step, which involves typically addition of acid after the low pH 
elution step. The required working volume of the low pH inactivation tank is estimated by 
adding the volume of the acidic and the neutralisation buffers to the total Protein A eluate 
volume. The final antibody solution is then purified by one or two sequential polishing 
chromatography steps sized by applying the same design methodology as described for 
the first chromatography step. It should be highlighted that in case a chromatography 
step was operated in flow-through mode the size of the column was estimated 
considering the loading capacity rather than the binding capacity since the impurities 
bind to the resin and the product flows through. 
The last two steps in antibody manufacture is a virus filtration step followed by the final 
concentration and formulation step. For the virus filtration step the total required 
membrane area is estimated based on the mass load per batch for the unit operation 
and the capacity of the membrane. To calculate the required total area of the 
ultrafiltration membrane the assumption is made that the product can be concentrated 
and exchange buffers in a two-step operation. This assumption holds when the required 
concentration factor and the hold-up volume of the UFDF system are low enough. When 
these assumptions fail a four-step procedure is implemented where the antibody solution 
is first concentrated to an intermediate level, then buffer exchange takes place followed 
by an over-concentration step above the desired final concentration. The final step in the 
procedure would involve the recovery of the hold-up volume of the system to retrieve any 
product left in the system and maximise yield (Rao et al., 2012). For the purpose of this 
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study the first approach is followed assuming a low hold-up volume and a maximum 
concentration factor of 10 to achieve the desired final concentration. 
The process economics model considers additionally support equipment used 
throughout the bio-manufacturing process such as stainless steel hold-tanks for the cell 
culture media, buffers and the product. For instance, a chromatography step operating 
in bind-and-elute mode typically requires five different buffer solutions for equilibration, 
wash, elution, strip and regeneration of a chromatography resin plus a hold-tank for the 
eluted product. The working volumes for all these hold-tanks can be estimated based on 
assumptions regarding the number of column volumes needed and the calculated 
chromatography column volume provided by the process economics model. 
Through mass balance and design calculations for each unit operation the volume of the 
product and all related buffers for each process step is estimated thus providing the size 
and the number of the necessary hold-tanks. The requirements for cleaning-in-place 
(CIP) buffer, water for injection (WFI) and process water (PW) are estimated assuming 
a diameter to height ratio for the hold-tanks, a CIP buffer flowrate per diameter and a 
duration for the WFI and PW rinse steps. To estimate the cost of each hold-tank the 6/10 
approach was used (Peters & Timmerhaus, 1991). 
The term COG is defined as the sum of direct and indirect costs associated with 
manufacturing.  A COG breakdown is presented in Table 2.5. Direct costs account for 
the cost of staff and materials. Materials include consumables and chemical reagents 
used for different buffers and media. The cost of the staff was estimated based on the 
utilisation of the staff resources rather than an annual-salary per staff (Farid et al., 2007). 
The annual cost of direct labour is calculated as the product of the number of operators, 
an hourly wage per operator, the number of batches and the batch time required for each 
unit operation. The cost of additional personnel for supervision, management and QCQA 
was estimated based on the direct labour cost (Farid et al., 2007; Simaria et al., 2012). 
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The total cost of labour is the sum of all costs related to the staff involved in 
manufacturing.  
The cost of chemical reagents involves the cost for WFI, PW and chemical reagents for 
buffers and media. Consumables include chromatography resins, pre-packed 
chromatography columns and filters/membranes (depth filters, virus filtration 
membranes, UFDF membranes). Other consumables include 0.45μm guard filters for 
the hold-tanks. The cost of these guard filters was estimated based on the 6/10 rule. 
Moreover, an additional cost to account for miscellaneous materials such as QCQA 
consumables and chemical reagents and personal protective equipment (PPE) is 
estimated through the direct cost of chemical reagents and consumables. 
Indirect costs include the depreciation of the fixed capital investment (FCI), the cost of 
general utilities and the cost to maintain and insure the facility as well as local taxes 
(Farid et al., 2007; Simaria et al., 2012). The FCI is estimated based on the Lang factorial 
method by multiplying the total cost of purchased equipment with a number 
corresponding to the type of the facility of interest (Eq.2.6). Novais et al. (2001) 
suggested a Lang factor of 8.13 for conventional (fixed, stainless steel equipment) bio-
manufacturing facilities. The depreciation of the FCI is calculated assuming a 10-year 
lifespan for the fixed equipment installed in the facility.  
The term general utilities is used to include the cost of monitoring and running a 
manufacturing facility. For instance, general utilities would account for HVAC systems 
used to maintain the clean status required in different rooms in the facility and is 
expressed in monetary units per square meter of the facility (Farid et al., 2007). Farid 
(2001) reported after discussion with industrial experts a value of 300 £/m2. Using the 
Chemical Engineering index for the years 2000 (CE2000 = 394.1) and 2016 (CE2016 = 
541.7) it can be estimated an updated value of approximately 400 £/m2. In order to 
calculate the cost of general utilities it is required to estimate the size of the facility. 
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George (2008) suggested a function after analysing data on different facility sizes and 
their corresponding FCI to estimate the size of a facility based on its FCI (Eq.2.7). 
Additionally, the annual cost to maintain and insure the facility and cover obligations 
regarding local taxes related to the facility is estimated based on the FCI. Indirect cost 
or overheads will also occur regardless of the operational status of the facility. In case of 
multiproduct facilities these overheads can be distributed across all products 
(nP) manufactured annually. As mentioned, the COG is the sum of direct and indirect 
cost associated with manufacturing and the value of COG/g is estimated by dividing the 
COG with the annual product demand. 
Table 2.1: A breakdown of the cost of goods for a bio-manufacturing facility 
Cost Category Sub-category Equation 
Direct Chemical Reagents f(utilisation) 
Consumables f(utilisation) 
Miscellaneous Materials 0.1 ∗ (Reagents + Consumables) 
Direct Labour f(utilisation) 
Supervisors 0.2 ∗ Direct Labour 
QCQA 1 ∗ Direct Labour 
Management 1 ∗ Direct Labour 
Indirect Depreciation 0.1 ∗ FCI 
Maintenance 0.1 ∗ FCI 
Insurance 0.01 ∗ FCI 
Local Taxes 0.02 ∗ FCI 
General Utilities 400$/m2 ∗ Facility Footprint (m2) 
COG  Direct + Indirect/pipeline 
COG/g  
COG
Annual Product Demand
 
FCI = Lang Factor ∗ ∑ (Process & Ancillary Equipment cost)
Unit
Operations
         (Eq. 2.6) 
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Facility Footprint (m2) = 0.093 ∗ 1730 ∗ (
FCI
106
)
0.9136
                    (Eq. 2.7) 
2.4. A decision-support tool for the chromatographic purification train 
2.4.1. Structure and functionality of the tool 
To provide a greater flexibility and detail in the design of the chromatographic purification 
train a decision-support tool was developed in MS Excel as an extension on the process 
economics model (Figure 2.4). The tool receives the target product profile as a user 
specified input. Additionally, the tool offers to the user several options in the design of a 
purification train. For instance, the user can specify the mode of operation and type of 
chromatography resin for each step or allow for any mode and type to be used at any 
step. A restriction that the tool sets by default is the orthogonality in resin selection, 
constraining any type of resin to be used only once in the purification train. The last input 
the tool receives is a list of chromatography resins with their respective properties and 
purification performance. That resin list acts as a library that the tool can refer to in order 
to iterate through different purification trains. 
Each resin candidate in the library is assigned an index (i) used by the tool to recognise 
it. Key information each resin candidate should provide include the dynamic binding 
capacity, yield, maximum linear velocity, resin lifespan and price as well as the ability to 
separate a product from its impurities. Moreover, essential information would be the 
position in the purification train at which a resin can provide the given performance for a 
given product. Due to the structure of the tool it is possible to evaluate the same resin 
multiple times using different values for its purification performance depending on the 
conditions. For instance, with reference to the fractionation diagram approach a number 
of purity-yield pairs can be selected and added to the resin list as alternative 
performances of the same resin. Although this approach could increase substantially the 
computational cost it offers the ability to evaluate in more detail a resin by leveraging 
experimental data. 
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Figure 2.4. A schematic illustration of the structure of a decision-support tool for 
the chromatographic purification train 
Having defined the inputs, the tool is using a brute force search algorithm written and 
executed in VBA to search among all possible resin sequences and identify those that 
meet all the specifications defined by the user. The successful purification trains are then 
recorded and compared with each other using the weighted-sum method considering 
two attributes with opposite objectives. The score function is given in Eq.2.5. The weight 
coefficients in the score function (Eq.2.5.2) are also user specified to assign the desired 
level of significance to each attribute. The tool offers the flexibility to the user to define 
the appropriate attributes to compare the performance of different purification trains. 
Additionally, metrics that are calculated and considered as restrictions in the tool include 
the yield of the purification train (Eq.2.8) along with the reduction capabilities for HCPs 
(Eq.2.9), HMW (Eq.2.10) and LMW species (Eq.2.11). In equations Eq.2.8 – 2.11, “i” 
indicates a resin in a purification train of three chromatography steps, LRV stands for the 
logarithmic reduction value and RHMW/RLMW indicate the percentage removal of 
HMW/LMW species. 
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Train Yield = ∏ Yieldi
3
i=1
≥ Target train yield                                 (Eq. 2.8) 
HCPsOUT = HCPsIN ∗ 10
− ∑ LRVi
3
i=1 ≤ HCPsTarget                             (Eq. 2.9) 
HMWOUT = HMWIN ∗ ∏(1 − RHMW)i
3
i=1
≤ HMWTarget                      (Eq. 2.10) 
LMWOUT = LMWIN ∗ ∏(1 − RLMW)i
3
i=1
≤ LMWTarget                       (Eq. 2.11) 
The overall outcome of the tool is a list of descending score order with all the purification 
trains that met the target product profile and all the user specified restrictions. Then the 
process economics model offers the option to import a subset of the successful 
purification trains and evaluate the complete manufacturing process for each of them. 
Information related to each chromatography resin in all suggested purification trains is 
received by the process economics model to adjust its assumptions and database and 
re-synthesise the process sequence in order to reflect the changes from the default 
purification train. 
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Chapter 3. High throughput process development workflow 
with advanced decision-support for antibody purification 
3.1. Introduction  
The development of a chromatographic purification process in bio-manufacturing is 
highly challenging and complex. The large number of parameters that could potentially 
have a significant impact on the chromatographic separation performance requires 
extensive experimentation and usually a substantial amount of clarified material in order 
to optimise the operating conditions (Coffman et al., 2008). An additional consideration 
especially at early-stage process development could be the number of different drug 
candidates under development along with the uncertainty around their commercialisation 
that could limit even further allocated resources and shorten the available development 
timeline. 
Due to the complex nature of mAbs and their impurities, a sequence of chromatography 
steps is typically designed and developed to achieve the desired level of product quality. 
For each step in the purification train there are several commercially available options 
regarding the selection of a chromatography resin. A crucial decision at early-stage 
process development is the selection of the appropriate chromatography resin for each 
step in the correct order in the purification train. Resin selection is a rather complex task 
considering different resins with a wide operating range and number of process 
parameters for screening. An additional complication might be that different resins can 
be operated under different conditions thus intensifying substantially laboratory activities 
for experimentation (e.g. buffer preparation). The impetus for the development of a 
systematic methodology to address the challenges involved in optimal chromatography 
resin selection was discussed by Rathore (2001). Although the concept of a rational and 
systematic resin selection was highlighted and demonstrated for an AEX 
chromatography step, there were still unresolved issues mainly around the experimental 
design. 
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High-throughput experimentation (HTE) has emerged as a powerful technique to 
accelerate process development with relatively small amounts of feedstock material 
(Chhatre & Titchener-Hooker, 2008). The integration of HTE with other methods such as 
DoE and multi-variate data analysis has led to the establishment of hybrid approaches 
in the development and optimisation of chromatographic separation processes (Susanto 
et al., 2009; Bhambure & Rathore, 2013; Traylor et al., 2014). Previous studies have 
focused mainly on individual techniques with limited examples of complete workflows 
integrating scale-down experimentation with DoE, MVDA and decision-making tools. In 
addition, a further challenge often associated with HTE is how best to leverage the large 
amounts of raw data generated and to evaluate trade-offs in the datasets to make 
decisions on optimal strategies. The work here focuses on the establishment of a high-
throughput process development (HTPD) workflow that combines a variety of different 
methods in a semi-automated manner so as to streamline screening of different cation 
exchange (CEX) chromatography resins and optimisation of process parameters under 
uncertainty. 
The overall aim of this research is to identify the appropriate combination of experimental 
approaches and decision-support techniques, in order to provide a consistent 
methodology for rapid generation and analysis of chromatographic purification data. A 
single chromatography step is investigated rather than the complete purification train in 
order to provide a detailed investigation of process parameters that could impact the 
performance of each resin candidate. The proposed HTPD workflow suggests the use 
of miniature pre-packed chromatography columns coupled on an automated liquid 
handling system, for the rapid generation of purification data. Additionally, the integration 
of DoE with the fractionation diagram method (Ngiam et al., 2001; Ngiam et al., 2003; 
Salisbury et al., 2006) was introduced to cope with the vast amounts of data generated 
through HTE. Furthermore, a combination of multivariate data analysis, multi-criteria 
decision-making and robustness analysis was established to define a potential window 
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of operation for the chromatographic purification of a highly aggregated antibody 
solution.  
The chapter is structured as follows. Section 3.2 focuses on describing the individual 
experimental, data analysis and decision-making methods used in the HTPD workflow. 
An example of implementing the HTPD workflow is demonstrated in Section 3.3 to 
facilitate resin screening and process parameter optimisation for bind-and-elute ion-
exchange chromatography used for intermediate antibody purification. 
3.2. Materials and methods 
A case study was formulated in collaboration with MedImmune to demonstrate the HTPD 
workflow, using a bispecific monoclonal antibody with high aggregate concentration post 
Protein A chromatography. The bispecific antibody was produced in Chinese hamster 
ovary (CHO) cells and cell culture material was clarified and partially purified by 
MedImmune. The cell culture broth was clarified by a series of depth filters and the 
clarified material was further processed using a Protein A chromatography column 
followed by a low pH hold to inactivate any enveloped viruses. The preparation of the 
feedstock material for the investigation of the CEX chromatography step was completed 
with the neutralisation of the low pH antibody solution. Miniature chromatography 
columns, pre-packed with 200μL and 600μL of resin (Atoll GmbH, Weingarten, Germany) 
were used in the screening study. Eight CEX resins were included: PorosTM XS and 
PorosTM HS50 (Life Technologies, California, U.S.A), Toyopearl® GigaCap S-650(S) and 
Toyopearl® GigaCap CM-650(M) (Tosoh Biosciences, Redditch UK), CaptoTM S Impact 
(GE Healthcare Life Sciences, Buckinghamshire, UK), Fractogel® EMD COO- (M) and 
Eshmuno® CPX (EMD Merck Millipore, Darmstadt, Germany) and UNOsphereTM Rapid 
S (Bio-Rad Laboratories, California, U.S.A). 
The main steps involved in the HTPD workflow are outlined in Figure 3.1. The design 
and execution cycle is the central component of the workflow that combines DoE, the 
fractionation diagram method, high-throughput experimentation and multivariate data 
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analysis. A key output of the design and execution cycle is the regression models (i.e. 
binding and elution models) which can be imported into decision-support tools for further 
evaluation. Starting with a screening study and regression models are used in the resin 
selection tool to determine the best resin candidate. On the other hand, an optimisation 
study leverages binding and elution regression models using a robustness analysis tool 
to identify a window of operation under uncertainty in process parameters. 
Experimentation is performed using miniature pre-packed chromatography columns of 
200μL and 600μL for screening and optimisation studies, respectively. 
It is essential to gather relevant information regarding the product and the process before 
proceeding into any experimental work. For instance, information on previously tested 
CEX chromatography resins, potentially significant process parameters and ranges, 
level and composition of impurities as well as properties related to the molecule under 
investigation could all provide critical insights and hence promote and improve the design 
of the experiments. After discussion with the purification process development team and 
the industrial supervisors of the project in MedImmune (Granta Park, Cambridge, UK), 
eight CEX chromatography resins (as named above) were chosen. Due to the high 
aggregate concentration (~20%) of the antibody solution post Protein A chromatography, 
the primary consideration was the identification of resin candidates that could remove a 
sufficient amount of high molecular weight (HMW) species. 
Additional information required is the mode of operation of the selected resin candidates. 
Given the high isoelectric point (>8.5) of the particular bispecific mAb, CEX 
chromatography resins were operated in bind-and-elute mode. A typical chromatography 
cycle operating in bind-and-elute mode involves six main steps: equilibration, load, wash, 
elution, strip and resin regeneration. The two steps investigated here were the load (or 
binding) step and the elution step. The operation conditions for resin equilibration and 
wash were dictated by the operating conditions for binding and elution, respectively, 
while a universal protocol was used to strip and regenerate all CEX resins. Binding and 
elution conditions were evaluated through two different sets of DoE. 
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Figure 3.1: Schematic illustration of the proposed High-Throughput Process 
Development workflow for a chromatography operation in bind-and-elute mode. 
The Design & Execution Cycle consist the central component of the workflow 
starting with the design of the DoE space. High-throughput experimentation 
follows to investigate the suggested DoE space. After sample analysis, DoE 
responses are estimated and imported into the DoE table to initiate regression 
analysis. Completion of the cycle results in regression models estimating DoE 
responses as functions of DoE factors. Finally the regression models are imported 
into the decision-making components of the workflow allowing for the screening 
and selection of the best chromatography resin candidate and optimise its 
operating conditions under uncertainty 
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3.3. Results and discussion 
3.3.1. Design of experiments 
The HTPD workflow starts with the construction of the DoE space to investigate the 
binding conditions for each CEX resin. A definitive screening design was created in JMP 
with four continuous factors (process parameters) and a single response (Table 3.1). 
The conditions of the mobile phase (pH and conductivity), the linear velocity and the 
concentration of the feed were the four factors considered in the DoE with DBC10% as 
the only response to be maximised. Linear velocity was adjusted in order to keep the 
residence time between two scales constant. At micro-scale the bed-height was 1cm and 
3cm for a 200μL and a 600μL miniature chromatography column, respectively while a 
typical bed-height at pilot- and large-scale would be around 20cm. Thus operating a 
20cm bed-height column at a linear velocity of 300cm/h would result in a residence time 
of 4min. The corresponding linear velocity at micro-scale can be estimated by keeping 
constant the residence time. For this example, using a 600μL column the linear velocity 
would be 45cm/h. 
The definitive screening design platform in JMP Pro 11 created a design of nine runs 
with four factors to screen in order to maximise the DBC10% for each CEX resin. 
Breakthrough curves resulted from the DoE runs were analysed in MS Excel to calculate 
the DBC10% at each set of operating conditions and for each CEX resin. DBC10% values 
were imported in JMP and through a stepwise regression analysis, a MLR regression 
model was developed estimating DBC10% as a function of the DoE factors and for each 
CEX resin. Each model demonstrated an R2 and adjusted R2 value above 80% and a p-
value less than 0.05 through analysis of variance (ANOVA) indicating that variability of 
the response from its mean value is not due to chance. 
A set of operating conditions that seemed to favour every CEX resin was identified in 
order to simplify subsequent experimentation to evaluate the elution operating 
conditions. Three process parameters were selected as the DoE factors (elution pH, 
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elution linear velocity and load challenge) in the elution definitive screening design 
created to screen for maximum purity and yield for each CEX resin. The conductivity 
gradient profile of the mobile phase during elution was kept the same throughout the 
experimental runs and for all CEX resins. A stepwise elution profile over 20 column 
volumes (CVs) from 0mM to 450mM with a 50mM step of sodium chloride (NaCl) was 
applied. 
Table 3.1: Design of Experiments used in the HTPD workflow for screening and 
optimisation of CEX chromatographic separation for a bispecific antibody 
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Factors (Range) 
 Load pH 
(4.5 – 7.5) 
 Load Conductivity 
(0 – 150mM) 
 Load Linear 
Velocity 
(300 – 500cm/hr) 
 Feed Concentration 
(4 – 12g/L) 
Responses (Objective) 
 DBC10% (Maximise) 
Factors (Range) 
 Elution pH 
(5.0 – 7.0) 
 Elution Linear Velocity 
(300 – 500cm/hr) 
 Load Challenge 
(30 – 90g/L) 
 YieldElution 
(50 – 100%) 
Responses (Objective) 
 Purity (Maximise) 
 Yield (Maximise) 
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Factors (Range) 
 Load pH 
(4.5 – 5.5) 
 Load Conductivity 
(0 – 75mM) 
 Load Linear 
Velocity 
(350 – 500cm/hr) 
Responses (Objective) 
 DBC10% (Maximise) 
Factors (Range) 
 Elution pH 
(4.5 – 5.5) 
 Elution Linear Velocity 
(300 – 500cm/hr) 
 Load Challenge 
(40 – 120g/L of resin) 
 YieldElution 
(50 – 100%) 
Responses (Objective) 
 Purity (Maximise) 
 Yield (Maximise) 
 Elution Pool Volume (Minimise) 
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The term load challenge expresses the binding capacity of a CEX resin as a fraction of 
its DBC10%. Additionally, the product recovery term, YieldElution, was considered as the 
fourth factor in the elution definitive screening design as discussed in Chapter 2, Section 
2.2.3.2., in order to achieve the integration of DoE and the fractionation diagram 
approach. Hence the resulted DoE space consisted of four factors leading to nine 
experimental runs investigating two responses. Two CEX resins demonstrated the 
lowest DBC10% and therefore load challenge was not considered as a factor in their 
elution definitive screening design. The evaluation of all three DoE responses (DBC10%, 
purity and yield) was achieved using the resin selection tool. 
3.3.2. Resin comparison and selection 
The structure and the main components of the resin selection tool are illustrated in Figure 
2.2. Additionally, Table 3.2 provides a summary of its main components used in the case 
study. To initiate the comparison and selection protocol it is necessary to define the 
desired decision attributes along with their relative importance. As discussed above, due 
to the high concentration of HMW species it was crucial to identify CEX resin candidates 
that had high HMW removal capabilities (over 70%). Therefore, HMW removal (Eq.3.1) 
was selected as the first decision attribute and it was assigned the maximum factor of 
significance (significance = 1). High HMW removal may result in product loss in cases 
with poor selectivity and peak resolution; thus, a second metric was introduced to 
evaluate the purity. For the purposes of the screening study it is equally important to 
identify the best resin candidate and determine how the rest of the candidates compare. 
Therefore, instead of comparing the resin candidates using the purity of the bispecific 
antibody a different metric was introduced to capture the change in purity relative to the 
theoretical maximum improvement. Equation 3.2 describes that change in purity which 
was given a significance of 0.7. The third decision attribute considered was the step yield 
(Eq.2.4) followed by productivity (Eq.3.3) assigned a relative significance of 0.5 and 0.3, 
respectively. The determination of the factor of significance for each decision attribute 
was achieved empirically after discussions with members of the purification team at 
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MedImmune in Cambridge, UK. Using the factors of significance, the weight coefficient 
for each decision attribute can be calculated as demonstrated in the Appendix  
HMW Removal (%) = 1 − (
HMWElution pool
HMWFeed
)                                  (Eq. 3.1) 
Purity Change (%) =
PurityElution pool − PurityFeed
1 − PurityFeed
                          (Eq. 3.2) 
Productivity (g L hr⁄⁄ ) =
LC ∗ Yield
tCYC
                                          (Eq. 3.3) 
where: 
tCYC (hours) = (
LC
CFeed
+ CVEquilibration
uLoad
+
CVWash + CVElution
uElution
+
CVStrip & Regen.
uStrip & Regen.
) ∗ H 
HMWElution pool: Mass of HMW species collected in the elution pool (g) 
HMWFeed: Initial mass content of HMW species in the feed stream (g) 
tCYC: Processing time for a single chromatography cycle (hours)  
LC: Load challenge (g/L of resin) 
u: Linear velocity (cm/h) 
CV: Number of column volumes 
H: Column bed-height (cm) 
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Table 3.2: Case study formulation of the decision-making components in the HTPD workflow 
HTPD 
workflow step 
Variables Fixed Inputs Constraints Objective Outcome 
Resin 
Comparison 
& Selection 
Tool 
Set point of 
process 
parameters 
(DoE factors) 
 ML Regression 
coefficients 
 DoE factors’ limits 
 Weight of Decision 
Attributes:  
o WHMW removal = 0.4 
o WPurity change = 0.3 
o WYield = 0.2 
o WProductivity = 0.1 
 DBC10% > Load Challenge 
 Low limits < Variables < Upper 
limits 
 Attribute targets in priority order: 
1. HMW removal ≥ 70% 
2. Purity change ≥ 50% 
3. Yield ≥ 50% 
4. Productivity ≥ 25 g/L/h 
Maximum:  
Number of achieved 
Decision Attributes 
in priority order 
 Resin Ranking 
 Set-point of 
process 
parameters 
 Selected Resin 
Window of 
Operation & 
Robustness 
Analysis 
Set point & 
acceptable 
range of 
process 
parameters 
(DoE factors) 
 ML Regression 
coefficients 
 DoE factors’ limits 
 Number of Monte 
Carlo runs = 10000 
Attributes’ threshold values: 
 DBC10% ≥ 110g/L 
 Purity ≥ 91% 
 Yield ≥ 75% 
 Pool volume ≤ 5CV 
Minimum:  
Probability of 
process failure 
P(fail) 
 Window of 
Operation 
 Distribution of 
attributes 
 Sensitivity to 
process 
deviations 
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The resin selection tool receives user specifications and first it calculates the weight 
coefficient for each attribute based on their relative significance and organises 
accordingly the order that each attribute is evaluated. Then an evolutionary engine 
(SOLVER Optimisation tool, MS Excel) searches for the set-point of process parameters 
for each CEX to achieve threshold values of the decision attributes as shown in Table 
3.2. The final decision was based on the weighted sum method assigning a performance 
score (Eq.2.5) to each CEX resin based on the value it achieved for each decision 
attribute (Equations: 2.4, 3.1, 3.2 and 3.3). The CEX resin that met the maximum number 
of decision attributes and achieved the highest performance score (in that order) was 
selected as the most suitable candidate to undergo further experimentation to optimise 
its operating conditions. An illustration of the final outcome of the tool for the bispecific 
mAb case study is presented in Figure 3.2.  
Two CEX resin candidates managed to achieve all four decision criteria in their 
respective order. It should be noted that the yield requirement was dropped to a low level 
in order to allow a high HMW removal. Due to high aggregate concentration and poor 
peak resolution achieved with the 200μL chromatography columns a substantial 
reduction of HMW species was only achieved through decreased product recovery. 
Although limitations were observed regarding the use of the 200μL miniature columns 
(e.g. flowrate limitations of the robotic arm and poor peak resolution due to the small 
bed-height), they were universal for all CEX resins. Therefore, for comparability purposes 
the 200μL chromatography columns were considered sufficient providing the advantage 
of low material consumption especially when multiple CEX resins are screened. 
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Figure 3.2: A visualisation of the resin selection tool developed to identify CEX 
resins that meet the desired decision attributes. User specifications define the 
priority order of the decision attributes. Achieved attributes are determined using 
the satisficing method. Each resin candidate is assigned a performance score 
combining their respective attribute normalised values. Ranking is performed 
considering first the resin candidates with the highest number of achieved 
attributes and then their performance score. The set-point of each process 
parameter is presented in the table. CEX resin in order of appearance 1 – 8: Poros 
XS, Poros HS 50, Toyopearl GigaCap S 650 (S), Toyopearl GigaCap CM 650 (M), 
Capto S Impact, Fractogel COO (M), Eshmuno CPX and UNOsphere Rapid S. 
Regression correlations used by the resin selection tool were developed through 
DoE analysis. Experimentation was performed using 200μL miniature pre-packed 
chromatography columns operated with a Tecan Freedom EVO® 200. 
Between the two successful CEX resin candidates the performance score achieved by 
Resin-7 was approximately 85% compared to 55% achieved by Resin-1. Hence, Resin-
7 was determined as the top-ranked CEX resin that was selected to undergo further 
experimentation to optimise its operating conditions. Figure 3.2 also provides a ranking 
of all the CEX resins included in screening and the set-points of the operating 
parameters. Given the configuration of the resin selection tool for the particular bispecific 
mAb, the vast majority of the CEX resins managed to remove HMW species and increase 
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purity. However, a low level of yield was observed throughout all resin candidates that 
partially rendered them incapable of reaching the productivity target. 
3.3.4. Window of operation 
Leveraging the CEX resin screening results summarised in Figure 3.2, the subsequent 
optimisation experiments were designed for the selected Resin-7 (Table 3.1). It should 
be noted that binding conditions were optimised considering only to maximise DBC10%. 
On the other hand, the elution pool volume that was collected was introduced as the third 
DoE response after purity and yield due to its impact on productivity. A stepwise 
regression analysis identified a model to describe each of the four DoE responses as a 
function of the DoE factors. Figure 3.3 shows the prediction profilers of each DoE 
response along with a model-fit summary. 
 
Figure 3.3: Prediction profilers generated using JMP Pro 11 to visualise each 
attribute (DoE response) as a function of process parameters (DoE factors) for 
CEX Resin – 7. Solid lines represent the average response and dotted lines 
indicate the confidence interval at a 95% confidence level. DoE was executed 
using 600μL miniature pre-packed chromatography columns operated with a 
Tecan Freedom EVO® 200.  
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Instead of using the prediction profilers to identify a sweet spot, the MLR coefficients 
were linked into a stochastic simulation engine evaluating simultaneously the set-point 
and the acceptable range of each process parameter. Through a series of Monte Carlo 
simulations a window of operation was determined where the probability of failing to meet 
the threshold values of any attribute is minimised. The contour plots in Figure 3.4 
demonstrate the areas where all attributes are satisfied (white areas) operating under no 
deviations from the set-point. Additionally, black shaded circular areas present the 
window of operation considering a level of uncertainty for each process parameter. 
 
Figure 3.4: Window of operation under uncertainty for CEX Resin – 7. White (blank) 
areas demonstrate the operating space under no process deviations from the set-
point. Black areas define a window of operation that satisfies the attributes under 
uncertainty by minimising the probability of failing any of the threshold values of 
the attributes. Number of Monte Carlo simulations per iteration = 10000.  
Typically, a window of operation would focus on defining the boundaries of an operating 
space and determine its centre point as the sweet-spot due to its greatest distance from 
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the boundaries and thus potentially increasing the robustness of a process. Additionally, 
stochastic simulations could be performed on the sweet-spot once it has been identified 
to determine its robustness. Although this approach helps to define a set-point for each 
process parameter, it neglects to determine an acceptable range within which each 
process parameter is allowed to vary without compromising any quality and performance 
attributes. Moreover, iterative calculations would be necessary to assess the acceptable 
range. Additionally, when multiple parameters are investigated a series of contour plots 
would be necessary to describe a window of operation especially when parameter 
interactions have a significant impact on the attributes. Using the methodology as 
described in Section 2.2.3.4., it is possible to determine an acceptable operating range 
for each process parameter along with its set-point. Thus providing a greater 
understanding regarding the impact of process parameters on different attributes and 
hence guide subsequent experimentation at larger scales. 
Using the Monte Carlo simulations dataset that resulted in a minimum probability of 
process failure a distribution for each attribute was created and a tornado plot was drawn 
to evaluate the significance of each process parameter (Figure 3.5). The process 
parameter with the most significant impact on DBC10% was identified as the load (binding) 
pH, while all operating parameters demonstrated an impact on purity and yield. It should 
be noted that it can be expected that the linear velocity of the mobile phase during elution 
would have no effect on the volume of the elution pool as it can be seen in Figures 3.3 – 
3.5. Furthermore, the benefits of using the 600μL miniature chromatography columns 
should be highlighted as it was possible to achieve a greater peak resolution compared 
with the 200μL columns. That led to a more realistic approximation of the trade-offs 
between purity and yield.  
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Figure 3.5: Robustness analysis for CEX Resin – 7. Distribution and sensitivity of 
attributes operating with the identified window of operation under uncertainty. 
Solid bars in the tornado graphs for the sensitivity analysis indicate lower 
parameter values than the set-point and hollow bars indicate higher values. 
Number of Monte Carlo simulations = 10000. 
3.3.5. Targeted bench-scale experimentation 
The validity of the predictions made through the implementation the HTPD workflow was 
assessed by performing targeted experiments at bench-scale with a 20cm bed-height 
chromatography column packed with Resin-7. Bench-scale experimentation evaluated 
the operation at the centre of the suggested window of operation (set-point of process 
parameters) while additional runs were performed deliberately introducing deviations 
from the set-point within and outside the window of operation. 
The DBC10% was evaluated first in order to determine whether the predicted value of load 
challenge was feasible. Experimentally achieved (i.e. actual) DBC10% values were plotted 
against predicted to visualise their accuracy. It can be noted that DBC10% was 
consistently overestimated leading to a shift of the data-points in Figure 8a from the 
diagonal line to the right. In order to improve the accuracy of the predictions, the 
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predicted DBC10% was corrected to account for the collection of a column volume of 
equilibration buffer in the flow-through pool at the beginning of the loading phase and the 
hold-up mass from the application of the last column volume (Eq.3.4). Additional 
breakthrough curves were generated to address the validity of the correction made 
(Figure 3.6b). 
DBC10%
Corrected = DBC10%
Predicted − 2 ∗ CFeed                                  (Eq. 3.4)   
Linear gradient elution experiments followed to evaluate the predictive ability of the 
elution performance at bench-scale. Experimental values were plotted against predicted 
for each attribute (purity, yield and elution pool volume) as shown in Figure 3.6c – e. 
Statistical tests were performed to assess the significance of the difference between the 
means (t-Test) and the variances (F-Test) of the predicted and the actual values. The 
test results suggested a good agreement between the predicted and the experimental 
values for purity and yield and confirmed the over-prediction of the DBC10% without the 
application of the correction for the hold-up mass. Additionally, there was a statistically 
significant difference between the variances of the predicted and the actual datasets on 
elution pool volume, however within the corresponding probabilistic limits defined by its 
distribution in Figure 3.5d. In summary, implementation of the proposed HTPD workflow 
enabled the comparison of a number of CEX resins under conditions that favour each 
candidate. Two CEX resins qualified as the top-ranked candidates for this particular 
purification challenge. The CEX Resin-7 was selected based on its performance score 
for further experimentation to identify a window of operation. The results suggested a 
mean predicted purity and yield level of 93% and 76%, respectively with an elution pool 
volume of 4.0 CV. Targeted bench-scale experimentation within the predicted window of 
operation resulted in similar performance (92% purity, 74% yield and 3.9 CV) and hence 
provided a preliminary justification of the predictive ability of the model. 
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Figure 3.6: Actual vs Predicted plots and Statistical tests to visualise and verify 
the proposed window of operation for CEX Resin – 7. Actual refers to the 
experimental values obtained at bench-scale using a 20cm bed height 
chromatography column operated with an AKTA Avant 25. Predicted values were 
obtained using regression correlations developed through analysis of the DoE 
space. DoE was performed using 600μL miniature pre-packed chromatography 
columns and operated with a Tecan Freedom EVO® 200. 
Note: A 95% confidence level was used. The null hypothesis considers the two samples sets are 
from the same distribution. P-values ≤ 0.05 reject the null hypothesis. Sample size: 7 for a) and 
b) and 3 for c), d) and e). 
3.4. Conclusions 
This chapter demonstrated a hybrid approach for the development of a CEX 
chromatographic separation process to purify a high-aggregated bispecific antibody. The 
proposed workflow offers significant benefits in terms of materials’ consumption (80% 
reduction in feedstock material and 50% reduction in buffer consumption) and time 
requirements compared with bench-scale experimentation in order to achieve a similar 
level of process understanding. A key focus of the HTPD workflow was the establishment 
of a systematic framework providing the methods and the tools to cope with the large 
datasets resulting from HTE and automate a significant part of data manipulation and 
analysis. 
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A biopharmaceutical company could identify very rapidly limitations that a specific resin 
type has for a given product and re-orient development activities accordingly. For 
instance, as demonstrated here through an industrially relevant case study, a number of 
well-studied commercial CEX chromatography resins managed to remove only a portion 
of HMW species thus putting an additional burden on downstream unit operations to 
provide the desired product profile. Through the introduction of a systematic HTPD 
workflow process bottlenecks can be identified rapidly at an early stage in process 
development. Therefore, it would be possible to consider alternative options in order to 
develop a cost-effective purification process that can meet product and process 
specifications. Finally, the insights that were gained through the analysis to identify a 
window of operation and assess its robustness can be further leveraged to guide 
subsequent experimentation at larger scales. Further experimentation could focus on 
optimising process parameters that were identified as significant thus mitigating the 
experimental effort. 
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Chapter 4. A process economics evaluation of pre-packed 
chromatography columns in antibody purification 
4.1. Introduction 
Single-use technologies (SUT) have gained a significant momentum in bio-
manufacturing offering a lower capital investment and facility footprint when compared 
to conventional facilities using fixed, stainless steel process equipment. An example of 
this momentum from the industry is the introduction by GE Healthcare of modular, 
prefabricated cGMP bio-manufacturing facilities (KUBio) with a flexible production line.  
Chapter 1 (Section 1.3.2) described available SUT in bio-manufacturing and discussed 
the main advantages, limitations and challenges related to the introduction of disposable 
unit operations in the process sequence. Evidently, the decision to adopt SUT in bio-
manufacturing relies upon multiple criteria and objectives. For instance, disposable 
equipment could decrease the fixed capital investment and mitigate validation activities 
however size limitations could render infeasible their fit into a large scale facility. 
Therefore, different considerations such as the drug development stage and available 
resources as well as the desired annual throughput and the performance of each unit 
operation could potentially have conflicting effects on the final decision. 
The traditional industrial approach in manufacturing of therapeutic antibodies has 
developed a platform process usually involving three distinct and orthogonal 
chromatographic purifications steps (Kelley et al., 2009). Already published work has 
discussed the economic impact of disposable bags (Sinclair & Monge, 2002) and 
compared single-use, stainless steel (Novais et al., 2001; Sinclair & Monge, 2005) and 
hybrid bio-manufacturing facilities (Farid et al., 2005). However, there is no published 
work focusing on the economics of pre-packed chromatography columns in bio-
manufacturing. Additionally, there is a lack of commercially available computer aided 
tools flexible enough to facilitate a comprehensive investigation of pre-packed columns. 
This chapter focuses on the chromatographic purification and attempts to identify 
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benefits and limitations of pre-packed columns from a process economics point of view. 
The overall objective here is the evaluation of pre-packed chromatography columns as 
an alternative to self-packed columns in the purification of therapeutic antibodies using 
the cost of goods per gram of product (COG/g) as the key performance metric. A process 
economics model was developed emphasising on the design of the purification train to 
capture all chromatography related activities and required resources to allow for the 
detailed cost comparison of pre-packed and self-packed columns. A series of 
hypothetical scenarios were designed based on evidence from the industry and 
academia to simulate a wide decision space and address the impact of multiple 
parameters on the cost-effectiveness of pre-packed columns. The key focus of the 
scenario analysis was to determine whether the benefits and limitations of pre-packed 
columns have a significant impact on the COG/g and identify the scale of manufacturing 
where pre-packed columns are no longer a feasible or an economically attractive option.   
4.2. Materials and methods 
To facilitate the investigation of pre-packed chromatography columns a process 
economics model was developed in MS Excel as described in Chapter 2 (Section 2.3). 
A benefit of the model is offered through its structure which allows the investigation of 
individual unit operations and the whole manufacturing train. Throughout this chapter a 
generic platform manufacturing process for mAbs was used as shown in Figure 4.1. 
Three different chromatography steps were assumed in the purification train using a 
Protein A resin for the capture step, a cation exchange resin for the intermediate step 
and an anion exchange resin for the polishing step. 
Before assessing the economics of the complete manufacturing process, the first part of 
this chapter focuses on an individual chromatography unit operation in order to perform 
an in-depth comparison of the costs related to self-packed and pre-packed columns. Key 
operational differences between self-packed and pre-packed columns are the time and 
cost related for packing and unpacking activities. The number of times that a 
chromatography column needs to be packed can be estimated based on the effective 
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chromatography resin lifespan, the number of chromatography cycles per batch and the 
number of batches performed annually. Increasing packing activity would lead to a surge 
in the cost of labour and the related chemical reagents and consumables. On the other 
hand it is assumed that the corresponding packing system and the stainless steel 
chromatography column can handle the increased utilisation through proper operation 
and maintenance. Moreover, from a process economics point of view a key model 
parameter is the ratio of the price of a chromatography resin over the price of an empty 
pre-packed column. Changing from a self-packed to a pre-packed chromatography 
column of the same size would cause an increase in the cost of consumables due to the 
addition of the cost of the empty pre-packed column. 
 
Figure 4.1: A generic manufacturing process flowsheet for mAbs 
To investigate these differences a representative range of chromatography column 
diameters was selected for evaluation under different levels of facility utilisation and a 
range of resin prices (Table 4.1). Facility utilisation was estimated assuming a maximum 
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of 20 batches per year using a single production bioreactor. To automate and accelerate 
the simulation of different scenarios a procedure was programmed in VBA to assign the 
desired values to model parameters and assumptions and create a record of the cost 
breakdown for a chromatography step. Following the deterministic comparison of self-
packed and pre-packed columns using the base assumption values (Table 4.1), a 
worst/best case sensitivity analysis was performed to determine model parameters with 
the greatest impact on the cost of goods for a single chromatography column (Table 4.2).  
Table 4.1: Range of parameters used to compare the manufacturing costs between 
pre-packed and self-packed chromatography columns of the same size and 
packed with the same resin 
Parameter Range 
Diameter (cm) [5, 20, 45, 60] 
Resin Price ($/L) [500, 2000, 8000] 
Batches [1, 2, 4, 8, 12, 16, 20] 
Column type [Self-packed, Pre-packed] 
Empty Pre-packed Column Price ($/cm) 2000 
Resin Lifespan (#cycles) 25 
DBC (g/L) 50 
Number of Cycles per Batch 5 
Table 4.2: Model parameters included in the sensitivity analysis to determine their 
significance in the manufacturing costs of a single chromatography step utilising 
either a self-packed or a pre-packed column  
Parameter Worst Base Best 
DBC (g/L) 20 60 100 
Resin Price ($/L) 15000 5000 1000 
Empty Pre-packed Column Price ($/cm 
of diameter) 
3500 2000 500 
Buffer Price ($/L) 7 5 2 
Resin Lifespan (#cycles) 20 50 100 
Elution Pool Volume (#CV) 7 3 1.5 
Linear Velocity (cm/hr) 100 300 500 
Note: Using a 30cm in diameter column operated for 5 cycles per batch over 20 batches 
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Evaluation of a single chromatography step isolated from the rest of the process allows 
the direct comparison of manufacturing costs related to self-packed and pre-packed 
columns. Nevertheless, a unit operation is always part of a process flowsheet thus 
development and optimisation should consider the complete manufacturing process. 
Hence, to put into perspective the impact of pre-packed columns on the whole process 
a series of scenarios was created to simulate pre-clinical, clinical and commercial 
manufacturing of mAbs. Model parameters such as the annual product demand and cell 
culture titre for each scenario are defined in Table 4.3. In order to achieve a realistic 
approximation of the different manufacturing stages a set of assumptions was made 
based on previous published work by (Simaria et al., 2012) regarding a hypothetical mAb 
and the population to be treated at each stage. In order to estimate the annual product 
demand, average body weight for each patient of 100kg was assumed. Using Eq.4.1 and 
the assumptions in Table 4.4 the total annual demand can be approximated. For each 
manufacturing stage an overproduction factor was applied to account for additional 
material required for QCQA and process development activities. Finally, at the pre-
clinical stage a total annual demand of 0.5kg was assumed regardless of the size of the 
study in order to have enough material to be used in process development.  
Demand = Overproduction factor ∗ #Patients ∗
#Doses
patient
∗ Dosage ∗ Body weight    (Eq. 4.1) 
Table 4.3: Key model assumptions used to evaluate the cost-effectiveness of pre-
packed chromatography columns considering the complete manufacturing 
process 
Stage 
Total Demand 
(kg/year) 
Cell Culture 
Titre (g/L) 
No. of 
Batches 
Pipeline 
Pre-Clinical 0.5 2.5 1 12 
Clinical Phase I & II 5 2.5 1 9 
Clinical Phase III 20 5 2 2 
Commercial 200 5 20 1 
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Table 4.4: Annual product demand approximation for each phase in the drug 
development pathway 
 
Pre-
Clinical 
Clinical 
Phase I 
Clinical 
Phase II 
Clinical 
Phase III 
Commercial 
Success Rate 0.69 0.54 0.34 0.70 0.91 
Patients Treated - 40 150 1300 15000 
Doses/patient - 1 18 18 18 
Dosage (mg/kg) - 15 7 7 7 
Overproduction Factor - 2.5 2.5 1.25 1 
Total Demand (kg/year) 0.5 0.2 4.8 20.0 200.0 
Note: Average body weight = 100kg 
Considering the flowsheet in Figure 4.1 with three chromatography steps and given the 
two options for each step (self-packed or pre-packed column), there are eight possible 
configurations for the purification train. A procedure was written in VBA to automate the 
simulation of every scenario in Table 4.3 and for each purification train configuration. 
Additionally, using transition probabilities for each development stage as reported by 
Paul et al. (2010) the required number of drug candidates in the pipeline at each stage 
can be estimated based on the desired number of successful product launches per year. 
Therefore the influence of the biopharmaceutical pipeline size on the decision to 
introduce pre-packed chromatography columns can be evaluated. A stochastic analysis 
using the Monte Carlo approach was performed to address the robustness of the 
decision to introduce pre-packed columns at each manufacturing stage in Table 4.3. For 
each chromatography step in the purification sequence probabilistic values were drawn 
using triangular distributions with minimum, mode and maximum values as specified in 
Table 4.5. 
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Table 4.5: Key model parameters and their distributions that were included in the 
robustness analysis on the decision to introduce pre-packed columns at different 
manufacturing stages 
Step Parameter Distribution (Min., Mode, Max.) 
C
a
p
tu
re
 
DBC (g/L) Tr(35, 40, 45) 
Resin Price ($/L) Tr(9000, 12000, 15000) 
Resin Lifespan (#cycles) Tr(40, 50, 60) 
Empty Pre-packed Column Price ($/cm 
of diameter) 
Tr(1800, 2000, 2200) 
In
te
rm
e
d
ia
te
 
DBC (g/L) Tr(55, 60, 65) 
Resin Price ($/L) Tr(3000, 4000, 5000) 
Resin Lifespan (#cycles) Tr(75, 100, 125) 
Empty Pre-packed Column Price ($/cm 
of diameter) 
Tr(1800, 2000, 2200) 
P
o
li
s
h
in
g
 
DBC (g/L) Tr(85, 100, 115) 
Resin Price ($/L) Tr(2000, 3000, 4000) 
Resin Lifespan (#cycles) Tr(75, 100, 125) 
Empty Pre-packed Column Price ($/cm 
of diameter) 
Tr(1800, 2000, 2200) 
Note: Tr(a,b,c) refers to the triangular probability distribution where a, b, c are the minimum, most 
likely, and maximum values, respectively.
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4.3. Results and discussion 
Evaluation of pre-packed chromatography columns as an alternative to self-packed 
columns was performed through a series of scenarios designed to capture key process 
economics drivers. Assuming the same size of a chromatography column for both 
technologies packed with the same resin and operated under the same conditions a 
relativistic impact of pre-packed columns on manufacturing costs is demonstrated in 
Table 4.6. 
Table 4.6: A qualitative comparison of the manufacturing costs associated with 
self-packed and pre-packed columns of the same size, packed with the same 
chromatography resin and operated under identical conditions 
Manufacturing Costs Self-packed Pre-packed 
Direct Costs 
Labour 1 1 
Chemical Reagents 1 1 
Packing Labour 1 0 
Packing Chemical Reagents 1 0 
Consumables 1 1(+) 
Indirect Costs 
Self-packed Column 1 0 
Chromatography Skid 1 1 
Buffer & Product Hold-tanks 1 1(-) 
Column Packing System 1 0 
The manufacturing costs in Table 4.6 refer only to the costs associated with a 
chromatography unit operation. Labour and chemical reagents account for the cost of 
operating a chromatography column including personnel, buffers for operation and 
cleaning of hold-tanks. Since the size and operating conditions are the same for both 
column technologies it is expected that the required time and volume of buffers for 
operation and therefore the volume of the hold-tanks would remain constant. However, 
any hold-tanks associated with packing and unpacking buffers would be eliminated in 
case of pre-packed columns. Additionally, the necessary chromatography skid would 
remain the same regardless of the technology of the column. On the other hand, any 
cost related to column packing would be eliminated for a pre-packed column. These 
costs include the associated personnel and chemical reagents for packing and 
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unpacking activities along with the cost for the necessary column packing system. 
Finally, in case of self-packed columns consumables would involve the cost of the 
chromatography resin and the guard filters for the hold-tanks. On the other hand, in case 
of pre-packed columns the cost of consumables would be the sum of the cost of the pre-
packed column and the guard filters for associated hold-tanks. 
The cost of consumables for a self-packed chromatography unit operation as estimated 
in the process economics model is a function of the volume of the chromatography 
column and thus a function of its diameter and bed-height. Additionally, the cost of a pre-
packed column is estimated as the sum of the cost of the chromatography resin and the 
cost of the disposable empty column. Here, the cost of the empty pre-packed column is 
calculated based on the diameter of the column using a unit price per centimetre. Due to 
the same size and operating conditions between the two column technologies the cost 
of the disposable guard filters for the hold-tanks would be constant. Hence, guard filters 
could be excluded in order to evaluate the relationship between the cost of the resin and 
the disposable empty pre-packed column. 
A graphical representation of the relationship between the cost of a chromatography 
resin and the cost of a pre-packed column is shown in Figure 4.2. As shown in Figure 
4.2 increasing resin price and diameter values lead to the dominance of the resin cost. 
At small diameters (up to 10cm) the cost of the resin varies between approximately 5% 
and 50%. For instance, a Protein A resin with a price of 12500$/L would account for 50% 
of the total cost of a pre-packed column packed with the same resin. It should be noted 
that the curves in Figure 4.2 were generated assuming a price for the empty pre-packed 
column of 2000$/cm of diameter. 
The cost breakdown in Table 4.7 might give the impression that pre-packed columns 
offer a significant reduction in manufacturing costs however, the end result would also 
be subject to the ratio between direct and indirect costs. It is expected that indirect costs 
would decrease in the case of a pre-packed column of the same size compared to a self-
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packed column. On the other hand, the answer is not straightforward for the direct costs 
since the intensity of packing activities could change the balance among different cost 
components. 
 
Figure 4.2: Cost of a chromatography resin relative to the total cost of a pre-packed 
chromatography column against the price of the resin at different column 
diameters 
Figure 4.3 shows different cost ratios for pre-packed columns over self-packed. The top-
half of Figure 4.3 plots the consumables cost ratio (i.e. consumables for pre-packed over 
self-packed column) with increasing facility utilisation and increasing column diameter. 
As shown in Figure 4.2 increasing resin price and column diameter lead to the 
dominance of the cost of the chromatography resin over the empty pre-packed column. 
Figure 4.3 confirms that relationship and demonstrates that the consumables cost ratio 
of pre-packed over self-packed decreases with increasing resin price and/or diameter. 
On the other hand, increasing facility utilisation has a moderate effect on the 
consumables cost ratio as direct costs would increase for both column technologies.  
The bottom-half of Figure 4.3 plots the cost ratios of labour, chemical reagents and 
indirect costs. These cost categories demonstrate a clear benefit from the introduction 
of pre-packed columns. Their cost ratios are throughout different levels of facility 
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utilisation and column diameters below 1, indicating that these costs are reduced for the 
pre-packed option. Furthermore, increasing diameter and/or facility utilisation above 20% 
have no further cost benefits as labour, reagents and indirect cost ratios reach a plateau 
value. 
 
Figure 4.3: Cost ratios of pre-packed over self-packed columns 
Overall, Figure 4.3 demonstrates the conflicting effect that pre-packed columns have on 
the manufacturing costs for a single chromatography step. While labour, reagents and 
indirect costs benefit from the introduction of pre-packed columns the same cannot be 
claimed for the cost of the consumables especially with small column diameters. 
To better understand how different costs vary between self-packed and pre-packed 
columns a COG/batch breakdown was plotted at different diameters and resin prices. 
Assuming full facility utilisation (20 batches), 5 chromatography cycles per batch and a 
resin lifespan of 25 cycles a self-packed chromatography column would have to be 
packed four times. Alternatively, four pre-packed columns would be needed. It should be 
noted that the process economics model generates all cost estimates on an annual 
basis. Thus, any cost per batch can be estimated by dividing the annual cost with the 
number of batches in a manufacturing campaign. The bar charts in Figure 4.4 
demonstrate the contribution of different costs in the COG/batch. 
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Figure 4.4: Chromatography cost of goods per batch breakdown for a self-packed 
and a pre-packed chromatography column at different diameters and a) resin price 
= 500$/L, b) resin price = 2000$/L, c) resin price = 8000$/L 
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As shown in Figure 4.4 the costs associated with packing and unpacking activities 
account for only a small percentage (2.5 – 6.5%) of the cost of goods. At small diameters 
indirect costs dominate the COG. At this size the introduction of pre-packed columns 
causes the greatest decrease in the COG/batch of approximately 13%. Moreover, the 
drop in the COG is consistent throughout different prices of a chromatography resin. On 
the other hand, pre-packed columns offer a 2% drop in the COG/batch using a 60cm 
diameter column. As column diameter increases the cost savings of pre-packed columns 
decrease. Nevertheless, pre-packed columns offer a reduction in the COG throughout 
different sizes and resin prices. 
A sensitivity analysis followed to determine key model parameters and assumptions that 
cause the greater deviations in the cost of goods. Figure 4.5 presents a tornado graph 
for each column type demonstrating the parameters with the greatest impact on the 
COG/batch for a single chromatography column (COGCHROM/batch) of 30cm in diameter 
operated for 5 cycles per batch over 20 batches. Three parameters show more significant 
impact: the dynamic binding capacity (DBC), the lifespan of the chromatography resin 
and its price. Additionally, these three parameters have a stronger influence on the pre-
packed option, with low DBC and resin lifespan values resulting in greater increase in 
COGCHROM/batch compared to the self-packed option. For both chromatography column 
technologies a low DBC value shows the greatest impact on the COGCHROM/batch. 
Evaluating a single chromatography step in isolation from the rest of the manufacturing 
process provided insights regarding the re-distribution of manufacturing costs caused by 
the introduction of pre-packed columns. To address the impact of the decision to 
introduce pre-packed columns throughout the purification train a generic process 
flowsheet was created to simulate the manufacture of a hypothetical mAb at pre-clinical, 
clinical and commercial stage. 
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Figure 4.5: Tornado graphs visualising key model parameters related to 
chromatography and their impact on the COGCHROM/batch for a) self-packed and b) 
pre-packed column of the same size and packed with the same resin 
As discussed in Section 4.2, given three chromatography steps and two column 
technologies there are eight possible configurations for the purification train. Figure 4.6 
shows the cost differences of all purification train configurations that involve at least one 
pre-packed column against the base case of a full self-packed train. The conflicting effect 
that pre-packed columns have on the manufacturing costs can also be observed here. 
Direct costs throughout different manufacturing stages and purification train 
configurations demonstrate an increase from the base case of a full self-packed train. 
The incorporation of a single pre-packed column for the last polishing step (train 
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configuration: SP-SP-PP) demonstrates the minimum impact on direct costs while the 
greatest impact can be observed for a purification train using only pre-packed columns 
(PP-PP-PP). The same trend is also noticeable for indirect costs, however, with the 
opposite effect. Indirect costs benefit throughout the manufacturing stages from the 
introduction of pre-packed columns with the most significant savings achieved through 
the use of a full pre-packed purification train. 
 
Figure 4.6: Changes in direct and indirect costs of a complete manufacturing 
process using different configuration of the purification train relative to a full self-
packed purification train at different manufacturing stages 
The conflict stems from the fact that pre-packed columns cause approximately the same 
level of increase in direct costs as the level of decrease in indirect costs. Therefore, the 
final offset in the COG would only be subject to the ratio between direct and indirect 
costs. Figure 4.7 plots the direct to indirect cost ratios for a full self-packed and a full pre-
packed purification train at different manufacturing stages. The full pre-packed option 
demonstrates a consistent increase of the ratio between direct and indirect costs. 
However, that increase is capable of changing the cost balance only at the pre-clinical 
stage. At this stage a full self-packed purification train would result in almost a perfect 
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balance between direct and indirect cost reaching a ratio close to 1. With the introduction 
of a full pre-packed train at this stage that ratio exceeds the unit slightly. In contrast, the 
impact on the direct/indirect ratio although present it does not change the balance at 
clinical and commercial manufacturing. It should be highlighted that different 
manufacturing stages involve different pipeline sizes and thus a different level of indirect 
costs dilution among projects. In this case study the size of the pipelines (Table 4.4) was 
estimated targeting the successful commercialisation of at least one new therapeutic 
mAb given the transition probabilities in Table 4.5.  
 
Figure 4.7: Direct over indirect cost ratios for full pre-packed and full self-packed 
purification trains across different manufacturing stages 
The changes in the total COG/g for the whole manufacturing process for different 
configurations of the purification train and across all manufacturing stages are 
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summarised in Figure 4.8. The cost-effectiveness of the process is not demonstrating a 
significant improvement from the conventional configuration of the purification train using 
only self-packed columns. The greatest cost reduction can be observed with the 
introduction of a full pre-packed purification train at clinical phase III reaching 
approximately 6%. Pre-clinical, clinical phase III and commercial manufacturing appear 
to benefit from pre-packed columns with a maximum cumulative cost reduction reaching 
just above 10%. This can be justified though the combination of Figure 4.6 and Figure 
4.7. For instance, at commercial scale direct costs are two times higher than indirect 
costs. The introduction of pre-packed columns causes approximately a 10% decrease in 
indirect costs and less than 3% increase in direct costs. Hence, an overall 3% reduction 
in the COG/g. On the other hand, at clinical phase I & II the increase in direct costs 
caused by pre-packed columns offsets a similar decrease in indirect costs leading to a 
slight increase in the COG/g by less than 2%. 
 
Figure 4.8: Changes in COG/g of a complete manufacturing process at different 
configuration of the purification train relative to a full self-packed purification train 
at different manufacturing stages 
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As discussed, considering Figure 4.8 the most cost-effective configuration of the 
purification train would be the utilisation of pre-packed columns for all chromatography 
steps at pre-clinical, clinical phase III and commercial manufacturing. In contrast, at 
clinical phase I & II the full self-packed configuration offers the lowest COG/g. A direct 
comparison between full self-packed and full pre-packed configurations across all 
manufacturing stages is shown in Figure 4.9. The COG breakdown offers an alternative 
visualisation of the re-distribution of the manufacturing costs caused by the introduction 
of pre-packed columns. Additionally, the effect of the manufacturing scale on the COG/g 
is illustrated starting with approximately 1750$/g at the pre-clinical stage and reaching 
150$/g (a 90% decrease) at commercial scale. 
To further understand the drivers behind the moderate change in the total COG/g caused 
by pre-packed columns it is necessary to determine the gravity that the chromatographic 
purification train has on the manufacturing costs. Figure 4.10 demonstrates a COG 
breakdown per unit operation across different manufacturing stages highlighting the 
contribution of each chromatography step in the total cost for a full self-packed train and 
a full pre-packed train. As expected, mainly due to its resin price, the capture step 
dominates the cost of the whole purification train and covers a significant percentage of 
the cost of the downstream processing train. In most cases the combined cost of the 
other two chromatography steps match the cost of the capture chromatography step. By 
comparing the percentage contribution of corresponding individual chromatography 
steps the impact of pre-packed columns can be quantified. For instance, at pre-clinical 
stage a small reduction in the cost contribution occurs for the intermediate and polishing 
chromatography steps with the introduction of pre-packed columns. On the other hand, 
a small increase for the capture step can be detected. This observation agrees also with 
Figure 4.8 where the option of having a self-packed capture step followed by two pre-
packed steps (SP-PP-PP) comes very close to the full pre-packed configuration. 
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Figure 4.9: Direct comparison and cost of goods breakdown of a full self-packed 
and a full pre-packed purification train across different manufacturing stages 
 
Figure 4.10: Cost of goods breakdown per unit operation across different 
manufacturing stages for a full self-packed and a full pre-packed purification train 
Note: SEED: Flasks & Seed bioreactors, BIOR: Production bioreactor, CENT: Disk-stack 
centrifuge, DEPF: Depth filtration, CAP: Capture chromatography, VI: Virus inactivation, INT: 
Intermediate chromatography, POL: Polishing chromatography, VF: Virus filtration and UFDF: 
Ultrafiltration/Diafiltration 
In order to assess the robustness of the decision regarding the selection of the most 
cost-effective configuration for the purification train at each manufacturing stage a series 
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of Monte Carlo simulations were performed. The stochastic inputs that were challenged 
in the analysis are presented in Table 4.6. The DBC, the resin lifespan and the resin 
price for each chromatography step were selected based on the observations made 
through the tornado graphs in Figure 4.4. Additionally, the unit price of an empty pre-
packed column was included in the analysis in order to leverage the effect of any 
deviations in the price ratio between the chromatography resin and the empty pre-packed 
column. The resulted distributions of the COG/g are presented in Figure 4.11 for a full 
self-packed (black coloured histograms) and a full pre-packed (grey coloured 
histograms) purification train configuration at different manufacturing stages. 
 
Figure 4.11: COG/g distributions generated through Monte Carlo simulations for a 
full self-packed (Full SP: black coloured histograms) and a full pre-packed (Full 
PP: green coloured histograms) purification train across different manufacturing 
stages 
The COG/g distributions confirm the decision made through the initial deterministic 
analysis. At pre-clinical, clinical phase III and commercial manufacturing stages 
evaluated in this case study the pre-packed option demonstrates greater cost-
effectiveness than the conventional full self-packed option, even under uncertainty on 
key parameters. Moreover, at clinical phase I & II there is a small shift to the right of the 
COG/g distribution for the case of a full pre-packed purification train relative to a full self-
packed train. 
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The deterministic and stochastic analysis performed so far demonstrate a moderate 
benefit from introducing pre-packed columns into the manufacturing process for mAbs 
from a cost of goods perspective. However, the annual product demand for a commercial 
mAb could be above the 200kg limit that was challenged here. Therefore, the cost-
effectiveness of pre-packed columns should be further evaluated at larger scales of 
manufacturing. Figure 4.12 shows a plot of the COG/g with increasing annual product 
demand up to a tone of mAb. On the horizontal axis of the plot there are tabulated five 
model parameters: the technology of the chromatography columns, the capacity of the 
production bioreactor, the number of upstream processing (USP) trains operating in 
staggered mode, the annual product demand and the number of batches performed 
annually. 
 
Figure 4.12: Cost of goods breakdown of a full self-packed and a full pre-packed 
purification train across different commercial annual product demands with 
increasing and fixed the capacity of the production bioreactor 
With a single USP train the facility can run up to 20 batches within a year, thus in order 
to keep the capacity of the production bioreactor constant throughout late clinical and 
commercial manufacturing more batches have to be performed. Hence additional USP 
trains have to be included to maintain the same batch throughput. On the other hand, 
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there is the option to increase the capacity of the production bioreactor and maintain a 
single USP train. A comparison between the two options is visualised in Figure 4.12. The 
option of multiple staggered USP trains to maintain the bioreactor capacity constant 
demonstrates higher COG/g than the alternative of increasing bioreactor capacity. 
The option of adding multiple USP trains and keep the batch throughput constant 
ensures that the size and the operation of each process step is maintained. In contrast, 
increasing the batch throughput could require bigger size of process equipment. 
Although there is a wide range of self-packed column diameters (up to 200cm) available 
in the market, the largest pre-packed column diameter that was considered in this 
research was 60cm. Recently, Repligen (Waltham, Massachusetts) commercialised the 
largest yet pre-packed column of 80cm in diameter. In case of high batch throughput 
where the required chromatography column diameter is bigger than 60cm, multiple pre-
packed columns would have to be operated in parallel. Table 4.7 summarises the size 
and the processing time for each chromatography step in the purification train using self-
packed and pre-packed columns. The size of the purification train changes with 
increasing batch throughput. For instance, at 1000kg/year and 20 batches annually the 
capture chromatography step requires 4 pre-packed columns of 60cm in diameter 
operated over 7 cycles per batch. In contrast only a single self-packed column of 140cm 
in diameter operated over 6 cycles per batch can be used to achieve the same batch 
throughput. The increased number of pre-packed columns operated in parallel requires 
the addition of multiple chromatography skids. Therefore, indirect costs would not 
necessarily decrease as it is observed with lower batch throughputs (Figure 4.6) where 
a single chromatography column of no more than 60cm can be used for each 
chromatography step. 
Overall, a full pre-packed purification train shows comparable COG/g with a full self-
packed train. The greatest cost reduction from the introduction of pre-packed columns, 
of approximately 10%, can be seen at 350kg/year with a manufacturing capacity of 2 x 
4000L operating 35 batches annually. As annual product demand increases the drop in 
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the COG/g starts to disappear. At 1000kg/year with 20 batches and 750kg/year with 75 
batches the pre-packed option breaks even with the self-packed option. Finally, the 
intensive utilisation of the DSP train that’s associated with the increased number of 
batches to maintain constant the batch throughput causes a significant increase in the 
cost of labour. That increase in the cost of labour is mainly responsible for the higher 
COG/g compared with the operation of a single USP train. At 1000kg/year with 100 
batches there is no significant difference between the pre-packed and the self-packed 
options. It should be highlighted, that in case of multiple USP trains the indirect costs 
related with the chromatographic purification train account for a small percentage of the 
total indirect costs for the whole process. Additionally, considering that direct costs are 
approximately 3 times higher than indirect costs the pre-packed option shows very 
similar COG/g with the self-packed option. 
Table 4.7: Purification train size across increasing annual product demand with 
increasing bioreactor capacity using self-packed and pre-packed (SP / PP) 
columns 
Chromatography 
Step 
Parameter 
Annual Product Demand (kg/year) 
200 350 500 750 1000 
Capture No. of Columns 1 / 1 1 / 1 1 / 2 1 / 3 1 / 4 
 No. of Cycles 6 / 6 6 / 10 6 / 7 6 / 7 6 / 7 
 Diameter (cm) 60 / 60 80 / 60 100 / 60 120 / 60 140 / 60 
 Processing (hr) 8/ 8 8 / 14 7 / 10 8 / 10 7 / 10 
Intermediate No. of Columns 1 / 1 1 / 1 1 / 1 1 / 2 1 / 3 
 No. of Cycles 7 / 7 7 / 7 5 / 9 5 / 7 6 / 6 
 Diameter (cm) 45 / 45 60 / 60 80 / 60 100 / 60 110 / 60 
 Processing (hr) 9 / 9 9 / 9 7 / 12 7 / 9 7 / 8 
Polishing No. of Columns 1 / 1 1 / 1 1 / 1 1 / 1 1 / 1 
 No. of Cycles 8 / 8 6 / 6 5 / 5 5 / 8 6 / 10 
 Diameter (cm) 30 / 30 45 / 45 60 / 60 80 / 60 80 / 60 
 Processing (hr) 9 / 9 7 / 7 5 / 5 5 / 8 6 / 11 
4.4. Conclusions 
The main objective of this chapter was to address the cost-effectiveness of pre-packed 
chromatography columns when compared to conventional self-packed columns in 
antibody purification. A series of scenarios were performed investigating 
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chromatography operations as individual units in order to provide an in depth 
understanding of the costs associated with self-packed and pre-packed columns. 
Furthermore, pre-packed chromatography columns were evaluated considering their 
impact on the complete manufacturing process. Through a scenario analysis the 
utilisation of pre-packed columns at a range of manufacturing capacities for mAbs using 
a typical platform process sequence was evaluated. The re-distribution of direct and 
indirect costs caused by pre-packed columns demonstrated a definitive influence on the 
decision regarding the selection of the most cost-effective chromatography column type. 
On the other hand, the size limitations of pre-packed chromatography columns did not 
appear to hinder their use at large scales of manufacturing. Moreover, in cases where 
both column technologies offer insignificantly different COG values the use of pre-packed 
columns could be considered due to the increased flexibility they offer especially in 
multiproduct facilities. However, the potential loss of in-house column packing know-how 
should also be weighed against the savings in time and cost due to reduced validation 
effort for packing and unpacking activities.
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Chapter 5. Integration of high-throughput purification data with 
process economics modelling and decision-support tools  
5.1. Introduction 
The challenges associated with the development of a chromatographic separation unit 
operation were discussed in Chapter 1. Additionally, the significance of rational and 
systematic chromatography resin selection was highlighted in Chapter 3. Previous 
publications have demonstrated the integration of high-throughput screening (HTS) 
purification data with optimisation algorithms to identify the optimal resin candidates for 
a single chromatography step (Nfor et al., 2011) and a two-step purification train (Liu et 
al., 2017). Other work has focused on developing combinatorial optimisation algorithms 
for 2-step and 3-step column purification trains with the goal of determining the most 
cost-effective chromatography resin sequence and column sizing strategy, using 
advanced evolutionary algorithms (Simaria et al., 2012; Allmendinger et al., 2014) and 
mathematical programming approaches (Liu et al., 2014). This chapter presents a 
framework for integrating HTS chromatography data with a process economics model 
and a decision-support tool for the purification train to optimise all the chromatography 
steps in a purification train in terms of resin sequence and column type (pre-packed or 
self-packed columns) for both clinical and commercial manufacture. 
This chapter builds on the HTPD workflow illustrated in Chapter 3 and the process 
economics model illustrated in Chapter 4. A decision-support tool was built as a “bridge” 
linking the HTPD workflow (Chapter 3) with the process economics model (Chapter 4) in 
order to promote the evaluation of different chromatography resin candidates from a 
facility perspective and investigate the impact of different purification trains on the total 
manufacturing costs. The decision-support tool for the chromatographic purification train 
was developed and linked with the process economics model. The structure and 
functionality of the tool were described in Chapter 2, Section 2.4. The main features of 
the tools are: a brute force algorithm to screen all possible purification trains for their 
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purification capabilities and a multi-attribute decision-making technique to rank 
alternatives based on multiple objectives. This tool was necessary to explore in an 
automated fashion the large decision space when considering multiple resins for multiple 
chromatography steps. 
The rest of Chapter 5 presents two case studies demonstrating the functionality of the 
proposed decision-support tool for the purification train and its integration with an HTPD 
workflow and a process economics model. The first case study focuses on the synergy 
between the process economics engine and the decision-support tool for the purification 
train. Following the scenario analysis presented in Chapter 4 for a hypothetical mAb 
multiple chromatographic purification trains are evaluated against the platform 
considering both self-packed and pre-packed columns. A second case study was 
formulated in collaboration with MedImmune to screen multiple CEX chromatography 
resins for a series of mAbs and leverage the high-throughput data through an integrated 
framework. To accommodate the screening of multiple resins for multiple mAbs certain 
modifications and improvements were implemented on the central component of the 
HTPD workflow (Design & Execution cycle, Figure 3.1). Finally, a linear mathematical 
formulation was applied in an option evaluation method to identify the optimum resin 
sequence and column type across different manufacturing stages. The integrated 
framework enabled quality and performance targets as well as productivity and financial 
objectives to be considered when weighing up different chromatography options. 
5.2. Materials and methods 
The structure of the proposed decision-support tool for the purification train was 
discussed in Chapter 2 and illustrated in Figure 2.5. Additionally Chapter 2 discussed 
the information flow of the process economics model (Figure 2.3) and the main 
components of the HTPD workflow are presented in Chapter 3 (Figure 3.1). A key 
objective of this chapter is the consolidation of the work presented and discussed in 
previous chapters of the thesis. A schematic representation of this consolidation is shown 
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in Figure 5.1. Following the steps involved in the design and execution cycle of the HTPD 
workflow a resin database can be generated containing properties for each resin 
candidate and their respective performance for a particular mAb. The resin database can 
be imported into the chromatography resin library of the decision-support tool to evaluate 
the performance of different purification trains. 
Successful purification trains that meet user specifications and quality attributes were 
ranked based on their performance using the weighted sum method (Eq.2.5). For the 
purposes of resin ranking two attributes were selected. The first attribute is the 
productivity of the chromatographic purification train (Eq.5.1). The second attribute is a 
metric that attempts to capture simultaneously the price, the binding capacity and the 
lifespan of a chromatography resin. This metric is referenced here as the resin cost per 
gram and is expressed in monetary units per gram of product that can be processed 
(Eq.5.2). The objective is to maximise productivity and minimise the resin cost per gram 
of product. 
Train Productivity (g L hr⁄⁄ ) =
∑ (DBC ∗ Yield)i
3
i=1
∑ tCYC,i
3
𝑖=1
                            (Eq. 5.1) 
Resin Cost (£ g⁄ ) = ∑ (
Resin Price
DBC ∗ Resin Lifespan
)
i
3
i=1
                              (Eq. 5.2) 
where: 
i: index of chromatography resin in a purification train with 3 steps 
tCYC: processing time for a single chromatography step (Eq.3.3) 
Properties and performance attributes for each chromatography resin of the top-ranked 
purification trains were imported into the process economics model in order to adjust 
assumptions related to each chromatography step, update the cost database with the 
new resin prices and re-synthesise the purification train to meet the operating 
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specifications for each successful train. To demonstrate the functionality of the decision-
support tool in combination with the process economics model a case study was 
designed evaluating a number of different purification trains across different 
manufacturing stages. The annual product demand, the cell culture titre, the number of 
batches performed annually and the size of the pipeline are summarised in Table 4.5. 
One of the most challenging elements of the decision-support tool for the purification 
train is the chromatography resin library. The great difficulty in creating properly a resin 
library stems from the large number of factors that could potentially offset the level of 
confidence in the correct approximation of the performance of a purification train. 
Although the biotech industry has gained significant experience in antibody purification 
that has led to the development of platform processes (Shukla et al., 2007) not all mAbs 
respond equally well to the same purification train. Moreover, chromatography steps and 
resin types might have been standardised, nevertheless there are several different resin 
choices from a number of vendors that could fit into the purification train. Additionally, 
the performance of a chromatography resin in a given position in the purification train is 
subject to the profile of the impurities delivered by the previous unit operation. For 
instance, assuming the last chromatographic polishing step has a tolerance for HMW 
species of 5% that would require the previous steps in downstream processing to deliver 
an antibody solution with less than 5% of HMW species. Such heuristics have been 
presented in the literature in order to demonstrate the implementation of different 
approaches in optimisation of antibody purification processes (Simaria et al., 2012; Liu 
et al., 2014). 
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Figure 5.1: Integrated framework in chromatography process development. 
Schematic illustration of the consolidation of a process economics model, a 
decision-support tool for the chromatographic purification train and a high-
throughput process development workflow 
A similar approach was followed here to demonstrate the synergistic functionality of the 
decision-support tool for the purification train and the process economics model (Figure 
5.1). For the purposes of the first case study a conceptual chromatography resin library 
was created assuming resin properties and performance inspired by the literature, 
application notes from different chromatography resin vendors and the industrial sponsor 
(MedImmune). The conceptual resin library for a hypothetical mAb is presented in Table 
5.1. A number of different performance characteristics were assumed for each resin 
along with its position in the purification train. A level of uncertainty was introduced 
regarding the impurities profile delivered by the primary recovery and clarification 
process. The overall aim was to identify the optimum resin sequence and column type 
for each profile of impurities across pre-clinical, clinical and commercial manufacturing. 
A critical assumption made in the process economics model is the ability of the proposed 
platform purification train to deliver the desired target product profile. The first case study 
challenges this assumption by introducing different impurities loads for the same mAb 
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and evaluating the economics of multiple purification trains that could meet the target 
product profile. The profiles of different impurities along with quality and performance 
targets for a purification train are presented in Table 5.2. 
Both attributes (productivity and resin cost) that were selected to compare the 
performance of different purification train using the weighted sum method have an impact 
on the COG. Parameters such as yield, dynamic binding capacity, processing time and 
resin price dictate the size of unit operations and the manufacturing costs. Therefore, for 
the purpose of the first case study each attribute in the score function of the decision-
support tool was considered equally important (w = 0.5). 
The first case study had as the main objective to present the integration of a decision-
support tool with a process economics model. Nevertheless, the true purpose of the 
decision-support tool is to act as a link between the HTPD workflow and the process 
economics model. Hence, a second case study was formulated to demonstrate this 
consolidation. Impurities profiles post primary recovery and clarification are shown in 
Table 5.2. Four different mAbs partially purified using Protein A chromatography 
following the process as discussed in Chapter 2 were provided by MedImmune. High-
throughput experimentation was performed as described in Chapter 2 for the 
intermediate chromatography step to screen different CEX resins. Finally, a mixed-mode 
(hydrophobic interaction and anion-exchange) resin was considered for the last 
chromatography step in the purification train. Assumptions regarding the properties and 
the performance of the capture and polishing steps for each mAb are presented in Table 
5.4. It should be highlighted that high-throughput experimentation was performed only 
for the intermediate chromatography step (CEX) while the values summarised in Table 
5.4 for the capture and polishing steps were derived after discussions with the industrial 
collaborator, MedImmune.
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Table 5.1: Conceptual chromatography resin library for a hypothetical mAb used for the purpose of demonstrating the synergistic 
functionality of a decision-support tool for the purification train and a process economics model (Case study 1) 
Resin Name Position 
Mode of 
Operation 
DBC 
(g/L) 
Yield 
Linear 
Velocity 
(cm/hr) 
Elution 
CVs 
Wash 
CVs 
Resin 
Lifespan 
(#cycles) 
HMW 
Reduction 
(%) 
LMW 
Reduction 
(%) 
HCPs 
LRV 
Price 
($/L) 
Platform Protein A 1 Bind and Elute 40 97% 350 2.5 2.0 50 15 15 3.5 12000 
Platform CEX 2 Bind and Elute 60 93% 350 4.0 2.0 100 85 90 2.5 4000 
Platform AEX 3 Flow-Through 100 97% 350 0.0 0.0 100 75 50 2.0 3000 
Protein A - 1 1 Bind and Elute 50 90% 250 3.5 2.0 50 15 15 3.5 13000 
Protein A - 2 1 Bind and Elute 40 95% 350 3.0 2.0 100 45 35 2.5 16250 
Protein A - 3 1 Bind and Elute 30 95% 350 2.5 2.0 50 25 20 2.0 11050 
CEX - 1 1 Bind and Elute 65 85% 400 4.0 2.0 100 65 55 1.1 4550 
CEX - 3 1 Bind and Elute 75 90% 500 3.5 2.0 80 50 75 1.6 2730 
MMCEX - 1 1 Bind and Elute 65 90% 300 5.0 2.0 50 20 60 2.5 5200 
MMCEX - 2 1 Bind and Elute 40 95% 450 3.5 2.0 50 80 90 2.0 6500 
CEX - 1 2 Bind and Elute 90 85% 500 3.0 2.0 100 80 75 0.5 4550 
CEX - 5 2 Bind and Elute 100 90% 350 4.0 2.0 80 75 50 2.4 4940 
CEX - 6 2 Bind and Elute 55 95% 300 3.0 2.0 100 85 80 1.2 3900 
MMAEX - 2 2 Bind and Elute 60 95% 350 4.0 2.0 60 60 50 1.7 3640 
MMAEX - 1 2 Flow-Through 80 95% 300 0.0 0.0 100 45 60 1.4 3900 
AEX - 1 2 Flow-Through 75 95% 300 0.0 0.0 150 30 90 0.2 1300 
AEX - 2 3 Flow-Through 100 95% 450 0.0 0.0 100 75 75 1.1 5200 
MMAEX - 3 3 Flow-Through 80 90% 350 0.0 0.0 100 65 80 2.3 4940 
MMAEX - 4 3 Flow-Through 100 95% 400 0.0 0.0 100 85 85 1.5 5850 
CEX - 2 3 Bind and Elute 65 90% 250 2.5 2.0 100 60 75 1.0 3770 
CEX - 4 3 Bind and Elute 70 95% 350 5.0 2.0 100 80 35 1.5 2340 
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Table 5.2: Profile of impurities delivered by the primary recovery and clarification 
process to the first chromatography step (capture) and quality and performance 
targets as received by the decision-support tool for the purification train 
 
Case study 1 Case study 2 
Light 
Lower 
Medium 
Upper 
Medium 
Heavy 
mAb 
1 
mAb 
2 
mAb 
3 
mAb 
4 
HMWIN 
(%) 
3.0 6.0 12.0 20.0 6.1 6.3 7.1 20 
LMWIN  
(%) 
1.0 2.0 5.0 7.0 0.0 0.1 0.0 0.0 
HCPsIN 
(106 
ng/mg) 
1.0 1.5 3.5 5.0 4.0 1.1 3.6 NA 
YieldTarget 
(%) 
75.0 Unconstrained 
HMWTarget 
(%) 
0.4 0.4 0.4 0.4 1.5 
LMWTarget 
(%) 
0.1 0.1 0.1 0.1 0.1 
HCPsTarget 
(ng/mg) 
100.0 100.0 100.0 100.0 NA 
wproductivity 0.5 0.0 – 1.0 
Note: YieldTarget refers to the yield of the chromatographic purification train 
Case study 1 considered alternative resins for all three chromatography steps. In 
contrast for Case study 2 it was assumed a certain resin for the capture step and the 
polishing step. This difference could have a significant impact on the ability of the certain 
decision attributes to compare efficiently different purification trains. For instance, the 
high price of a Protein A resin and its relatively low binding capacity could dominate the 
resin cost per gram (Eq.5.2). Therefore, any small deviations among different CEX resin 
prices could become undetected or even misleading in predicting the most cost-effective 
train. In order to determine if this indeed was the case in Case study 2 the weight 
coefficients were varied for 0 to 1. 
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The link between the decision-support tool for the purification train and the HTPD 
workflow was achieved through the modification of the fractionation diagram approach. 
The fractionation diagram approach as described in Chapter 2 and used in Chapter 3 
considered only HMW species as the only impurity in the antibody solution neglecting 
other product and process-related impurities. In contrast, this chapter requires the 
evaluation of host cell proteins (HCPs) and LMW species along with HMW species. 
Hence, the fractionation diagram approach had to be extended in order to account also 
for HCPs. Samples collected through high-throughput experimentation were sent for an 
in-house analysis by Medimmune to measure the concentration of HCPs using ELISA 
on a disc. HCPs concentration values were received in units of ng/ml thus for a given 
fraction volume the mass of HCPs in each fraction (f) can be calculated. Additionally, 
following the same methodology in the fractionation diagram approach, the cumulative 
mass faction of HCPs (Z) can be estimated using Eq.5.3. Finally, each pair of purity-yield 
corresponds to a concentration of HCPs in the elution pool which can be determined as 
described in chapter 2 and initially proposed by Ngiam et al. (2001). By determining the 
elution pool volume, the required fractions for collection are identified thus enabling the 
estimation of the total mass of HCPs collected in the elution pool. 
Z =
∑ MHCPs,f
f+n
f
∑ MHCPs,f
F
1
       ∀ n ∈ ℕ, n ≤ F − 1                        (Eq. 5.3) 
The design and execution cycle illustrated in Figure 3.1 was followed for mAb-1, mAb-2 
and mAb-3 shown in Table 5.2 (Case study 2) to screen eight CEX resins: PorosTM XS 
and PorosTM HS50 (Life Technologies, California U.S.A), Toyopearl® GigaCap S-650(S) 
and Toyopearl® GigaCap CM-650(M) (Tosoh Biosciences, Redditch UK), CaptoTM S 
Impact (GE Healthcare Life Sciences, Buckinghamshire UK), Fractogel® EMD COO- (M) 
and Eshmuno® CPX (EMD Millipore, Darmstadt Germany) and NuviaTM-HRS (Bio-Rad 
Laboratories, California U.S.A). On the other hand, mAb-4 is the same molecule as the 
one used to demonstrate the HTPD workflow in Chapter 3 and due to low availability of 
additional feedstock material the performance of each CEX resin was obtained from the 
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results of the screening part of the HTPD workflow in Chapter 3. As a consequence data 
on HCPs for mAb-4 are not available since HCPs were not considered in the initial 
configuration of the fractionation diagram approach. For the rest of the molecules in Case 
study 2 (mAb-1 to mAb-3) raw data manipulation was performed applying the 
modifications implemented in the fractionation diagram approach to include HCPs. 
In order to simplify and accelerate experimentation only one set of operating conditions 
was evaluated for each mAb, thus eliminating the need for the development of a DoE 
space. This approach can rapidly provide information regarding the fit of a CEX resin into 
a platform purification train, although operating under the same conditions does not 
guarantee the optimum performance for every CEX resin for a given mAb. Nevertheless, 
the implementation of the fractionation diagram approach offers the ability to identify 
several purity-yield pairs thus promoting a comprehensive evaluation of a given set of 
operating conditions (i.e. pH, linear velocity etc.). Furthermore, due to the structure of 
the chromatography resin library the same resin can be evaluated multiple times simply 
by assigning a different index value to it every time it is imported into the library under 
different conditions. 
Results from the implementation of the design and execution cycle led to the construction 
of a chromatography resin library for each mAb. The resin library that was generated for 
each mAb can be found in the Appendix (Table A.4 – A.7). Subsequently, the decision-
support tool evaluated all possible CEX resins that can be used in the intermediate step 
of the purification train and can achieve quality and performance specifications given in 
Table 5.2. Then each successful purification train was assigned a score and ranked 
against each other. Finally, properties related to each top-ranked purification train were 
imported to the process economics model to evaluate its cost-effectiveness considering 
the complete manufacturing process. 
For the purposes of the Case study 2, the 4 mAbs included in the evaluation are 
considered to have successfully passed the pre-clinical stage of the drug development 
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pathway and preparing to enter clinical trials. Therefore, the manufacturing costs were 
estimated for the clinical phase I & II, clinical phase III and commercial stage. The 
scenario inputs used for Case study 2 are summarised in Table 5.3, assuming only these 
four mAbs in the pipeline of the facility at early stage in the clinical trials and the 
commercialisation of a single mAb. 
Table 5.3: Scenario inputs in the process economics model used in Case study 2 
to demonstrate the implementation of the integrated framework 
Stage 
Total Demand 
(kg/year) 
Cell Culture 
Titre (g/L) 
No. of 
Batches 
Pipeline 
Clinical Phase I & II 5 2.5 1 4 
Clinical Phase III 20 5 2 1 
Commercial 200 5 20 1 
The overall objective here was to identify the optimum CEX resin candidate for each mAb 
to be included in the purification train across clinical and commercial manufacture and 
minimise the total COG. The flow of information in the integrated framework is presented 
in Figure 5.2. Purification data can be generated rapidly through the design and 
execution cycle of the HTPD workflow and create a database with a purification profile 
for each resin candidate. That resin database is then imported into the chromatography 
resin library of the decision-support tool for the purification train using a brute force 
algorithm to screen all possible resin sequences and creates a record with the 
purification train that have successfully met the quality and performance threshold. The 
target values for quality and performance attributes that were considered in both case 
studies and for each mAb are shown in Table 5.2 along with the impurities loads. 
All successful purification trains are ranked based on the cost of the resin sequence and 
the productivity of the train using the weighted sum method. Then the user can specify 
the number of these successful purification trains for further evaluation using the process 
economics model. For instance, it might be desirable to evaluate the top-5 or the top-10 
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from the pool of successful purification trains. The decision-support tool allows the user 
to specify the size of pool containing the top-ranked purification trains and import them 
into the process economics model. Once a purification train has been imported into the 
process economics model relevant assumptions are adjusted to simulate the 
performance of the new train and generate a COG value. 
In order to identify the optimum purification train for each mAb it is important to recognise 
the possibility that a certain train might not be the most cost-effective throughout different 
manufacturing stages. Moreover, the decision regarding the selection of the appropriate 
resin sequence should be consistent throughout all manufacturing stages in order to 
avoid introducing a different chromatography resin in the purification train at later 
development stages. Furthermore, pre-packed columns were evaluated in both case 
studies at each manufacturing stage and for every successful purification train as 
determined by the decision-support tool. Hence, in this chapter the investigation of 
different purification strategies was performed considering three main factors: the 
manufacturing stage “m”, the purification train (or resin sequence) “p” and the 
chromatography column type “c”. Additionally, the final decision was based on the 
cumulative COG achieved for each combination of manufacturing stage, resin sequence 
and chromatography column type (COGm,p,c). 
The mathematical formulation for the option evaluation method used to identify the 
optimum purification strategy for each mAb in both case studies is as follows. A binary 
variable (bm,p,c) was assigned to each COGm,p,c value since the decision to choose any 
purification strategy (m,p,c) would be either true or false. To achieve the unique selection 
of a resin sequence across all manufacturing stages an additional set of binary variables 
(Ip) was introduced along with a set of constraints to ensure the consistency of the 
selected resin sequence throughout all manufacturing stages (Eq.5.4 to Eq.5.6). Finally 
optimisation was performed in MS Excel by employing the Simplex LP engine in 
SOLVER optimisation tool add-in with the objective to minimise the sum of COG across 
all the manufacturing stages (Eq.5.7). The abbreviations MM, MP and MC indicate the 
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maximum number of manufacturing stages, alternative purification trains (resin 
sequences) and column type configurations, respectively. 
Binary Variables: b, I ∈ [0, 1] 
Constraints: 
∑ ∑ bm,p,c
MC
c=1
MP
p=1
= 1   ∀ m ∈ [1, MM]                                      (Eq. 5.4) 
∑ ∑ bm,p,c
MC
c=1
MM
m=1
= MP ∗ Ip   ∀ p ∈ [1, MP]                                  (Eq. 5.5) 
∑ Ip
MP
p=1
= 1                                                           (Eq. 5.6) 
Objective function: 
min [ ∑ ∑ ∑(bm,p,c ∗ COGm,p,c)
MC
c=1
MP
p=1
MM
m=1
]                                    (Eq. 5.7)
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Table 5.4: Key assumptions regarding the properties and the performance of platform resins for the capture and polishing chromatography 
steps for each mAb involved in Case study 2 
mAb 
Resin 
Name 
Mode of 
Operation 
Position DBC (g/L) Yield (%) 
Linear 
Velocity 
(cm/hr) 
Elution 
CVs 
Wash 
CVs 
Resin 
Lifespan 
(#cycles) 
HMW 
Reduction 
(%) 
HCPs 
LRV 
Price 
($/L) 
1 
Protein A Bind & Elute 1 40 95 300 3.5 2.0 50 10.0 3.5 10000 
MM-AEX Flow-Through 3 80 97 300 0.0 0.0 100 90.0 1.0 3200 
2 
Protein A Bind & Elute 1 40 95 300 3.2 2.0 50 10.0 3.5 10000 
MM-AEX Flow-Through 3 80 99 300 0.0 0.0 100 90.0 1.0 3200 
3 
Protein A Bind & Elute 1 40 97 300 2.5 2.0 50 10.0 3.5 10000 
MM-AEX Flow-Through 3 90 99 300 0.0 0.0 100 90.0 1.0 3200 
4 
Protein A Bind & Elute 1 30 93 300 3.0 2.0 50 10.0 NA 10000 
MM-AEX Flow-Through 3 65 95 300 0.0 0.0 100 90.0 NA 3200 
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Figure 5.2: Schematic illustration of the information flow within the integrated framework. HTPD: High-Throughput Process Development, 
MADM: Multi-Attribute Decision-Making, COG/g: Cost of goods per gram of product, BLP: Binary Linear Programming 
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5.3. Results and discussion 
The overall objective of this chapter was to further leverage the work presented in 
previous chapters. An integrated framework in chromatography process development is 
demonstrated combining high-throughput experimentation with process economics and 
decision-making analysis. A decision-support tool for the purification train was developed 
as described in Chapter 2 to link a HTPD workflow for the chromatographic purification 
of therapeutic antibodies with a process economics model for bio-manufacturing 
facilities. Initially, a case study was formulated to present the synergy between the 
process economics model and the decision-support tool. A second case study followed 
to demonstrate the implementation of the integrated framework using four mAbs 
provided by MedImmune. 
5.3.1. Case study 1: Decision-support tool and process economics model synergy 
For the purpose of Case study 1, according to the number of chromatography resins 
available for each position in the purification train (Table 5.1) there are more than 300 
possible purification trains. Figure 5.3 presents the number of successful purification 
trains across different impurities profiles. As impurities become more challenging the 
number of successful trains decreases. The fewest purification train alternatives that 
were identified by the decision-support tool correspond to the heavy load of impurities. 
In order to proceed with the process economics evaluation and optimisation the size of 
the top-ranked train pool was set to the minimum number of successful purification trains 
across all impurities loads. 
The top-six purification trains for each impurities load were further evaluated considering 
the whole manufacturing process. Additionally, for each top-ranked purification train the 
process economics model simulated its operation using either a full self-packed or a full 
pre-packed column train. Insights that were gained through the evaluation of pre-packed 
chromatography columns (Chapter 4) concluded that the greatest cost benefits can be 
observed when all three chromatography steps operate using pre-packed columns. 
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Hence, in this chapter only the full self-packed and the full pre-packed configurations of 
the purification train were evaluated in order to simplify and accelerate the scenario 
analysis. The comparison between self-packed and pre-packed purification trains is 
consistent through different impurities loads with relatively small deviations. The changes 
caused in the COG/g from the introduction of a full pre-packed column train against a full 
self-packed train with the same resin sequence are presented in Figure 5.4. Pre-packed 
columns demonstrate a reduction in the COG/g at pre-clinical, clinical phase III and 
commercial scale with the greatest benefits observed at phase III of approximately 6%. 
On the other hand, a small increase in the COG/g using pre-packed columns appears at 
clinical phase I & II. The same trend was also noticed in Chapter 4 and it was expected 
here since the same scenario inputs were used. The error bars in Figure 5.4 represent 
the standard deviation of the COG/g among the top-ranked trains.     
 
Figure 5.3: Number of successful purification trains for different impurities loads 
as identified using the decision-support tool for the chromatographic purification 
train 
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Figure 5.4: Average change in the COG/g among different loads of impurities for a 
full pre-packed train relative to a full self-packed train across all manufacturing 
stages. Error bars show two standard deviations 
According to Figure 5.4 the decision to introduce pre-packed chromatography columns 
in the purification train is consistent throughout different impurities loads and across all 
top-ranked purification trains. The most cost-effective configuration would be a full self-
packed purification train for the manufacture of material for clinical phase I & II and a full 
pre-packed purification train for pre-clinical, clinical phase III and commercial 
manufacture. 
Using the weighted sum method each successful purification train was assigned a score 
expressing its performance it terms of productivity and the resin cost per gram of product. 
Figure 5.5 plots the top-six purification trains for each impurities load based on their 
respective resin cost and productivity values. According to Figure 5.5 as the load of 
impurities increases the purification trains that manage to meet the quality and 
performance threshold achieve a high resin cost and a low productivity. At a light load of 
impurities the vast majority of the top-ranked purification trains are located on the bottom-
right quadrant of the scatter plot in Figure 5.5 with high productivity and low resin cost. 
On the other hand, at a heavy load of impurities top-ranked purification trains are mostly 
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located on the top-left quadrant of the scatter plot with low productivity and high resin 
cost. It is worth highlighting that the top-ranked purification trains for the lower and upper 
impurities loads demonstrate almost parallel profiles with average productivity and high 
resin cost.  
 
Figure 5.5: Resin cost per gram of product against productivity of the purification 
train considering the top-six purification trains for different loads of impurities 
Due to the fact that both the resin cost and productivity have a direct impact on the COG, 
the top-six purification trains for each impurities load were evaluated considering the 
whole manufacturing process using the process economics model. A summary of key 
results for each purification train is presented in Table 5.5. For each impurities load, 
Table 5.5 provides the top-six resin sequences with descending score order along with 
the train yield and the delivered impurities profile. The last column in Table 5.5 shows 
the cumulative COG across pre-clinical, clinical and first year of commercial 
manufacturing. Highlighted purification trains in Table 5.5 indicate the train with the 
minimum cumulative COG for each load of impurities. 
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Table 5.5: Top-six purification trains and their respective quality and performance profile for Case study 1 
Impurities Load Capture Intermediate Polishing Score 
Train Yield 
(%) 
HMW Out 
(%) 
LMW Out 
(%) 
HCPs 
Out 
(ng/mg) 
Total Clinical & first 
Year Commercial COG 
($M) 
Light CEX-3 MMAEX-1 Plat. AEX 100.0% 82.9 0.26 0.06 10.0 35.0 
  CEX-3 MMAEX-2 AEX-2 88.5% 81.2 0.19 0.04 39.8 36.9 
  CEX-3 MMAEX-2 Plat. AEX 85.3% 82.9 0.19 0.08 5.0 35.9 
  MMCEX-1 CEX-5 AEX-2 75.4% 77.0 0.20 0.07 1.0 38.3 
  MMCEX-2 CEX-1 Plat. AEX 74.9% 78.3 0.04 0.02 31.6 39.1 
  MMCEX-1 CEX-5 MMAEX-4 73.2% 77.0 0.12 0.04 0.4 38.3 
Lower MMCEX-2 CEX-1 Plat. AEX 87.9% 78.3 0.08 0.03 47.4 39.1 
Medium MMCEX-1 CEX-5 MMAEX-4 85.0% 77.0 0.25 0.08 0.6 38.3 
  MMCEX-2 MMAEX-1 AEX-2 83.7% 85.7 0.21 0.03 47.4 38.9 
  MMCEX-2 CEX-5 AEX-2 83.0% 81.2 0.10 0.03 4.7 39.0 
  MMCEX-2 CEX-5 MMAEX-4 79.5% 81.2 0.06 0.02 1.9 39.0 
  MMCEX-2 MMAEX-1 Plat. AEX 79.4% 87.5 0.20 0.05 6.0 38.3 
Upper MMCEX-2 CEX-5 AEX-2 86.7% 81.2 0.22 0.09 11.1 39.0 
Medium MMCEX-2 CEX-5 MMAEX-4 83.0% 81.2 0.13 0.06 4.4 39.0 
  MMCEX-1 Plat. CEX MMAEX-4 75.4% 79.5 0.33 0.05 1.1 38.2 
  MMCEX-1 CEX-6 MMAEX-4 70.6% 81.2 0.32 0.09 22.1 37.7 
  MMCEX-2 Plat. CEX AEX-2 70.2% 83.9 0.13 0.02 8.8 39.4 
  MMCEX-2 CEX-5 MMAEX-3 68.8% 77.0 0.33 0.08 0.7 40.1 
Heavy MMCEX-2 Plat. CEX Plat. AEX 73.4% 85.7 0.24 0.06 1.6 38.8 
  MMCEX-2 CEX-5 MMAEX-4 67.2% 81.2 0.25 0.09 6.3 39.0 
  MMCEX-2 Plat. CEX AEX-2 50.2% 83.9 0.24 0.03 12.6 39.4 
  MMCEX-2 Plat. CEX MMAEX-4 37.2% 83.9 0.15 0.02 5.0 39.5 
  MMCEX-2 Plat. CEX MMAEX-3 12.9% 79.5 0.36 0.02 0.8 40.6 
  MMCEX-2 CEX-6 MMAEX-3 0.0% 81.2 0.35 0.05 15.8 40.3 
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According to Table 5.5, in most cases the lowest cumutive COG can be observed with 
purification trains that have managed to achieve a high place in the ranking list. An 
exception is for the upper medium load of impurities where the fourth ranking purification 
train demonstrated the lowest cumulative COG however with a small difference from its 
alternatives. The most cost-effective (first option) purification train for each impurities 
load is plotted in Figure 5.6. Although at each load of impurites a different resin sequence 
demonstrated the lowest cumulative COG, there is a common resin sequence among 
the heavy and the two medium impurity profiles. This common resin sequence is also 
part of the list with the successful purification trains for the light impurities load. However, 
its avarage productiviry and high resin cost prevented its progression to the top-ranked 
list. Nevertheless, it is of high value to identify resin sequences that could handle a variaty 
of impurity profiles especially at early stage in process development. The value stems 
from the uncertanty at early stage that is assoiated with the profile of the impurities that 
could be delivered to the chromatographc purification train. 
Additionally, Figure 5.6 illustrates the resin sequence and the cumuative COG for each 
purification train and plots the platform puritication train to visualise how it compares with 
the proposed alternatives. It should be highlighted that all the alternative purification 
trains suggest the replacement of the Protein A resin for the capture chromatography 
step. 
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Figure 5.6: Resin cost per gram of product against productivity of the purification 
train graph illustrating the most cost-effective (first option) purification train at 
different loads of impurities. A common purification train option and the platform 
option are also plotted. The resin sequence for each purification train is indicated 
along with the cumulative COG for pre-clinical, clinical and first year of 
commercial manufacture 
5.3.2. Case study 2: Integrated framework in chromatography process 
development 
An industrially-relevant case study was formulated to demonstrate the implemenation of 
the consolidation of the HTPD workflow (Chapter 3) with the process economics model 
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(Chapter 4) and the decision-support tool for the purification train. Due to the lack of 
experimental data for the capture and polishing chromatography steps for the four mAbs 
provided by MedImmune the evaluation here refers only to the intermediate 
chromatography step. Hence, resin screening and analysis considered certain resins for 
the capture and the polishing steps (Table 5.4). A consequence of this formulation is the 
low responsiveness of the resin cost metric to different CEX resins introduced in the 
purification train. Figure 5.7 presents the average and the standard deviation for the 
productivity and the resin cost across all four mAbs. The first three mAbs are represented 
with a single bar due to their similar performance. For the fourth mAb a separate bar was 
needed due to its signifiant differnent performance. It should be highlighted that for the 
fourth mAb the decsion-support tool could not identify a CEX resin among those tested 
that could fit into the given purification train and deliver the desired product profile. 
Instead, for the fourth mAb, the tolerance for HMW species had to be increased to 1.5% 
in order to identify any purification trains for further evaluation for Case study 2.   
 
Figure 5.7: Average productivity and resin cost across all successful purification 
trains that have met their respective quality and performance threshold. Error bars 
indicate two standard deviations 
As expected the resin cost across all successful purification trains demonstrates almost 
a constant value of 5.7$/g for mAbs 1-3 and 7.4$/g for mAb 4. Hence, the resin cost 
metric is unable in this case to provide a good comparator for different purification trains. 
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In order to neglect the resin cost per gram of product and rank the successful purification 
train only based on their productivity the weight coefficient for productivity was set to 1.0. 
Similarly to Case study 1, the top-six purification trains were selected for each mAb to 
be imported into the process economics model and simulate their respective COG 
values. For each top-ranked purification train and each mAb the process economics 
model simulated the COG for a full self-packed and a full pre-packed purification train. A 
comparison between full self-packed and full pre-packed purification trains across all 4 
mAbs is presented in Figure 5.8. Throughout different manufacturing stages pre-packed 
columns demonstrate a reduction in the COG compared to self-packed columns, 
regardless of the resin sequence and the mAb. In contrast to Chapter 4 and Case study 
1 of this chapter, here pre-packed columns demonstrate cost benefits throughout clinical 
manufacture. The difference can be observed for clinical phase I & II and the root cause 
of it can be explained considering the different size of the pipelines. For instance, Figure 
5.4 considers 9 products in the pipeline (Case study 1) while Figure 5.8 assumes only 4 
products at clinical phase I & II (Chapter 2). That difference translates into a change in 
the direct to indirect costs ratio which has a definitive impact of the cost-effectiveness of 
pre-packed columns as discussed in Chapter 4.  
A summary of the top-ranked CEX resins for each mAb is presented in Table 5.6. The 
resin indices refer to the resin lists in the Appendix (Table A.4 – A.7) for each mAb 
respectively. Different CEX resin options are presented in a descending order from high 
to low productivity. Additionally, only the concentration of HMW species and HCPs in the 
final product are indicated since the initial concentration of LMW species was very low 
and below the specified targets in Table 5.2. 
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Figure 5.8: Average percentage change in COG/g for pre-packed purification trains 
relative to self-packed at different manufacturing stages across the top-ranked 
purification trains and across all 4 mAbs 
The last column in Table 5.6 shows the cumulative COG for clinical (phase I, II & III) and 
first year commercial manufacture and highlighted rows indicate the CEX resin that 
demonstrated the lowest cumulative COG. The cumulative COG values in Table 5.6 
correspond to purification trains that use pre-packed columns throughout all 
chromatography steps. For mAb-1 and mAb-2 the first option with the highest productivity 
train resulted also in the most cost-effective option. In contrast, for mAb-3 and mAb-4 
the CEX resins that resulted in the lowest cumulative COG achieved a lower position in 
the top-ranked list. Nevertheless, the differences in productivity among the top-six CEX 
resins for each mAb were relatively low. On the other hand, greater deviations can be 
observed among the train yields for different CEX resins. Hence, the cumulative COG 
was plotted against the purification train yield to determine their correlation. Evidently, 
Figure 5.9 shows a negative correlation between COG and yield. Increasing train yield 
results in a reduction in the cumulative COG throughout different mAbs. The yield of the 
purification train was defined as a constraint in the decision-support tool for the purposes 
of the Case study 1. In contrast, for Case study 2 that constraint was removed in order 
to focus the brute force screening on determining CEX resins capable of removing 
impurities. 
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Table 5.6: Top-six CEX resins and their respective quality and performance profile 
for Case study 2 
mAb 
CEX 
Resin 
(index) 
Train 
Productivity 
(g/L/hr) 
Train 
Yield 
(%) 
HMW 
Out 
(%) 
HCPs 
Out 
(ng/mg) 
Total Clinical & 
first Year 
Commercial COG 
($Million) 
1 R5 (32) 44.8 77.9% 0.39 69.8 46.5 
 R7 (20) 44.4 69.8% 0.35 61.2 48.5 
 R5 (24) 44.0 72.9% 0.31 61.1 47.3 
 R7 (12) 43.6 65.2% 0.28 57.8 50.1 
 R3 (6) 43.3 62.8% 0.39 75.1 50.6 
 R5 (16) 43.2 68.2% 0.25 55.0 48.9 
2 R7 (20) 46.5 70.7% 0.40 6.3 47.3 
 R7 (12) 45.3 66.3% 0.35 6.4 48.7 
 R5 (24) 44.4 69.9% 0.38 5.2 48.1 
 R7 (4) 44.3 61.9% 0.31 6.4 50.6 
 R5 (16) 43.4 65.5% 0.33 5.1 49.2 
 R5 (8) 42.5 61.1% 0.29 4.9 50.5 
3 R7 (20) 53.2 77.7% 0.33 49.3 45.6 
 R7 (12) 52.1 72.5% 0.25 46.8 46.9 
 R5 (24) 51.1 82.1% 0.33 48.3 45.0 
 R7 (4) 50.9 67.6% 0.19 44.2 48.4 
 R5 (16) 50.3 76.8% 0.27 43.9 46.0 
 R5 (8) 49.5 71.6% 0.21 35.8 46.8 
4 R1 (17) 35.4 57.5% 1.39 0.0 54.4 
 R7 (20) 35.1 60.1% 1.36 0.0 53.8 
 R1 (9) 34.4 53.2% 1.25 0.0 56.6 
 R7 (12) 34.2 56.0% 1.26 0.0 54.9 
 R7 (4) 33.4 51.9% 1.14 0.0 58.0 
 R2 (26) 31.9 64.8% 1.41 0.0 53.3 
The negative correlation between COG and yield can be justified considering a specific 
product demand. For instance, assuming a throughput of 10kg/batch and a process yield 
of 50% it would require the production of 20kg/batch during the cell culture. As the 
process yield decreases the batch throughput increases to meet the product demand. 
 
 
167 
 
Hence, decreasing process yield would require the use of larger process equipment to 
maintain the batch throughput, thus increasing the cost. 
 
Figure 5.9: Total COG for clinical (phase I, II & III) and first year commercial 
manufacture against product yield of the purification train across different mAbs. 
Solid shapes indicate the CEX resin that demonstrated the lowest cumulative COG 
for each mAb 
Cross-referencing the CEX resin indices in Table 5.6 and the corresponding resin list for 
each mAb in the Appendix (Table A.4 – A.7) it can be seen that certain CEX resins 
appear throughout the top-ranked lists in Table 5.6 for different mAbs. Figure 5.10 shows 
on the left vertical axis the frequency that a CEX resin appears in Table 5.6 for all mAbs. 
Two CEX resins show the greater frequency of approximately 38% and 45% for Resin-
5 and Resin-7, respectively. These two CEX resins combined dominate the top-ranked 
lists in Table 5.6 due to their use under different sets of yield and impurities removal 
capability. 
Through the use of the fractionation diagram approach incorporated into the HTPD 
workflow a series of Pareto diagrams can be generated to describe the profile of each 
impurity against product yield. The decision-support tool for the purification train can 
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import a large set of impurities-yield data-points and assign to each of them a different 
index number. The appearance of the same resin multiple times in the top-ranked list 
indicates its superior performance against other resin candidates. Additionally, it could 
also demonstrate a wider operating window considering that every time the same CEX 
resin appears in the top-ranked list is under different conditions. Furthermore, Figure 
5.10 plots on the right vertical axis the number of mAbs that each top-ranked CEX resin 
managed to purify. The most frequent CEX resin (Resin-7) managed to reach the top-
ranked list for every mAb that was included in this study. In contrast Resin-5 managed 
to reach the top-ranked list of the first three mAbs only to be excluded for mAb-4. It 
should be highlighted that mAb-4 had a challenging concentration of HMW species and 
the decision-support tool could not identify a CEX resin among those tested that could fit 
into the purification train and deliver the desired target product profile. Hence, in order to 
allow for the comparison among different CEX resins the target for HMW species was 
incrementally increased to 1.5%. 
Overall, Resin-5 and Resin-7 demonstrated superior performance against other CEX 
resin candidates. It should be mentioned that Resin-7 was also determined the best CEX 
resin candidate using the resin selection tool of the HTPD workflow in Chapter 3 (Figure 
3.2). Similarly to Case study 1 the synergy between the decision-support tools and the 
process economics model has revealed the optimum purification train and has identified 
a purification train that could handle multiple mAbs. A COG/g breakdown is shown in 
Figure 5.11 comparing the costs for the most cost-effective purification train using self-
packed and full pre-packed columns for each mAb and across clinical and commercial 
manufacture. The most cost-effective options are highlighted in Table 5.6. The use of 
pre-packed columns offers a reduction in the COG/g at clinical and commercial 
manufacture and across different mAbs with the greatest cost savings achieved at 
clinical phase III. 
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Figure 5.10: Frequency of appearance and number of purified mAbs for each CEX 
resin included in Case study 2. Resin-8 was used only for mAb-4 and it was 
replaced with Resin-9 for mAb 1-3 
 
Figure 5.11: COG/g breakdown for the first option (i.e. most cost-effective) for the 
purification train using self-packed and pre-packed chromatography columns 
across clinical and commercial manufacture and for each mAb included in Case 
study 2 
Finally, Figure 5.12 demonstrates the total COG across clinical and first year commercial 
manufacture for the first option (most cost-effective) and the second option regarding the 
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CEX resin for the intermediate purification step. Both options are plotted considering the 
use of pre-packed columns for all chromatography steps and throughout different 
manufacturing stages. Moving towards the selection of a platform CEX resin that could 
fit into the purification train for different mAbs, Figure 5.12 demonstrates that CEX Resin-
7 could be a suitable candidate. CEX Resin-7 ranks consistently in the top-two options 
with a difference in the cumulative COG of 1 – 4%. Having identified CEX resins with 
superior performance against other candidates it is important to attempt and determine 
the resin properties associated with their performance. 
 
Figure 5.12: Total COG for clinical (phase I, II & III) and first year of commercial 
manufacture of the first and the second option for the CEX resin for the 
intermediate chromatography step in the purification train across all mAbs 
included in Case study 2. Pre-packed columns were assumed throughout. 
As discussed in Chapter 4 the dynamic binding capacity of a chromatography resin has 
a strong impact on the economics of the unit operation with low DBC values leading to 
high cost (Figure 4.X). According to Figure 5.13, CEX Resin-5 and CEX-Resin-7 report 
consistently high DBC values throughout different mAbs. However, other CEX resins 
demonstrate comparable DBC without necessarily leading them to a high ranking place. 
For instance, CEX Resin-3 shows a high DBC, however it manages to purify only one 
mAb out of four (Figure 5.10). 
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Therefore, suitability and cost-effectiveness are not guaranteed simply with high DBC. 
Additionally, yield demonstrates a strong correlation with the COG (Figure 5.9). 
Nevertheless, neither the throughput or product recovery can be considered without 
being able to deliver the desired target product profile. Thus resins that demonstrate high 
yield and high DBC might be excluded from the evaluation due to their insufficient 
purification profile. In order to determine whether the purification profile of a 
chromatography resin could potentially provide early evidence of superior cost-
effectiveness, Figure 5.14 plots HMW reduction, HCPs logarithmic reduction values 
(LRV) and elution pool volume against yield for each CEX resin and across all mAbs 
included in Case study 2. A visual inspection of the data plotted in Figure 5.14 reveals 
the trade-offs among different attributes (e.g. HMW reduction, yield, etc.). 
 
Figure 5.13: Dynamic binding capacity for each CEX chromatography resin across 
different mAbs included in Case study 2. 
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Figure 5.14: Impurities removal and elution pool volume against yield for each CEX 
resin and each mAb included in Case study 2. Profiles generated through the 
implementation of the HTPD workflow using the resin databases shown in the 
Appendix (Table A.4 – A.7) 
For mAb-2 the greatest HMW reduction profile is provided by CEX Resin-8 followed by 
CEX Resin-6. On the other hand, the greatest reduction of HCPs was observed for CEX 
Resin-1. Nevertheless, none of these resins managed to reach the top-ranked list. In 
contrast, CEX Resin-5 and Resin-7 showed average HMW and HCPs reduction 
capabilities and managed to dominate the top-ranked list for mAb-2 (Table 5.6). It should 
be highlighted that CEX Resin-5 and Resin-7 demonstrate the two highest DBCs for 
mAb-2 with average yield. Similar trends can be observed for the other mAbs in Figure 
5.14. Hence, an overall trend emerges for these four mAbs and eight CEX resins. Figure 
5.15 illustrates a simplistic decision-tree for the selection of CEX resins for the 
intermediate chromatographic purification step. The first decision level is the impurities 
reduction capabilities followed by yield and concluding with DBC. As demonstrated in 
Case study 2, CEX resins can be considered only when they can meet product quality 
targets. The next major influence is the product recovery that can be achieved for a given 
impurities reduction level. Step yield affects directly the whole manufacturing process 
influencing the size and the operation of all process steps. Finally, having secured a good 
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yield and impurities reduction level the cost-effectiveness of the process can benefit from 
high DBC values. 
 
Figure 5.15: A simple decision-tree illustrating the main decision levels and their 
order for the selection of CEX resins for the intermediate chromatography step in 
the purification train for the mAbs included in Case study 2 
5.4. Conclusions 
This chapter focused on demonstrating an integrated framework in chromatography 
process development leveraging high-throughput purification data using advanced 
decision-support tools. Through the implementation of the integrated framework a great 
number of different purification trains can be evaluated considering the economics of the 
whole manufacturing process. The progressive flow of information in the framework 
allowed for a systematic data manipulation and storage providing the flexibility to the 
user to trace any piece of information at any point in the analysis. For instance, it would 
not be possible to determine a common purification train in Case study 1 without being 
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able to access the lists of successful purification trains in retrospect. The value of such 
a level of flexibility was demonstrated in both case studies by determining at least one 
purification train that could be used for different mAbs or could handle greater deviations 
in the profile of the product. Hence, through the integrated framework, a greater process 
understanding and the establishment of a platform process can be achieved. 
Furthermore, process bottlenecks can be identified and alternative solutions can be 
considered very rapidly at early-stage in process development. This capability of the 
framework was demonstrated through Case study 2. For the case of mAb-4 it was 
determined that none of the CEX resins that were tested could fit into the given 
purification train and deliver the desired product profile. Hence, further development 
efforts could be focused on different resin types for the intermediate chromatography 
step in the purification train to replace the CEX resin. Additionally, further research could 
be initiated to investigate the root cause of the inadequate performance of multiple well-
established CEX resins. 
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Chapter 6. Process validation 
Process validation is a major concern in the pharmaceutical industry and its main 
objective is to provide guarantees that the final product, which will be administrated to 
the patients, consistently meets specific pre-determined quality characteristics (FDA, 
2011). 
6.1. Initial approach in process validation 
Initially, the industry was very sceptical when it came to the introduction of new 
technologies into their manufacturing process, due to the uncertainty on how the 
regulators might respond. Additionally, the manufacturing processes were usually 
designed insufficiently and operated under sub-optimal conditions, which had 
tremendous implications in the profitability of the industry (Pujar et al., 2009; Rathore & 
Winkle, 2009). The ‘’traditional’’ process validation approach was based mainly, if not 
entirely, on empirical information. Additionally, there was a lack in predictive tools to 
evaluate the effects of scale-up on product quality and process performance. Moreover, 
there was little understanding on manufacturing failures and how they were caused 
(Rathore & Winkle, 2009). 
6.2. Quality by design approach in process validation  
Quality by design (QbD) is an initiative to help both the industry and the regulators to 
communicate more efficiently and accelerate process development, following a more 
systematic approach throughout the lifecycle of a therapeutic drug (ICH Q8(R2), 2009; 
Rathore & Winkle, 2009). QbD incorporates sound scientific knowledge and risk-based 
evaluation with management of the performance of the manufacturing process, in order 
to develop a flexible and robust process, capable of delivering consistently the desired 
product quality (Rathore & Winkle, 2009; Francis, 2012). QbD is based upon the 
fundamental principal that product quality cannot be tested and hence it has to be build-
in the process. 
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The guidelines provided by the regulators offer instructions for pharmaceutical 
development and product lifecycle management. They prompt the adaption of a more 
systematic approach in process development, using prior knowledge and experience. In 
such an approach results from design of experiments (DoE) studies and quality risk 
assessment are combined in order to acquire an in-depth process and product 
understanding (ICH Q8(R2), 2009; ICH Q9, 2005; ICH Q10, 2008). 
Furthermore, the guidelines encourage the incorporation of process analytical 
technologies (PAT) to help improve process understanding and identify the appropriate 
tools for analysing and controlling the manufacturing process (FDA, 2004; Rathore et al., 
2010). A central objective of the QbD approach is to define the target product profile 
(TPP), identify critical quality attributes (CQAs) and critical process parameters (CPPs) 
and develop connective correlations between them (Chhatre et al., 2011). Gaining an in-
depth process and product understanding can support the establishment of a design 
space. The design space is defined as ‘’the multidimensional combination and interaction 
of input variables and process parameters that have been demonstrated to provide 
assurance of quality.’’ Operating within the design space permits changes in the 
manufacturing process without initiating regulatory concerns. On the other hand, any 
changes that can cause operation outside the design space require revalidation to 
ensure that the process can still deliver the desired quality (ICH Q8(R2), 2009). 
In 2009, a consortium of leading biotech companies gathered to combine their 
knowledge and experience in QbD focusing on guidelines contained in ICH Q8, Q9 and 
Q10 (CMC Biotech Working Group, 2009). Through the collective effort of the consortium 
and its interaction with the regulators a case study (A-Mab) in bioprocess development 
was formulated to discuss the guidelines and their application to real world scenarios. 
The final document discusses different elements in QbD from product and process 
characterisation to determining CQAs and CPPs and establishing a design space and a 
process control strategy. 
 
 
177 
 
More recently, Roche/Genentech published a special Section of Biologicals 
demonstrating an integrated framework implementing QbD principles for mAbs (Kelley, 
2016). The first chapter of the publication described the overall QbD roadmap that was 
created to enhance and streamline decision-making in development activities. The 
authors highlighted the benefits of an enhanced approach in process development that 
links systematically a risk-based control strategy with advanced understanding of CQAs. 
Additionally, it was emphasised that development activities should begin considering the 
end goal. The control strategy should be progressively created to ensure the consistent 
delivery of the target product profile. Thus the starting point should be the definition of 
the target product profile with the determination of CQAs and CPPs gradually leading to 
the establishment of a design space (Finkler & Krummen, 2016). 
The rest of the chapters in this special Section of Biologicals describe in detail the key 
components of the proposed integrated framework in QbD. Alt et al. (2016) discussed a 
systematic approach towards an in-depth understanding of quality attributes and the 
determination of the impact on product safety and efficacy. Hakemayer et al. (2016) 
focused on developing the tools to facilitate process characterisation, identify potential 
CPPs and their acceptable operating range and define a design space. Kepert et al. 
(2016) discussed the tools created to establish a control system by defining acceptance 
criteria and a testing approach for impurities. The implementation of the control strategy 
was demonstrated by Ohage et al. (2016) along with a Post Approval Lifecycle 
Management (PALM) plan. The PALM plan enables the linkage between the 
development and the commercial stages of the product and helps to manage risks after 
commercialisation. The final chapter presented the integration of all the tools developed 
throughout the proposed QbD roadmap (Kelley et al., 2016). 
The work presented in the context of this thesis considered QbD principles and 
guidelines in the development of a decision-support framework in protein 
chromatography process development. Prior knowledge and experience from the 
sponsor company were used to guide the development of a high-throughput process 
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development workflow. Core objective of the HTPD workflow is to leverage high-
throughput purification data using a novel approach linking design of experiments (DoE) 
with the fractionation diagram method. Multi-variate data analysis of the DoE space 
enabled the development of predictive correlations to estimate potential CQAs as a 
function of potential CPPs. Furthermore, predictive correlations were integrated with a 
multi-attribute decision-making method to perform a fair comparison among different 
CEX chromatography resins and identify the most suitable candidate to deliver the 
desired product quality and process performance. Finally, the HTPD workflow described 
a novel methodology in identifying potential windows of operation under process 
deviations. Overall, the HTPD workflow offers the ability to gain an enhanced process 
understanding with limited feedstock material from an early stage in process 
development. Insights can be further leveraged in subsequent assessments for the 
establishment of a design space and a control strategy. 
The significant effort from the industry, the regulatory agencies and academia has 
highlighted the importance in adapting a QbD strategy from the beginning of a product’s 
lifecycle. As new therapeutic proteins and advanced therapy medicinal products 
(ATMPs) are discovered new challenges will emerge. Hence, the early establishment of 
a QbD driven framework is paramount to ensure consistent product quality. 
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Chapter 7. Concluding remarks and recommendations for 
future work 
The research project discussed throughout the chapters of the current thesis focused on 
the establishment of advanced decision-support tools in early-stage protein 
chromatography process development. The tools that were developed combine a variety 
of methodologies with the overall objective of gaining an in-depth process understanding 
and accelerating process development activities. This chapter summarises the main 
features of the decision-support tools developed throughout this research and the 
benefits associated with their use. Additionally, current limitations and potential areas of 
improvement are identified paving the road towards future research. 
7.1. High-throughput process development workflow 
Chapter 3 demonstrated the implementation of a high-throughput process development 
(HTPD) workflow for the chromatographic purification of a highly aggregated bispecific 
monoclonal antibody (mAb). The HTPD workflow links high-throughput experimentation 
(HTE) at micro-scale with design of experiments (DoE), regression analysis, multi-
attribute decision-making and stochastic analysis. HTE often results in a large number 
of samples which could potentially increase the analytical and data analysis effort 
(Chhatre et al., 2009). Additionally, a chromatogram offers much more information than 
a single pair of purity-yield values. Typically, a chromatogram can be transformed into a 
Pareto frontier demonstrating a relationship between product recovery and purity (Ngiam 
et al., 2001; Ngiam et al., 2003). Thus considering a single point on the Pareto curve 
neglects the rest of the purification profile. 
A key focus of the HTPD workflow was the establishment of a systematic framework 
providing the methods and the tools to cope with the large datasets and leverage 
information regarding the complete purification profile. A novel approach in 
chromatogram analysis was illustrated that integrates DoE with the fractionation diagram 
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approach in order evaluate the trade-offs between purity and yield at different operating 
conditions. Although the fractionation diagram approach can be used very efficiently for 
the transformation of a chromatogram into a Pareto frontier graph it requires meticulous 
calculations (Ngiam et al., 2001; Ngiam et al., 2003). Considering also the large number 
of chromatograms, the data analysis effort could increase substantially becoming a 
development bottleneck. The HTPD workflow leverages the advantages of the 
fractionation diagram approach and automates the whole analysis for all the 
chromatograms through the synergistic use of SOLVER (optimization tool add-in) and 
VBA in MS Excel. Hence, user intervention is mitigated to importing raw data received 
from different analytical tools in the laboratory and initiating a VBA script (Macro) to 
perform raw data manipulation. 
The HTPD workflow offers the ability to screen multiple chromatography resins and 
develop regression correlations between process parameters and quality/performance 
attributes. Chromatography resin selection can become challenging due to the need to 
satisfy usually conflicting resin properties. Furthermore, visual inspection of the results 
from the DoE analysis could prove even more challenging to determine with confidence, 
resin candidates with superior performance. To address these issues the HTPD workflow 
utilizes a resin selection tool build in MS Excel. The resin selection tool leverages the 
regression correlations developed for each resin candidate and uses SOLVER through 
VBA to optimize the set-point of process parameters and achieve user defined quality 
and performance targets. The comparison of the resin candidates is performed by 
combining two multi-attribute decision-making techniques: satisficing and weighted sum. 
The satisficing method compares prioritized threshold values of user defined targets to 
the performance of individual resin candidates and reports the values achieved for each 
attribute. Then, in case all attributes were satisfied for more than one resin, a 
performance score was estimated for each resin candidate based on the weighted sum 
of normalized attribute values. Thus the final comparison is based on a relative score 
among resin candidates rather than threshold values. 
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Another function of the HTPD workflow is the optimization of process parameters and 
the definition of windows of operation under uncertainty. Conventionally, windows of 
operation are identified and represented graphically (Salisbury et al., 2006; Boushaba et 
al., 2011). However, in cases where the number of parameters is greater than 2 and/or 
the interaction of different parameters has an impact on the shape of the window of 
operation, its graphical determination becomes extremely difficult. Additionally, 
depending on the sensitivity of the attributes on deviations from the set-point of different 
parameters the shape of the window of operations could change dramatically. To 
overcome these challenges a robustness assessment tool was built in MS Excel using 
SOLVER through VBA. A series of Monte Carlo simulations were performed introducing 
a level of uncertainty on each process parameter and the probability of failing to meet 
any of the user-specified threshold values of the desired attributes was calculated. Using 
SOLVER the robustness assessment tool manages to iterate through different set-point 
values for each parameter and determine a sweet-spot able to tolerate process 
deviations. 
Insights gained throughout the implementation of the HTPD workflow can be further 
leveraged to guide experimentation at larger scales towards the establishment of a 
design space and a control strategy. Evidently, the HTPD workflow is greatly influenced 
by the QbD paradigm towards gaining a thorough understanding of chromatographic 
separation processes for therapeutic proteins. The establishment of the workflow 
required iterative discussions with the industrial sponsor (MedImmune) in order to 
determine the appropriate experimental and analytical protocols and develop the 
framework to its current state. Nevertheless, there are still known and unknown 
challenges that would require the modification of certain components of the workflow in 
order to avoid creating a bottleneck in process development. 
Through the implementation of the HTPD workflow for the purposes of Chapter 3 and 
Chapter 5 a previously unreported source of error was identified. The potential error 
stems from the operation of the robotic arm in a liquid handling system and more 
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specifically the capacity of its pipettes. To achieve a target load challenge the required 
volume depends on the feed concentration. Therefore, at a low feed concentration and 
a high load challenge the necessary volume might exceed the maximum volume of the 
pipettes. Thus multiple aspiration/dispersion cycles would be required to achieve the 
target load challenge. In such cases, the delay of the robotic arm would increase the 
residence time that could cause a surge in the dynamic binding capacity. Hence, for 
future studies the delay of the robotic arm should be quantified and considered for the 
calculation of the flowrate at micro-scale. 
Another known challenge that the HTPD workflow currently faces is related to the 
analytics. High-throughput screening can lead to the generation of a large number of 
samples, thus potentially increasing manual intervention, materials consumption and 
analytical time. As an indication, during the implementation of the workflow demonstrated 
in Chapter 3, more than 4000 samples were generated for binding and elution studies 
combined. The use of a UPLC system in sample analysis was of great benefit due to its 
capability to process up to 8x96 samples without any manual intervention. However, 
using the current protocol it would require a few days of continuous operation for the 
UPLC system while generating the samples would take only a few hours. 
Further improvements on the operating protocol for the UPLC system could accelerate 
the analysis. Residence times for different impurities and the product can be determined 
prior to the analysis of the samples in order to determine the cut-points and potentially 
shorten the analytical timeframe. Such an approach might need fine tuning of the 
protocol for different molecules. Another suggestion would be to introduce an 
intermediate analytical step (e.g. Infinite® 200 PRO, Tecan) to selectively pick samples 
with a protein concentration above a pre-specified threshold. Proper calibration would be 
necessary to avoid excluding samples with protein or including empty samples. 
Additionally, a data management system has to be established to generate indices or 
barcodes for samples to enable sample tracking across different analytical tools in the 
laboratory. 
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A significant part of the HTPD workflow both on the experimental and the computational 
front is fully automated. For instance, both the resin selection tool and the robustness 
approach to determine windows of operation under uncertainty make use of the SOLVER 
optimization add-in tool in MS Excel through VBA. Additionally, through the same 
synergy of tools in MS Excel it was possible to fully automate raw data manipulation and 
analysis to determine the responses in the DoEs (e.g. DBC, Purity, etc.). On the other 
hand there are key points of manual intervention. For example in data transfer from 
different analytics to the tools of the HTPD workflow for further manipulation and 
analysis. Hence, in order for the HTPD workflow to become part of an automated process 
development platform additional modifications are required. Critical areas of 
improvement in automation that could be prioritized include:  
 The data transfer between the laboratory and the computational tools of the 
HTPD workflow 
 The data transfer between MS Excel and JMP 
 The model fitting process in JMP by developing a script that could follow a 
procedure as described by Kumar et al. (2013) and followed in the current thesis 
7.2. Process economics model 
Chapter 4 demonstrated the functionality of a process economics spreadsheet model 
simulating a typical manufacturing process for mAbs. The spreadsheet model offers a 
dashboard that allows the user to perform deterministic and stochastic analysis. The 
purpose of the model was to enable the evaluation of pre-packed chromatography 
columns as an alternative to traditional self-packed columns in antibody purification. 
Hence, a built-in function of the model is the sizing of pre-packed columns and the 
estimation of related direct and indirect costs. Additionally, great attention was given to 
the design of ancillary equipment (e.g. buffer hold-tanks) and estimating the 
requirements in materials for operating (e.g. guard filters) and cleaning (CIP buffers, WFI, 
etc.). 
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Single-use technologies (SUT) could potential offer significant cost benefits (Lopes, 
2015). Although pre-packed chromatography columns have been extensively used in 
research and process development activities (Scharl et al., 2016) there are limited 
studies discussing their fit into pilot and commercial scale facilities (Grier & Yakubu, 
2016). The utilization of pre-packed columns could eliminate the need for a packing 
system and a self-packed column. On the other hand, the cost of consumables is 
expected to increase. Hence, the main objective of Chapter 4 was the detailed 
investigation of the changes in the manufacturing costs associated with the use of pre-
packed columns for a given set of assumptions. Additionally, through a sensitivity 
analysis it was possible to address the significance of different parameters and 
assumptions on the cost of goods. Through a series of simulations the cost-effectiveness 
of pre-packed columns was evaluated for every chromatography step in a purification 
train. Additionally, it was demonstrated that pre-packed columns could potentially 
replace large scale self-packed chromatography columns despite the size limitations. 
The analysis in Chapter 4 demonstrated the cost-effectiveness of pre-packed columns 
despite the assumption regarding a column packing success rate of 100% that favors 
the self-packed columns. In practice, such a high column packing success rate would be 
very difficult to achieve. A lower packing success rate would lead to an increase in 
personnel and reagents cost for self-packed columns. Additionally, significant disruptions 
might occur in scheduling and operation of a manufacturing process and its support 
activities (e.g. media and buffer preparation, column packing, etc.). The consequences 
of a low column packing success rate in a process economics analysis would highlight 
even further the benefits of pre-packed columns. 
The cost-effectiveness of pre-packed columns depends on several factors related to the 
product, the process, the facility and the portfolio of a biopharmaceutical company. A 
cost of goods analysis focuses on capturing the costs related to manufacturing thus 
neglecting the cost associated with R&D. As discussed in Chapter 1, the introduction of 
single-use technologies could mitigate the cleaning activities in a bio-manufacturing 
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facility and reduce the effort in validation studies. Hence, a cash-flow analysis would be 
necessary to capture both the cost of goods and the cost of development for a drug 
candidate in order to determine the cost-effectiveness of an alternative technology. 
The process economics model developed here provides a framework to rapidly evaluate 
technical and financial metrics in manufacture related to pre-packed and self-packed 
chromatography columns and determine the most cost-effective configuration of the 
purification train for a given scenario. A level of flexibility was achieved through the 
utilization of VBA which allowed for the development of scripts (Macros) to automate the 
analysis of multiple scenarios and the creation of a database to store all the model 
outputs. 
A current limitation of the model is the restriction to simulate a certain flowsheet using a 
Chinese Hamster Ovary (CHO) cell-based manufacturing process. Any intention to 
simulate an alternative flowsheet would require additional model development effort. The 
biopharmaceutical industry has a number of different therapeutic proteins expressed 
intracellularly or extracellularly using different cell lines (e.g. bacterial, yeast or 
mammalian cell lines). Additionally, the process economics model was developed to 
simulate batch and fed-batch mode of operation thus, neglecting the option of continuous 
bio-manufacturing. The design calculations applied to a batch or a fed-batch process 
require further tuning to simulate accurately continuous and/or hybrid manufacturing 
strategies. Designing individual flowsheets for each case would require intense 
development work and could lead into a very large spreadsheet that would be difficult to 
use and maintain. Hence, in order to acquire a greater level of flexibility in synthesizing 
alternative flowsheets the use of an object oriented programming language would be 
preferred. Thus future work could focus on determining a suitable programming language 
to improve and re-write the design equations. 
An additional consideration for future work could be to update the cost database of the 
process economics model. Currently, the database is populated with equipment and 
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materials purchase cost and size values based on literature and commercially available 
computer-aided tools. Moreover, the cost of the vast majority of unit operations was 
estimated based on the 6/10 rule assuming a base size, a base cost and a scaling factor 
(Peters & Timmerhaus, 1991). A more systematic approach would be to create a list of 
alternative process equipment with their sizes and purchase costs for each unit operation 
in bio-manufacturing. One challenge of this approach could be the maintenance of the 
database as new equipment and technologies emerge. Moreover, in case an equipment 
or material is withdrawn from the market changes in the cost database would be needed 
to reflect the changes in availability. 
7.3. Integrated framework 
Although the process economics model offers the capability to simulate different 
chromatography resins through VBA, the requirements in user intervention increase 
exponentially with the number of alternative resins. Increased manual intervention is 
more prone to error and decelerates the whole analysis. To overcome this challenge a 
decision-support tool for the chromatographic purification train was developed in MS 
Excel as an extension of the process economics model. 
The tool for the purification train can be operated independently from the process 
economics model for the rapid evaluation of multiple purification trains using a brute force 
search algorithm written in VBA. Chapter 5 demonstrated the linkage of the decision-
support tool for the purification train and the process economics model. Additionally, the 
HTPD workflow was used to generate and manipulate purification data and create the 
appropriate datasets that can be further leveraged using the integrated framework. 
Hence, the purification performance of different chromatography resins can be assessed 
using real data within a process economics engine evaluating the cost-effectiveness of 
multiple purification trains across different stages in the drug development pathway. 
The level of difficulty to interpret a scenario output and determine the optimum 
purification strategy depends on the complexity of the scenario. In case of a relative 
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simple scenario set-up the optimum purification train could be identified using a graphical 
approach to visualize key metrics among a few options. However, in cases of a complex 
scenario set-up that searches for the optimum within a conditional environment across a 
large number of alternatives and across different manufacturing stages, simple 
visualization becomes challenging. In such cases the integrated framework offers a 
mathematical formulation for the linear transformation of the objective function and the 
constraints of an option evaluation method. The Simplex LP engine in SOLVER has been 
used very efficiently to identify the optimum configuration of the purification train in 
complex scenario configurations (Chapter 5, Case study 1 & 2). 
Implementation of the framework can be of great benefit in establishing platform 
purification processes and determining manufacturing bottlenecks at early-stage in 
process development. Through an industrially-relevant case study, high-throughput data 
were used to evaluate eight CEX resins for the intermediate chromatography step in the 
purification train and for four different mAbs. Two CEX resins demonstrated superior 
performance considering their technical and financial impact on the whole manufacturing 
process. 
Already published work (Simaria et al., 2012; Liu et al., 2014; Liu et al., 2015) has 
focused primiraly on the development of the optimisation algoritms to determine the most 
cost-effective resin sequence. Hence, a simplistic apparoch was followed in the 
development of the chromatography resin database. Typically, a resin database used in 
a process economics model simulating a bio-manufacturing facility would consider a 
chromatography resin operating at a set of conditions and delivering a certain purification 
and recovery performance. Therefore, potentially valuable information from the complete 
purification profile (e.g. purity versus yield curves) could be neglected. The integrated 
framework offers the ability through the use of the HTPD workflow to build a more 
comprehensive resin database that contains several data-points for each resin 
candidate. Thus providing a greater and more flexible decision space to the user by 
offering the ability to identify resin candidates that otherwise could be left unnoticed. 
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The challenges and limitations that were discussed so far with regards to the HTPD 
workflow and the process economics model also apply here. Future work could focus on 
developing experimental strategies that could provide a more comprehensive 
chromatography resin library. A DoE strategy can be created to perform resin screening 
considering all chromatography steps in the purification train. For instance, operating 
under different conditions the capture chromatography step might result in significantly 
different product profiles in the elution pool. Thus, a different product profile could be 
delivered to the next chromatography step and have a definitive impact on its 
performance. Therefore, the load of impurities to each chromatography step could be a 
factor in the DoE. 
Another advantage of the integrated framework is that it allows the use of purification 
data from any source or scale of experimentation. The user can follow the structure of 
the chromatography resin library (e.g. Table 5.3) and import relevant information from 
any data source. However, special care must be taken in cases of incorporating datasets 
from different sources at the same time. For instance, Chapter 3 showed that the 600μL 
miniature chromatography columns offer a better approximation of the purification 
performance of a bench-scale column compared to the 200μL columns. Purification data 
using the 200μL columns can provide critical insights and offer significant savings in 
materials consumption especially in screening studies.  Nevertheless, when creating a 
chromatography resin library a mathematical transformation might be required before 
combining data from different scales. 
Furthermore, high-throughput purification data and process economics data could be 
leveraged along with resin characteristics using multivariate data analysis to develop 
predictive correlations. These predictive correlations could potentially dictate the resin 
characteristics and purification performance that are required to design a cost-effective 
purification train that could deliver the desired product quality. A simplified example was 
given in Figure 5.15 illustrating a decision-tree for the selection of CEX resins for the 
intermediate chromatography step in the purification train. Through the implementation 
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of the integrated framework, it was possible to identify key parameters that had a 
significant impact on the decision to select a CEX resin candidate. However, additional 
experimental effort and more advanced data mining techniques such as Classification 
and Regression Trees (Yang et al., 2014) are required to define threshold values for key 
decision parameters (e.g. yield and DBC). Moreover, the development of predictive 
correlations would be subject to other process related factors (e.g. impurities load from 
previous step and purification performance of downstream steps). A potential challenge 
of this approach could be the data requirements to develop useful correlations that could 
screen resin characteristics for multiple resin sequences and identify the most suitable 
resin candidates for the design of a cost-effective purification process.      
To sum up, the process economics model offers a solid base that combined with 
additional work at the Advanced Centre for Biochemical Engineering at UCL could 
establish the framework for a multi-purpose tool package. A multi-purpose tool package 
could attempt to simulate various aspects in bioprocessing including: 
 Techno-economic evaluation 
 Drug development modelling 
 Capacity planning 
 Supply-chain modelling 
 Portfolio management 
Through the use of such a package a more comprehensive evaluation of alternative 
manufacturing technologies can be performed. For instance, in relation to the evaluation 
of pre-packed chromatography columns it would be possible to assess the potential cost 
savings during R&D related to column packing activities. Additionally other parameters 
could be factored in the analysis (e.g. relationship with vendors, availability of backup 
options for vendors, potential loss of packing know-how etc.). Furthermore, the 
integrated framework could become part of a platform approach in chromatography 
process development both in academia and industry. All individual components are 
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described throughout the thesis in order to allow other researchers and process 
developers to follow the integrated framework as it stands or even to dismantle it and 
use parts of it. Alternatively, the work presented here hopefully can inspire the 
development of novel and more advanced tools with greater automation and flexibility.
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Appendix 
Table A.1: List of process equipment and materials as assumed in the process 
economics model. Base costs are given in USD ($) 
Equipment & Materials 
Base 
Size 
Min. 
Size 
Max. 
Size 
Units 
Base 
Cost 
Scaling 
Factor 
Bioreactor 200 2 25000 L 240000 0.384 
Hold-Tanks 500 25 20000 L 40000 0.384 
Chromatography Skid 3 3 100 L/min 160000 0.245 
Chromatography Column 60 5 200 cm 66500 0.900 
Packing System 50 10 100 L/min 35000 0.363 
Centrifuge 600 50 3000 L/hr 430000 0.155 
Filter Housing 2 1 5 m2 3500 0.306 
TFF Skid 20 1 85  m2 245000 0.295 
PW Vessel 1000 1000 40000 L 27500 0.384 
WFI Vessel 1000 1000 25000 L 36500 0.384 
Hold-Tank Guard Filter 1000 20 20000 L 310 0.645 
Shake Flask 0.50 0.015 1.5 L 500 0.400 
Depth Filter 1 NA  NA  m2 300 NA 
Virus Removal Membrane 1 NA  NA  m2 6800 NA 
Ultrafiltration Membrane 1 NA NA m2 3200 NA 
Empty Pre-packed Column 1 NA NA cm 2000 NA 
Cell Culture Media 1 NA NA L 50 NA 
Buffers 1 NA NA L 5 NA 
PW 1 NA NA L 0.07 NA 
WFI 1 NA NA L 0.59 NA 
Incubator NA NA NA NA 5000 NA 
Sources: UCL Decisional Tools database, Simaria et al. (2012), Repligen, GE Healthcare, Sigma-
Aldrich (Merck) & Biosolve (BioPharm Services). Base costs are given in USD ($). 
Cost = CostBase ∗ (
Size
SizeBase
)
Scaling Factor
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Table A.2: Key assumptions for each unit operation used in the process 
economics model as identified through discussions with the industrial sponsor 
(MedImmune) 
Assumption Shake Flasks Seed Bioreactors 
Production 
Bioreactor(s) 
Preparation Time (hr) 1 5 5 
Load Time (hr) 0 3 3 
Operation Time (hr) 24 72 336 
Turnaround Time (hr) 2 48 48 
Inoculation Ratio (%) 10 10 10 
Fed-batch Media addition (%) NA NA 25 
H/D tank ratio NA 3 3 
Space Efficiency (%) 50 75 75 
Assumption Depth Filtration Virus Filtration 
Ultrafiltration/Dia
filtration 
Preparation Time (hr) 0.5 0.5 1 
Turnaround Time (hr) 1 1 1 
Duration Limit (hr) 5 6 8 
Flush Volume (L/ m2) 100 100 100 
Filter Flush Preparation 0.8 0.8 0.8 
Filter Flush Recovery 1.5 1.5 1.5 
Hold-up Volume (L/ m2) 10 2 0.3 
Flux (LMH) 200 250 40 
Step Yield (%) 95 99 98 
Capacity 200 L/ m2 10 kg/ m2 NA 
Acidic Buffer (%) NA 20 NA 
Neutralisation Buffer (%) NA 20 NA 
Diafiltration Cycles NA NA 5.5 
Diafiltration Time Limit (hr) NA NA 3 
Assumption 
Chrom. Self-
packed 
Chrom. Pre-
packed 
Disk-Stack 
Centrifuge 
Preparation Time (hr) 1 1 1 
Packing Prep. Time (hr) 8 0 NA 
Unpacking Prep. Time (hr) 4 0 NA 
Turnaround Time (hr) 1 1 1 
Duration Limit (hr) 16 16 4 
Resin Overfill (%) 10 10 NA 
Pre-packing (CVs) 14 0 NA 
Pre-First Operation (CVs) 16 16 NA 
Equilibration (CVs) 4 4 NA 
Wash (CVs) 2 2 NA 
Strip (CVs) 3 3 NA 
Regeneration (CVs) 3 3 NA 
Packing (CVs) 20 0 NA 
Unpacking (CVs) 5 0 NA 
Sanitisation (CVs) 4 4 NA 
Storage (CVs) 3 3 NA 
Step Yield (%) Resin Specific Resin Specific 85 
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Table A.3: Key design calculations to estimate the size of each unit operation used 
in the process economics model 
 Upstream Processing 
Unit 
Operation 
Sizing 
VBIOR =
Demand
Batches ∗ Titre ∗ YieldDSP
 
VSEED,q = VBIOR ∗ r
q,   for q = [1,2,3]  if  VSEED,q < min[BV] ⇒ VSEED,q = 0 
VFlask = r ∗ min[VSEED,q]q=1
3
       for VSEED,q > 0 
 Chromatography Step Centrifugation & Depth Filtration 
Unit 
Operation 
Sizing 
D =
√
4 ∗
MIN
DBC ∗ nCOL ∗ nCYC
π ∗ H
 
find DA for min [(D − DA)
2] 
Recalculate nCYC for DA 
nCYC ⟹ nCYC,new 
Sizing algorithm available 
in Figure A.1 
FlowrateCENT =
VIN
Duration ∗ #Units
 
ADEPF =
VIN
Capacity
 
VVI = VIN ∗ (1 + Acid) ∗ (1 + Neutr. ) 
AVF =
MIN
Capacity
 
AUFDF =
VIN
Flux
∗ (
1
Duration − tDiaf
+
DFC
tDiaf ∗ CF
) 
 
YieldDSP = ∏ Yieldstep
DSP
 
q: Seed bioreactor’s index 
r: Inoculation ratio 
VIN: Volume in (L) 
MIN: Mass in (g) 
D: Calculated chromatography column diameter (cm) 
DA: Available chromatography column diameter (cm) 
nCOL: Number of chromatography columns in parallel 
nCYC: Number of chromatography cycles per batch 
nCYC,new: Recalculated number of chromatography cycles per batch 
A: Filter/Membrane area (sqm) 
DFC: Diafiltration cycles 
tDiaf: Diafiltration time limit (hr) 
CF: Concentration factor 
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Figure 16: Algorithm for sizing chromatography columns used in the process 
economics model 
Method A.1: 
Method for calculating weight coefficient of each decision attribute considered in the resin 
selection tool based on its factor of significance. 
Consider four decision attributes (j = [1, 2, 3, 4]) with factors of significance (f = [a, b, c, 
d] where a, b, c and d ∈ ℝ+). The objective is to normalize the factors of significance (fj) 
and transform them into weight coefficients (wj). The ratios among a, b, c, and d should 
be reflected by the ratios among w1, w2, w3 and w4. Thus, w1 w2⁄ = a b⁄ . Given also 
that ∑ wj
4
j=1 = 1, the weight coefficients are calculated as; wj = 𝑓𝑗/ ∑ 𝑓𝑗
4
𝑗=1 . The benefit of 
Method A.1 is the flexibility that it offers to the user to define its own scale for the factors 
of significance instead of attempting to assign values strictly between 0 and 1. 
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Table A.4: CEX Chromatography resin list for mAb-1 used in Chapter 5, Case study 
2 
Index 
Resin 
Name 
DBC (g/L) Yield (%) Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
3 Resin-6 40 64.5 3.0 85.2 0.42 1000 
4 Resin-7 100 66.0 3.3 76.5 0.35 2500 
5 Resin-8 65 66.9 2.3 76.8 0.41 2000 
6 Resin-3 95 68.1 2.0 57.8 0.22 1900 
7 Resin-4 60 65.6 3.0 45.2 0.17 1900 
8 Resin-5 90 69.0 2.1 78.5 0.43 2300 
9 Resin-1 65 69.4 4.0 72.8 0.33 2800 
10 Resin-2 70 68.5 3.4 73.5 0.34 1800 
11 Resin-6 40 69.3 3.2 75.3 0.42 1000 
12 Resin-7 100 70.7 3.7 68.7 0.33 2500 
13 Resin-8 65 71.8 2.7 68.6 0.38 2000 
14 Resin-3 95 72.9 2.2 51.0 0.21 1900 
15 Resin-4 60 70.1 3.2 38.9 0.16 1900 
16 Resin-5 90 74.0 2.7 71.0 0.36 2300 
17 Resin-1 65 74.4 4.3 64.3 0.31 2800 
18 Resin-2 70 73.4 3.8 65.5 0.32 1800 
19 Resin-6 40 74.1 3.4 66.8 0.42 1000 
20 Resin-7 100 75.7 4.2 58.5 0.31 2500 
21 Resin-8 65 76.7 2.9 60.1 0.35 2000 
22 Resin-3 95 77.8 2.4 42.9 0.20 1900 
23 Resin-4 60 74.7 3.4 32.5 0.16 1900 
24 Resin-5 90 79.1 3.2 61.2 0.31 2300 
25 Resin-1 65 79.5 4.7 53.7 0.30 2800 
26 Resin-2 70 78.5 4.2 55.4 0.30 1800 
27 Resin-6 40 79.0 3.7 54.7 0.39 1000 
28 Resin-7 100 80.7 4.4 45.7 0.29 2500 
29 Resin-8 65 81.7 3.3 48.5 0.30 2000 
30 Resin-3 95 82.7 2.6 33.2 0.18 1900 
31 Resin-4 60 79.2 3.7 25.8 0.15 1900 
32 Resin-5 90 84.4 3.7 47.8 0.25 2300 
33 Resin-1 65 84.8 5.0 40.6 0.26 2800 
34 Resin-2 70 83.7 4.7 42.6 0.26 1800 
35 Resin-6 40 84.3 4.3 37.8 0.31 1000 
36 Resin-7 100 86.0 5.1 29.5 0.24 2500 
37 Resin-8 65 87.1 3.9 32.6 0.22 2000 
38 Resin-3 95 87.8 3.0 21.7 0.16 1900 
39 Resin-4 60 83.8 4.1 18.9 0.14 1900 
40 Resin-5 90 90.0 4.3 29.7 0.19 2300 
41 Resin-1 65 90.3 5.6 24.6 0.23 2800 
42 Resin-2 70 89.2 5.3 26.6 0.22 1800 
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Table A.4 (cont.): CEX Chromatography resin list for mAb-1 used in Chapter 5, 
Case study 2   
Index 
Resin 
Name 
DBC (g/L) Yield (%) Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
43 Resin-6 40 89.9 7.9 14.4 0.07 1000 
44 Resin-7 100 91.5 6.5 9.3 0.00 2500 
45 Resin-8 65 92.7 7.5 10.9 0.00 2000 
46 Resin-3 95 92.9 7.3 9.0 0.10 1900 
47 Resin-4 60 88.3 7.4 12.2 0.00 1900 
48 Resin-5 90 96.0 6.5 5.4 0.08 2300 
49 Resin-1 65 96.0 7.1 5.1 0.14 2800 
50 Resin-2 70 94.8 7.0 6.6 0.12 1800 
Table A.5: CEX Chromatography resin list for mAb-2 used in Chapter 5, Case study 
2  
Index 
Resin 
Name 
DBC (g/L) Yield Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
3 Resin-6 35 70.1 2.9 73.5 0.49 1000 
4 Resin-7 100 65.8 1.8 68.0 0.74 2500 
5 Resin-8 60 70.5 1.5 89.6 0.66 2000 
6 Resin-3 65 71.3 1.3 36.0 0.49 1900 
7 Resin-4 50 72.0 2.5 32.7 0.25 1900 
8 Resin-5 90 65.0 1.8 70.1 0.85 2300 
9 Resin-1 65 70.0 1.7 55.2 1.09 2800 
10 Resin-2 70 72.7 1.9 59.2 0.82 1800 
11 Resin-6 35 75.2 3.1 64.7 0.48 1000 
12 Resin-7 100 70.4 1.9 61.5 0.74 2500 
13 Resin-8 60 75.6 1.9 82.2 0.63 2000 
14 Resin-3 65 76.1 1.4 30.5 0.49 1900 
15 Resin-4 50 76.9 3.0 27.3 0.22 1900 
16 Resin-5 90 69.6 1.9 64.0 0.84 2300 
17 Resin-1 65 74.9 1.8 48.2 1.06 2800 
18 Resin-2 70 77.8 2.0 51.9 0.81 1800 
19 Resin-6 35 80.3 3.3 55.1 0.47 1000 
20 Resin-7 100 75.2 1.9 53.2 0.74 2500 
21 Resin-8 60 80.9 2.1 71.9 0.58 2000 
22 Resin-3 65 81.0 1.8 24.7 0.46 1900 
23 Resin-4 50 81.7 3.9 21.8 0.10 1900 
24 Resin-5 90 74.2 2.0 56.0 0.83 2300 
25 Resin-1 65 79.9 1.9 40.2 1.04 2800 
26 Resin-2 70 83.0 2.2 43.0 0.79 1800 
27 Resin-6 35 85.6 3.5 42.9 0.45 1000 
28 Resin-7 100 80.0 2.0 42.7 0.74 2500 
29 Resin-8 60 86.4 2.3 57.2 0.51 2000 
30 Resin-3 65 85.8 2.0 19.0 0.44 1900 
31 Resin-4 50 86.6 6.8 16.1 0.01 1900 
32 Resin-5 90 79.0 2.1 45.6 0.81 2300 
33 Resin-1 65 84.9 2.0 30.9 1.02 2800 
34 Resin-2 70 88.3 2.3 32.4 0.77 1800 
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Table A.5 (cont.): CEX Chromatography resin list for mAb-2 used in Chapter 5, 
Case study 2 
Index 
Resin 
Name 
DBC (g/L) Yield (%) Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
35 Resin-6 35 91.0 3.8 27.4 0.42 1000 
36 Resin-7 100 85.1 2.4 29.4 0.71 2500 
37 Resin-8 60 92.2 2.7 36.7 0.46 2000 
38 Resin-3 65 90.7 2.4 12.7 0.38 1900 
39 Resin-4 50 91.5 7.0 10.0 0.02 1900 
40 Resin-5 90 84.0 2.2 32.4 0.81 2300 
41 Resin-1 65 90.0 2.0 20.3 1.01 2800 
42 Resin-2 70 93.7 2.4 19.6 0.76 1800 
43 Resin-6 35 96.7 7.5 7.9 0.12 1000 
44 Resin-7 100 90.3 7.0 12.7 0.28 2500 
45 Resin-8 60 98.5 7.9 8.5 0.04 2000 
46 Resin-3 65 95.5 7.4 6.0 0.05 1900 
47 Resin-4 50 96.4 7.7 3.8 0.02 1900 
48 Resin-5 90 89.2 6.7 15.6 0.22 2300 
49 Resin-1 65 95.2 7.0 8.1 0.45 2800 
50 Resin-2 70 99.3 6.5 4.4 0.35 1800 
Table A.6: CEX Chromatography resin list for mAb-3 used in Chapter 5, Case study 
2 
Index 
Resin 
Name 
DBC (g/L) Yield Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
3 Resin-6 35 71.1 3.1 72.4 0.35 1000 
4 Resin-7 120 70.3 3.1 80.2 0.42 2500 
5 Resin-8 70 74.1 2.3 71.3 0.41 2000 
6 Resin-3 100 71.1 2.1 52.9 0.10 1900 
7 Resin-4 45 67.9 3.1 39.1 0.12 1900 
8 Resin-5 100 74.6 1.9 76.6 0.51 2300 
9 Resin-1 90 72.2 3.2 74.4 0.38 2800 
10 Resin-2 85 72.4 3.2 74.0 0.39 1800 
11 Resin-6 35 76.2 3.3 66.0 0.33 1000 
12 Resin-7 120 75.5 3.4 71.8 0.39 2500 
13 Resin-8 70 79.5 2.8 63.0 0.38 2000 
14 Resin-3 100 76.1 2.2 46.1 0.10 1900 
15 Resin-4 45 72.5 3.3 33.2 0.12 1900 
16 Resin-5 100 80.0 2.5 68.8 0.42 2300 
17 Resin-1 90 77.4 3.5 65.8 0.35 2800 
18 Resin-2 85 77.6 3.6 65.9 0.36 1800 
19 Resin-6 35 81.4 3.6 57.0 0.31 1000 
20 Resin-7 120 80.8 3.9 60.7 0.37 2500 
21 Resin-8 70 84.9 3.1 54.1 0.38 2000 
22 Resin-3 100 81.1 2.4 38.1 0.10 1900 
23 Resin-4 45 77.2 3.5 27.2 0.11 1900 
24 Resin-5 100 85.5 3.1 58.6 0.38 2300 
25 Resin-1 90 82.9 4.0 54.7 0.32 2800 
26 Resin-2 85 83.0 4.0 55.2 0.33 1800 
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Table A.6 (cont.): CEX Chromatography resin list for mAb-3 used in Chapter 5, 
Case study 2 
Index 
Resin 
Name 
DBC (g/L) Yield Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
27 Resin-6 35 86.8 4.0 44.7 0.26 1000 
28 Resin-7 120 86.4 4.3 46.2 0.34 2500 
29 Resin-8 70 90.5 3.5 41.8 0.35 2000 
30 Resin-3 100 86.3 2.7 28.6 0.10 1900 
31 Resin-4 45 81.8 3.8 21.2 0.11 1900 
32 Resin-5 100 91.3 3.5 44.4 0.33 2300 
33 Resin-1 90 88.5 4.3 40.7 0.17 2800 
34 Resin-2 85 88.6 4.5 41.5 0.31 1800 
35 Resin-6 35 92.5 4.5 28.1 0.21 1000 
36 Resin-7 120 92.2 4.7 27.4 0.31 2500 
37 Resin-8 70 96.4 4.1 25.2 0.28 2000 
38 Resin-3 100 91.6 3.0 17.4 0.09 1900 
39 Resin-4 45 86.5 4.5 15.2 0.10 1900 
40 Resin-5 100 97.5 4.3 24.9 0.25 2300 
41 Resin-1 90 94.4 4.8 23.0 0.09 2800 
42 Resin-2 85 94.5 5.0 23.8 0.27 1800 
43 Resin-6 35 98.6 8.1 5.6 0.09 1000 
44 Resin-7 120 98.5 6.5 2.9 0.18 2500 
45 Resin-8 70 99.0 7.9 2.7 0.12 2000 
46 Resin-3 100 96.9 7.3 4.4 0.00 1900 
47 Resin-4 45 91.1 7.3 9.3 0.00 1900 
48 Resin-5 100 99.5 6.5 0.0 0.14 2300 
49 Resin-1 90 99.5 6.5 0.5 0.02 2800 
50 Resin-2 85 99.5 7.0 1.2 0.07 1800 
Table A.7: CEX Chromatography resin list for mAb-4 used in Chapter 5, Case study 
2 
Index 
Resin 
Name 
DBC (g/L) Yield Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
3 Resin-6 30 51.0 2.0 54.7 NA 1000 
4 Resin-7 85 58.8 2.7 73.3 NA 2500 
5 Resin-8 25 70.5 1.7 43.7 NA 2000 
6 Resin-3 140 60.5 7.1 44.2 NA 1900 
7 Resin-4 45 62.3 5.6 39.3 NA 1900 
8 Resin-5 50 56.8 3.6 59.2 NA 2300 
9 Resin-1 90 60.2 2.7 70.1 NA 2800 
10 Resin-2 60 63.1 2.8 72.0 NA 1800 
11 Resin-6 30 54.8 2.0 49.7 NA 1000 
12 Resin-7 85 63.3 2.9 68.2 NA 2500 
13 Resin-8 25 75.8 1.8 37.2 NA 2000 
14 Resin-3 140 64.6 7.2 39.8 NA 1900 
15 Resin-4 45 66.5 5.8 35.0 NA 1900 
16 Resin-5 50 61.1 3.8 53.8 NA 2300 
17 Resin-1 90 65.0 2.8 64.0 NA 2800 
18 Resin-2 60 68.0 2.9 66.4 NA 1800 
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Table A.7 (cont.): CEX Chromatography resin list for mAb-4 used in Chapter 5, 
Case study 2 
Index 
Resin 
Name 
DBC (g/L) Yield Elution CVs 
HMW 
Reduction 
(%) 
HCPs LRV 
Price 
(USD/L) 
19 Resin-6 30 58.5 2.2 45.2 NA 1000 
20 Resin-7 85 67.9 3.0 63.1 NA 2500 
21 Resin-8 25 81.2 1.9 29.9 NA 2000 
22 Resin-3 140 68.9 7.3 35.1 NA 1900 
23 Resin-4 45 70.7 6.0 30.7 NA 1900 
24 Resin-5 50 65.6 4.0 47.5 NA 2300 
25 Resin-1 90 70.2 2.9 56.1 NA 2800 
26 Resin-2 60 73.3 2.9 58.9 NA 1800 
27 Resin-6 30 62.3 2.4 40.5 NA 1000 
28 Resin-7 85 73.8 3.4 51.6 NA 2500 
29 Resin-8 25 86.8 2.0 21.8 NA 2000 
30 Resin-3 140 73.2 7.4 29.9 NA 1900 
31 Resin-4 45 74.9 6.4 26.2 NA 1900 
32 Resin-5 50 70.4 4.5 40.0 NA 2300 
33 Resin-1 90 75.9 3.1 45.9 NA 2800 
34 Resin-2 60 79.3 3.0 48.4 NA 1800 
35 Resin-6 30 66.1 2.6 35.5 NA 1000 
36 Resin-7 85 80.2 4.0 37.3 NA 2500 
37 Resin-8 25 92.5 2.4 12.8 NA 2000 
38 Resin-3 140 77.6 7.5 24.4 NA 1900 
39 Resin-4 45 79.2 6.8 21.5 NA 1900 
40 Resin-5 50 75.4 5.0 31.0 NA 2300 
41 Resin-1 90 82.3 3.7 32.1 NA 2800 
42 Resin-2 60 86.2 3.5 33.0 NA 1800 
43 Resin-6 30 69.9 9.0 30.3 NA 1000 
44 Resin-7 85 88.6 8.5 12.9 NA 2500 
45 Resin-8 25 98.5 8.5 2.5 NA 2000 
46 Resin-3 140 82.1 7.5 18.4 NA 1900 
47 Resin-4 45 83.5 7.8 16.9 NA 1900 
48 Resin-5 50 80.9 8.5 20.0 NA 2300 
49 Resin-1 90 89.9 8.0 11.8 NA 2800 
50 Resin-2 60 95.3 7.0 6.7 NA 1800 
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Abbreviations 
Abbreviation Description Abbreviation Description 
AEX Anion Exchange HTE High-Throughput 
Experimentation 
ATF Alternative Tangential Flow  HTPD High-Throughput Process 
Development 
BE Bind-and-Elute HTS High-Throughput Screening 
BLA Biologics Licence 
Application 
ICH International Conference 
on Harmonisation of 
Technical Requirements for 
Registration of 
Pharmaceuticals for 
Human Use  
BLP Binary Linear Programming IEX Ion Exchange 
CEX Cation Exchange IND Investigational New Drug 
cGCP current Good Clinical 
Practice 
LMW Low Molecular Weight 
  mAb Monoclonal Antibodies 
cGLP current Good Laboratory 
Practice 
MADM Multi-Attribute Decision-
Making 
CHO Chinese Hamster Ovary MILFP Mixed-Integer Linear 
Fractional Programming  
CIP Cleaning-in-place MINLP Mixed-Integer Non-Linear 
Programming 
COG Cost of Goods MLR Multiple Linear Regression 
COG/g COG per gram of product NDA New Drug Application 
CPPs Critical Process 
Parameters 
NPV Net Present Value 
CQAs Critical Quality Attributes OFAT One-factor-at-a-time 
DBC Dynamic Binding Capacity PMDA Pharmaceutical and 
Medical Devices Agency, 
Japan 
DBC10% DBC at 10% breakthrough PW Process Water 
DoE Design of Experiments QbD Quality by Design 
DSP Downstream Processing QCQA Qaulity Control and Quality 
Assurance 
EMA European Medicines 
Agency 
R&D Research and 
Development 
Fab Antibody Fragment SEC Size Exclusion 
Chromatography 
FCI Fixed Capital Investment SIP Sterilisation-in-place 
FDA Food and Drug 
Administration 
SUT Single-Use Technologies 
FT Flow-Through UPLC Ultra-High Performance 
Liquid Chromatography 
GMP Good Manufacturing 
Practice 
USP Upstream Processing 
HA Hydroxyapatite 
Chromatography 
VBA Visual Basic for 
Applications 
HCPs Host Cell Proteins WFI Water For Injection 
HIC Hydrophobic Interaction 
Chromatography 
WPC Weak Partitioning 
Chromatography 
HMW High Molecular Weight 
  
 
